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A B S T R A C T
Background
Cystic fibrosis (CF) is the commonest inherited life-shortening illness in white populations, caused by a mutation in the gene that codes
for the cystic fibrosis transmembrane regulator protein (CFTR), which functions as a salt transporter. This mutation mainly affects
the airways where excess salt absorption dehydrates the airway lining leading to impaired mucociliary clearance. Consequently, thick,
sticky mucus accumulates making the airway prone to chronic infection and progressive inflammation; respiratory failure often ensues.
Other complications include malnutrition, diabetes and subfertility.
Increased understanding of the condition has allowed pharmaceutical companies to design mutation-specific therapies targeting the
underlying molecular defect. CFTR potentiators target mutation classes III and IV and aim to normalise airway surface liquid and
mucociliary clearance, which in turn impacts on the chronic infection and inflammation. This is an update of a previously published
review.
Objectives
To evaluate the effects of CFTR potentiators on clinically important outcomes in children and adults with CF.
Search methods
We searched the Cochrane Cystic Fibrosis Trials Register, compiled from electronic database searches and handsearching of journals
and conference abstract books. We also searched the reference lists of relevant articles, reviews and online clinical trial registries. Last
search: 21 November 2018.
Selection criteria
Randomised controlled trials (RCTs) of parallel design comparing CFTR potentiators to placebo in people with CF. A separate review
examines trials combining CFTR potentiators with other mutation-specific therapies.
Data collection and analysis
The authors independently extracted data, assessed the risk of bias in included trials and used GRADE to assess evidence quality. Trial
authors were contacted for additional data.
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Main results
We included five RCTs (447 participants with different mutations) lasting from 28 days to 48 weeks, all assessing the CFTR potentiator
ivacaftor. The quality of the evidence was moderate to low, mainly due to risk of bias (incomplete outcome data and selective reporting)
and imprecision of results, particularly where few individuals experienced adverse events. Trial design was generally well-documented.
All trials were industry-sponsored and supported by other non-pharmaceutical funding bodies.
F508del (class II) (140 participants)
One 16-week trial reported no deaths, or changes in quality of life (QoL) or lung function (either relative or absolute change in forced
expiratory volume in one second (FEV1) (moderate-quality evidence). Pulmonary exacerbations and cough were the most reported
adverse events in ivacaftor and placebo groups, but there was no difference between groups (low-quality evidence); there was also
no difference between groups in participants interrupting or discontinuing treatment (low-quality evidence). Number of days until
the first exacerbation was not reported, but there was no difference between groups in how many participants developed pulmonary
exacerbations. There was also no difference in weight. Sweat chloride concentration decreased, mean difference (MD) -2.90 mmol/L
(95% confidence interval (CI) -5.60 to -0.20).
G551D (class III) (238 participants)
The 28-day phase 2 trial (19 participants) and two 48-week phase 3 trials (adult trial (167 adults), paediatric trial (52 children)) reported
no deaths. QoL scores (respiratory domain) were higher with ivacaftor in the adult trial at 24 weeks, MD 8.10 (95% CI 4.77 to 11.43)
and 48 weeks, MD 8.60 (95% CI 5.27 to 11.93 (moderate-quality evidence). The adult trial reported a higher relative change in
FEV1 with ivacaftor at 24 weeks, MD 16.90% (95% CI 13.60 to 20.20) and 48 weeks, MD 16.80% (95% CI 13.50 to 20.10); the
paediatric trial reported this at 24 weeks, MD 17.4% (P < 0.0001)) (moderate-quality evidence). These trials demonstrated absolute
improvements in FEV1 (% predicted) at 24 weeks, MD 10.80% (95% CI 8.91 to 12.69) and 48 weeks, MD 10.44% (95% CI 8.56 to
12.32). The phase 3 trials reported increased cough, odds ratio (OR) 0.57 (95% CI 0.33 to 1.00) and episodes of decreased pulmonary
function, OR 0.29 (95% CI 0.10 to 0.82) in the placebo group; ivacaftor led to increased dizziness in adults, OR 10.55 (95% CI
1.32 to 84.47). There was no difference between groups in participants interrupting or discontinuing treatment (low-quality evidence).
Fewer participants taking ivacaftor developed serious pulmonary exacerbations; adults taking ivacaftor developed fewer exacerbations
(serious or not), OR 0.54 (95% CI 0.29 to 1.01). A higher proportion of participants were exacerbation-free at 24 weeks with ivacaftor
(moderate-quality evidence). Ivacaftor led to a greater absolute change from baseline in FEV1 (% predicted) at 24 weeks, MD 10.80%
(95% CI 8.91 to 12.69) and 48 weeks, MD 10.44% (95% CI 8.56 to 12.32); weight also increased at 24 weeks, MD 2.37 kg (95%
CI 1.68 to 3.06) and 48 weeks, MD 2.75 kg (95% CI 1.74 to 3.75). Sweat chloride concentration decreased at 24 weeks, MD -48.98
mmol/L (95% CI -52.07 to -45.89) and 48 weeks, MD -49.03 mmol/L (95% CI -52.11 to -45.94).
R117H (class IV) (69 participants)
One 24-week trial reported no deaths. QoL scores (respiratory domain) were higher with ivacaftor at 24 weeks, MD 8.40 (95% CI 2.17
to 14.63), but no relative changes in lung function were reported (moderate-quality evidence). Pulmonary exacerbations and cough
were the most reported adverse events in both groups, but there was no difference between groups; there was no difference between
groups in participants interrupting or discontinuing treatment (low-quality evidence). Number of days until the first exacerbation was
not reported, but there was no difference between groups in how many participants developed pulmonary exacerbations. No changes
in absolute change in FEV1 or weight were reported. Sweat chloride concentration decreased, MD -24.00 mmol/L (CI 95% -24.69 to
-23.31).
Authors’ conclusions
There is no evidence supporting the use of ivacaftor in people with the F508del mutation. Both G551D phase 3 trials demonstrated
a clinically relevant impact of ivacaftor on outcomes at 24 and 48 weeks in adults and children (over six years of age) with CF. The
R117H trial demonstrated an improvement in the respiratory QoL score, but no improvement in respiratory function.
As new mutation-specific therapies emerge, it is important that trials examine outcomes relevant to people with CF and their families
and that adverse events are reported robustly and consistently. Post-market surveillance is essential and ongoing health economic
evaluations are required.
P L A I N L A N G U A G E S U M M A R Y
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Ivacaftor (marketed as Kalydeco®), a new specific therapy for cystic fibrosis
Review question
How does ivacaftor affect clinical outcomes (survival, quality of life and lung function) in people with cystic fibrosis (CF)?
Background
In people with CF, airway surfaces do not have enough water because of an abnormal protein; this makes it difficult to clear thick and
sticky mucus, which leads to lung infections. Ivacaftor works on the abnormal protein in people with some mutations to allow the
airways retain more water and better clear mucus, so fewer lung infections develop.
Ivacaftor was aimed at people with class III and IV mutations, and has been studied in people with G551D (class III), R117H (class
IV) and F508del (class II) mutations.
Trial characteristics
We included five trials (447 participants) comparing ivacaftor to placebo (dummy treatment with no active medication) lasting between
four and 48 weeks. Three trials enrolled a total of 238 people with at least one copy of the G551D mutation, one trial enrolled 140
people with two copies of the F508del mutation and one enrolled 69 people with at least one copy of the R117H mutation. The
evidence is up to date as of 21 November 2018.
Key results
F508del mutation
The trial did not report any deaths or show improvements in lung function, quality of life scores or weight. Cough and pulmonary
exacerbations (flare ups of lung disease) were the most reported adverse events when taking both ivacaftor and placebo; there were a
similar number of flare ups for both groups. Sweat chloride concentrations were reduced with ivacaftor.
G551D mutation
No deaths were reported. Both children and adults taking ivacaftor showed improvements in lung function, but only adults reported
higher quality of life scores. People given placebo reported more coughing and experienced more episodes of decreased lung function;
more adults taking ivacaftor reported episodes of dizziness. Similar numbers of people taking ivacaftor and placebo delayed the course of
medication, or withdrew from the trial altogether, due to side effects (e.g. psychological issues, liver disease, severe breathing problems).
There were more serious pulmonary exacerbations whilst taking placebo compared to ivacaftor. Adults taking ivacaftor were admitted
to hospital less often and had fewer courses of intravenous antibiotics for exacerbations. Both children and adults and children increased
their weight with ivacaftor. There was a drop in sweat chloride concentrations with ivacaftor.
R117H mutation
No deaths occurred in this trial. While quality of life scores improved with ivacaftor, lung function did not. Cough and pulmonary
exacerbations (flare ups of lung disease) were the most reported adverse events when taking both ivacaftor and placebo; there were a
similar number of flare ups for both groups. There was no difference in weight; but as for other mutations there was a reduction in
sweat chloride concentration with ivacaftor.
Evidence suggests that ivacaftor is an effective treatment for people (over six years of age) with cystic fibrosis and the G551D mutation,
but not for those with the F508del or R117H mutations.
Quality of the evidence
In most trials, individuals were put into different treatment groups at random with equal chances of being given either placebo or
ivacaftor; no one could work out which treatment the next person would receive, so that healthier people did not receive ivacaftor and
make the results seem better. We were not sure whether anyone involved in the trial knew who was receiving which treatment and how
this might affect results. No trials reported all results clearly; sometimes they did not report them in a way that we could use in the
review and sometimes they did not report the data at all. This affected our certainty regarding the overall results. Information about
some side effects was limited as not many people experienced them, therefore, it is difficult to judge whether there was a difference
between treatment groups
We judged the evidence in this review to be moderate to low quality.
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Trial funding sources
All trials were sponsored by Vertex Pharmaceuticals Incorporated. The National Institute of Health (NIH), the Cystic Fibrosis Foun-
dation (CFF) and other non-pharmaceutical funding bodies also supported the trials.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Ivacaftor compared with placebo for cystic fibrosis with the F508del CFTR mutation
Patient or population: adults and children with cyst ic f ibrosis and with the F508del CFTR mutat ion
Settings: outpat ients
Intervention: ivacaf tor
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Ivacaftor
Survival
Follow-up: 16 weeks
No deaths reported. No deaths reported. NA 140
(1 study)
NA
QoL
Total score
Follow-up: NA
Not reported. NA NA NA
QoL (CFQ-R)
Respiratory domain
Follow-up: 16 weeks
See comment.1 See comment.1 NA 140
(1 study)
⊕⊕⊕©
moderate3
There was no sig-
nif icant dif f erence be-
tween groups at 16
weeks
FEV1 %predicted Rela-
tive change from base-
line
Follow-up:16 weeks
Not reported.2 The mean FEV1 (% pre-
dicted) was 2.4%higher
(0.95% lower to 5.75%
higher) in the ivacaf tor
group
NA 140
(1 study)
⊕⊕⊕©
moderate3
There was no sig-
nif icant dif f erence be-
tween groups at 16
weeks
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FEV1 % predicted Ab-
solute change from
baseline
Follow-up: 16 weeks
Not reported.2 The mean FEV1 (% pre-
dicted) was 1.7%higher
(0.65% lower to 4.05%
higher) in the ivacaf tor
group
NA 140
(1 study)
⊕⊕⊕©
moderate3
There was no sig-
nif icant dif f erence be-
tween groups at 16
weeks
Adverse events
Follow-up:16 weeks
The most commonly re-
ported adverse events
in the placebo group
were: pulmonary exac-
erbat ion, cough,
oropharyngeal pain and
fat igue
The most commonly re-
ported adverse events
in the ivacaf tor group
were: cough, pul-
monary exacerbat ion,
upper respiratory tract
infect ion and nasal con-
gest ion
NA 140
(1 study)
⊕⊕©©
low3,4
There was no sig-
nif icant dif f erence be-
tween groups in terms
of any other adverse
events
Time to first pulmonary
exacerbation
Follow-up: 16 weeks
Not reported. NA NA NA
*The basis for the assumed risk is the mean placebo group risk across studies, unless otherwise stated. The corresponding risk (and its 95% CI) is based on the assumed
risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CFQ-R: Cyst ic Fibrosis Quest ionnaire-Revised; CFTR: cyst ic f ibrosis transmembrane regulator; CI: conf idence interval; FEV1: f orced expiratory volume at 1 second; HR: hazard
rat io; MD: mean dif ference; QoL: quality of lif e.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1. Presentat ion of the data prevented including data in analysis therefore results are presented narrat ively.
2. Only dif f erences between placebo and ivacaf tor groups were presented, results within the placebo group were not presented
therefore an assumed risk cannot be calculated.
3. Downgraded once due to risk of bias f rom incomplete outcome data and/ or select ive report ing in all of the included studies.
4. Downgraded once due to imprecision: few events occurred therefore CIs for occurrence of specif ic events are very wide
(also see Analysis 1.2)
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B A C K G R O U N D
A glossary of terms specific to this review can be found in the
appendices (Appendix 1); a more general glossary of terms used
in Cochrane Reviews can be accessed at Cochrane Glossary.
Description of the condition
Cystic fibrosis (CF) is the most common inherited life-shorten-
ing illness in white populations, with a prevalence of 1 in 2000
at birth in Europeans (Bobadilla 2002) and varying prevalence in
North American populations depending on ethnic composition
(Hamosh 1998). According to the data report from the UK CF
Registry whichwas published in July 2014, there were 10,338 peo-
ple with a confirmed diagnosis of CF in the UK (UK CF Registry
Report 2013). The clinical features of CF arise from abnormali-
ties in a protein called the cystic fibrosis transmembrane conduc-
tance regulator (CFTR) (Riordan 1989; Southern 1997). Nor-
mally, CFTR protein is transported to the outer cell membrane,
where it has a role in co-ordinating the transport of the salt ions,
sodium (Na+) and chloride (Cl−), in and out of the cell. This salt
transport role is particularly important in the airways, pancreas,
sweat gland, and vas deferens.
In the lungs of people with CF, defective salt transport leads to
a reduction in airway surface liquid volume. This, in turn, leads
to compromised mucociliary clearance, which initiates a cycle
of infection, inflammation and progressive lung damage, eventu-
ally causing respiratory failure and premature death. Other conse-
quences of CFTR dysfunction, including those related to abnor-
malities in the inflammatory response, are probably important but
not as well characterized. In addition, CFTR-related ion transport
abnormalities can lead to other systemic complications. These in-
clude malnutrition and diabetes (through pancreatic damage, salt
depletion through excess loss in sweat) and subfertility (in men
and women) caused by various factors.
Over 1900 mutations have been identified in the CFTR gene,
which can be categorised according to the impact they have on
CFTR synthesis, processing, or function (CFMD 2012). These
categories have been described (Rowntree 2003; Southern 2007);
and a summary is presented in the additional tables (Table 1). The
most common mutation is the delta F508 (F508del) mutation
(class II mutation) and is present on at least one allele in 7990
(90.8%) people with CF in the UK. The second most common
mutation in the UK is the G551D mutation (class III mutation).
This mutation exists in 514 (5.84%) people with CF in the UK.
The R117H mutation (class IV mutation) is the third most com-
monmutation, present in 398 (4.52%) people with CF in the UK
(UK CF Registry Report 2013).
Description of the intervention
Understanding how the mutations, which are described in the
additional tables (Table 1), affect the production, structure, and
function of CFTR has led to the concept of mutation-specific
therapies. One strategy, relating mainly to mutations classes III to
V but also to class II, is to improve the function of CFTR that has
reached the cell membrane, but whose function is compromised
(McKone 2004). Drugs that improve CFTR function in the cell
membrane are called potentiators and have the potential to correct
the abnormal salt transport that characterises CF. Potentiators can
be administered orally, or as an inhaled preparation.
Two distinct approaches have resulted in the recognition of can-
didate drugs with this mode of action (Amaral 2007):
1. testing of compounds known to affect CFTR or other ion-
channels (either pharmaceutical drugs or chemicals which occur
naturally in plants, herbs, fruits or food components);
2. high throughput screening, which involves testing large
numbers of diverse chemicals, on laboratory cell lines, to identify
which of these may stimulate CFTR.
In addition to potentiators, other drugs which aim to correct de-
fects of the CFTR are also under investigation in clinical trials.
These include correctors (which increase the amount of CFTR in
the cell membrane by preventing early degradation - class II mu-
tations) and ’stop-codon therapies’ which act to prevent structural
abnormalities of CFTR that occur when premature stop codons
terminate protein synthesis too early - class Imutations). Cochrane
Reviews of trials assessing correctors and one assessing stop codon
therapies have been published (Aslam 2017; Southern 2018).
How the intervention might work
The CFTR potentiator ivacaftor was identified through high-
throughput screening by Vertex Pharmaceuticals Incorporated. In
cell and animal models, it was able to restore CFTR function for
class III mutations and correct the abnormal transmembrane salt
transport (Van Goor 2009). However, the precise mechanism of
action of ivacaftor is unclear, owing to the limited amount of data.
The correction of the basic defect in CF in the airways of the
lung could lead to the normalization of airway surface liquid; the
resulting re-establishment of mucociliary clearance, would then
have a beneficial impact on the chronic infection and inflammation
that characterizes CF lung disease.
Why it is important to do this review
Since CFTR potentiators are novel therapies, it is important that
randomised controlled trials (RCTs) testing these agents are crit-
ically appraised. This will enable examination of the evidence re-
lating to the benefits and harms of CFTR potentiators. It is im-
portant that funding bodies have a clear evidence base on which
to assess new therapies for CF that aim to correct the basic defect,
particularly given the large prevalence of people with mutations
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that might be impacted by CFTR potentiators. It is likely that
these therapies will represent a significant healthcare resource. In
addition, critical appraisal of included trials will help inform fu-
ture trial design.
This review aims to collate evidence fromRCTs that have evaluated
the benefits and harms of CFTR potentiators in people with CF.
This is an update of a previously published version (Patel 2012;
Patel 2015).
O B J E C T I V E S
To evaluate the effects of CFTR potentiators on clinically impor-
tant outcomes in children and adults with CF.
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs of parallel design (published or unpublished). Cross-over
trials were considered inappropriate given the potential longer-
term impact of this therapy on outcomes.
Types of participants
We have included trials involving children or adults with CF, as
confirmed either by the presence of two disease-causing muta-
tions, or by a combination of a positive sweat test and recognised
clinical features of CF. We included trials involving people with
any level of disease severity and any relevant mutation class, where
CFTR has been demonstrated to successfully embed within the
cell membrane and display defective function.
Types of interventions
In a post hoc change we have only included trials comparing
CFTR potentiators to placebo or another intervention. Trials
where CFTR potentiators are used in combination with other
CFTR function modulators were excluded. There are many ongo-
ing trials that use a CFTR potentiator alongside a CFTR corrector
and we believe it would be more appropriate to conduct a separate
systematic review for these trials (Southern 2018).
Types of outcome measures
Primary outcomes
1. Survival (in a post hoc change mortality data were also
considered)
2. Quality of life (QoL) (measured using validated
quantitative scales or scores (e.g. Cystic Fibrosis Questionnaire-
Revised (CFQ-R) (Quittner 2009))
i) total QoL score
ii) different sub-domains which may be reported
3. Forced expiratory flow rate at one second (FEV1) (relative
change from baseline)
Secondary outcomes
1. Adverse effects
i) graded by review authors as mild (therapy does not
need to be discontinued)
ii) graded by review authors as moderate (therapy is
discontinued, and the adverse effect ceases)
iii) graded by review authors as severe (life-threatening or
debilitating, or which persists even after treatment is
discontinued)
iv) other adverse effects of therapy (of any severity) that
are not classifiable according to these categories, including
pulmonary exacerbation (protocol defined or physician defined)
and time-to-exacerbation data
2. Hospitalisation
i) number of days
ii) number of episodes
3. School or work attendance (i.e. number of days missed)
4. Other physiological measures of lung function (litres or per
cent (%) predicted for age, sex and height)
i) FEV1 absolute values (rather than “relative change
from baseline”, which is specified as primary outcome)
ii) forced vital capacity (FVC) (absolute values and
change from baseline)
5. Extra courses of antibiotics (measured as time-to the next
course of antibiotics and the total number of courses of
antibiotics)
i) oral
ii) intravenous
iii) inhaled
6. Radiological measures of lung disease (assessed using any
scoring system)
i) chest radiograph scores
ii) computerised tomogram (CT) score
7. Acquisition of respiratory pathogens
i) Pseudomonas aeruginosa
ii) Staphylococcus aureus
iii) Haemophilus influenzae
iv) other significant pathogen
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8. Eradication of respiratory pathogens (as defined by trial
authors)
i) P aeruginosa
ii) S aureus
iii) H influenzae
iv) other significant pathogen
9. Nutrition and growth (measured as relative change from
baseline) (including z scores or centiles)
i) weight
ii) body mass index (BMI)
iii) height
10. Sweat chloride (change from baseline) as a measure of
CFTR function
11. Cost of treatment
Search methods for identification of studies
There are no restrictions regarding language or publication status.
Electronic searches
We identified relevant trials from theGroup’s Cystic Fibrosis Trials
Register using the term: ’drugs that augment function of abnormal
CFTR protein in the cell membrane’. Relevant trials have been
tagged with this term for indexing purposes in the Group’s Cystic
Fibrosis Trials Register.
This is compiled from electronic searches of the Cochrane Cen-
tral Register of Controlled Trials (CENTRAL) (updated each new
issue of the Cochrane Library), weekly searches of MEDLINE, a
search of Embase to 1995 and the handsearching of two journals
- Pediatric Pulmonology and the Journal of Cystic Fibrosis. Unpub-
lished work was identified by searching through the abstract books
of three major cystic fibrosis conferences: the International Cystic
Fibrosis Conference; the EuropeanCystic Fibrosis Conference and
the North American Cystic Fibrosis Conference. For full details
of all searching activities for the register, please see the relevant
sections of the Group’s website.
Date of latest search of the Group’s Cystic Fibrosis Trials Register:
21 November 2018.
We also searched online clinical trial registries (Appendix 1). Date
of last search of clinical trial registries: 21 November 2018.
Searching other resources
We screened references of included trials to identify other poten-
tially relevant trials. We also contacted authors of included trials,
leaders in the field, and companies known to be developing and
investigating CFTR potentiators, to identify any trials that may
have been missed by these searches.
Data collection and analysis
Selection of studies
For the original review, two authors (SP and IS) independently
assessed the suitability of each trial identified by the search. From
the 2018 update onwards MS and IS independently assessed the
suitability of each trial and if disagreement arose regarding suit-
ability for inclusion, we attempted to reach a consensus by discus-
sion, failing which a third author (KWS) arbitrated.
Data extraction and management
For the updated review, two authors (MS and IS) independently
extracted relevant data from each included trial using a standard-
ised data extraction form. If disagreement arose on data extraction,
we attempted to reach a consensus by discussion, failing which a
fourth author (KWS) arbitrated.
We intended to report on our primary outcome ’survival’ as sur-
vival to time X (time-to-event data). However, these data were
not available, so we considered mortality data (number of deaths)
as an alternative outcome (post hoc change). For lung function,
where possible we reported the relative change from baseline in
FEV1, since this way of presenting FEV1 is very important in clin-
ical practice. If this was not possible, we reported absolute change
from baseline in FEV1 as a secondary outcome. We extractedQoL
as the absolute change from baseline.
With regards to the secondary outcome ’Adverse effects’, we ex-
tracted the total number of participants who experienced adverse
effects or required trial drug interruption or termination. When
extracting data on pulmonary exacerbations, we noted whether
they were protocol-defined or physician-defined. We reported the
number of participants who experienced episodes of pulmonary
exacerbation or reported time-to-exacerbation data. We extracted
the number of participants who required hospitalisations. With
regards to ’Extra courses of antibiotics’, we reported on the total
number of courses of antibiotics.
For the secondary outcomes ’Change from baseline in weight’
and ’Change from baseline in sweat chloride concentration’, we
extracted the absolute change from baseline results.
For continuous outcomes, where standard deviations (SDs) were
not provided, we calculated the standard error of the mean (SEM)
from the 95% confidence intervals (CIs) and inserted the results
into a generic inverse variance (GIV) analysis.
If the trial author presented non-parametric data, we reported
results in the written text and not in the analysis.
We have reported data at 4 weeks, 16 weeks, 24 weeks and 48
weeks.
Assessment of risk of bias in included studies
Two authors (MS and IS) assessed the risk of bias for each trial
using theCochrane risk of bias tool (Higgins 2011a). This includes
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assessment of the followingmethodological aspects of the included
trials:
1. procedure for randomisation (selection bias);
2. allocation concealment (selection bias);
3. masking (blinding) of the intervention from participants,
clinicians, and trial personnel evaluating outcomes (performance
bias);
4. missing outcome data (attrition bias);
5. selective outcome reporting (reporting bias);
6. other sources of bias.
We also assessed whether all participants were included in an in-
tention-to-treat analysis, regardless of whether they completed the
treatment schedule or not. If disagreement arose on the assessment
of risk of bias of a trial, we attempted to reach a consensus by
discussion, failing which a third author (KWS) arbitrated.
Measures of treatment effect
For binary outcomes, we calculated a pooled estimate of the treat-
ment effect for each outcome using the pooled odds ratio (OR)
and 95% CIs or 99% confidence intervals for analysis of separate
adverse events. If calculating a pooled OR was not appropriate,
we calculated an estimate of the treatment effect for each outcome
using the OR and 95% CIs.
For continuous outcomes, we calculated the mean change from
baseline for each group or the mean post-intervention values and
95% CIs for each group. We produced a pooled estimate of treat-
ment effect by calculating the mean difference (MD) and 95%
CIs. For QoL, CFQ-Rwas themost frequently used questionnaire
and so we calculated the MD and 95% CIs. No other question-
naire was used.
For time-to-event outcomes, such as ’Time to first pulmonary
exacerbation’, we usedmeasures of survival analysis, and calculated
hazard ratios (HR) and 95% CIs between different arms of the
trial.
In future updates of this review, if different trials present data for
the same outcomes in different forms (e.g. absolute values of lung
function measures, or change in these measures from a baseline),
we will combine these in a meta-analysis where appropriate.
Where the trials did not report change data, but instead presented
absolute post-treatment data without baseline data (so it was not
possible to calculate change data), we planned to use absolute post-
treatment data instead of change from baseline. However, if the re-
port presented baseline and post-treatment data for any outcome,
we calculated SDs for the change from baseline, for example if the
CI was available. If there was not enough information available
to calculate the SDs for the changes, we planned to impute them
from other trials in the review, where data were available and trials
were similar (i.e. when they used the same measurement scale, had
the same degree of measurement error, had the same time periods
between baseline and final value measurement and had conducted
the randomisation process appropriately). If neither of thesemeth-
ods were possible, we planned to calculate a change-from-baseline
SD, making use of an imputed correlation coefficient (methods
described in chapter 16 in the Cochrane Handbook of Systematic
Reviews of Interventions (Higgins 2011b)).
Unit of analysis issues
Within this review, we have only included results from RCTs of
parallel design in which individual trial participants were ran-
domised. We excluded cross-over trials, because they are not ap-
propriate for evaluating therapies that potentially correct the un-
derlying defect (Higgins 2011b). We did not identify any clus-
ter RCTs. Further updates of this review will include any eligible
cluster RCTs identified and these will be included and analysed
as described in the Cochrane Handbook for Systematic Reviews of
Inteventions (Higgins 2011b).
Where trials with multiple intervention groups reported dichoto-
mous data i.e. adverse effects, we pooled the data to form one in-
tervention group and compared data to the placebo group as rec-
ommended in chapter 16 of theCochrane Handbook for Systematic
Reviews of Inteventions (Higgins 2011b).
Dealing with missing data
In order to allow an intention-to-treat analysis, we extracted data
on the number of participants with each outcome event, by al-
located treated group, irrespective of compliance and whether or
not the participant was later thought to be ineligible or otherwise
excluded from treatment or follow-up. We calculated the number
of participants with outcome data and checked if this was consis-
tent with the number of originally randomised participants. We
checked that this finding was consistent with findings on the on-
line ongoing trials database (clinicaltrials.gov). If there were any
discrepancies or any uncertainty, we contacted the primary inves-
tigators for clarification. For more detail about what we requested
and what information we were provided with, see the risk of bias
section below (Incomplete outcome data (attrition bias)).
Assessment of heterogeneity
We assessed heterogeneity through a visual examination of the
forest plots, and by considering the I² statistic (Higgins 2003)
together with the Chi² test (P < 0.1) (Deeks 2011). The I² statistic
reflects the likelihood that the variation of results across trials is
due to heterogeneity rather than chance, and we interpreted this
statistic using the following classification:
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
If we had identified heterogeneity between trials, we would have
conducted a sensitivity analysis including only homogenous trials
to determine the effect of heterogeneity on the overall treatment
effect of the intervention.
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Assessment of reporting biases
In order to identify selective outcome reporting, where possible
we compared outcomes described in the trial protocol with those
reported in the publication(s). We requested protocols for specific
trials from the primary investigators, corresponding author, or rel-
evant pharmaceutical company when they were not available.We
have recorded the proportion of protocols that were available to
us. If the protocol was not available, we checked published in-
formation on the trial registry databases. We also compared out-
comes listed in the ’Methods’ section of the final paper with those
presented in the ’Results’ section. If the published papers partially
reported negative findings (i.e. P > 0.05), we contacted the pri-
mary investigators for these data.
Weplanned to assess publicationbias by constructing and assessing
the symmetry of a funnel plot. This would have been possible if
we had included more than 10 trials in the review.
Data synthesis
We used a fixed-effect model to analyse data from trials which we
did not consider to be heterogeneous (see classifications above).
If substantial or considerable heterogeneity had been present (I²
greater than 50%), we used a random-effects model to analyse
data.
Subgroup analysis and investigation of heterogeneity
We planned to investigate any heterogeneity that we identified
using subgroup analyses of potential confounding factors. For this
review, we planned that these confounding factors would be:
• age (children (defined as younger than 18 years of age)
versus adults);
• gender;
• different mutation classes (Table 1).
As we did not seek individual patient data from trial investigators,
we did not undertake a subgroup analysis on the basis of disease
severity. Such an analysis may be incorporated in future updates
of this review.
Sensitivity analysis
If we had been able to combine a sufficient number of trials (at least
10), we planned to examine the impact of risk of bias on the results
examined by comparing meta-analyses including and excluding
trials with concerns of high risk of selection or reporting bias due
to issues relating to randomisation, allocation concealment, or
masking of interventions from participants or trial personnel.
Summary of findings and quality of the evidence
(GRADE)
In a post hoc change from protocol, we have presented three
summary of findings tables (Summary of findings for the main
comparison; Summary of findings 2; Summary of findings 3) un-
der the comparison of ’Ivacaftor compared to placebo’ according
to mutation class (see Table 1).
The following outcomes were reported in all tables (chosen based
on relevance to clinicians and consumers):
• survival;
• QoL (total score);
• QoL (respiratory domain);
• FEV1 (relative and absolute change);
• adverse events; and
• time to first pulmonary exacerbation.
For clarity in the tables, adverse events are not presented according
to the subdomains in Effects of interventions; instead the authors
have inserted a general statement about the summary of findings
for these outcomes and the evidence is graded based on all of the
subdomains combined.
We determined the quality of the evidence using the GRADE ap-
proach; and downgraded evidence in the presence of a high risk of
bias in at least one trial, indirectness of the evidence, unexplained
heterogeneity or inconsistency, imprecision of results, high proba-
bility of publication bias. We evidence by one level if they consid-
ered the limitation to be serious and by two levels if very serious.
R E S U L T S
Description of studies
Results of the search
The search of the Group’s Cystic Fibrosis Trials Register identified
a total of 201 publications (abstracts and full papers) representing
67 trials. A further 91 trials were identified from ongoing trials
databases. Five trials (67 references) were included and 62 trials
(115 references) were excluded. The two trials (two references)
awaiting classification have both been published as conference ab-
stracts; further details below (Kazani 2016; Uttamsingh 2016). In
a post hoc change (2018), references to corrector and potentia-
tor combination therapy trials have not been listed in the review,
meaning 79 trials (110 references) identified have not been listed
in the reference section of this review. The results of the search are
displayed in the PRISMA diagram below (Figure 1).
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Figure 1. Study flow diagram.
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No additional trials were identified by screening references of in-
cluded trials or by contacting authors of included trials, leaders in
the field, and companies known to be developing and investigat-
ing CFTR potentiators.
Included studies
We included five trials (67 references) with 447 participants in
this review (Accurso 2010; ENVISION2013; DISCOVER2011;
KONDUCT 2015; STRIVE 2011). All trials were available as full
texts.
Trial design
All five included trials were RCTs of parallel design. The respon-
sible funding body in all included trials was Vertex Pharmaceu-
ticals Incorporated. The National Institute of Health (NIH), the
Cystic Fibrosis Foundation (CFF) and other non-pharmaceutical
funding bodies were also involved in supporting the trials (Accurso
2010; ENVISION2013; DISCOVER 2011; KONDUCT 2015;
STRIVE 2011).
The F508del trial (n = 140) was a phase 2 trial that lasted 16
weeks (DISCOVER 2011). Participants who met pre-defined el-
igibility criteria and completed Part A of the trial were continued
onto an open-label extension phase (Part B) lasting 96 weeks (n
= 48); data from this extension were not eligible for inclusion in
this review (DISCOVER 2011). There were three trials of people
with the G551D mutation; the phase 2 trial had three arms and
lasted 28 days (Accurso 2010); the two phase 3 trials lasted 48
weeks (ENVISION 2013; STRIVE 2011). Participants in these
trials who completed 48 weeks of treatment (n = 194) were en-
tered into an open-label extension phase, which lasted up to 96
weeks; participants from this trial were not eligible for inclusion in
this review because they were not re-randomised to treatment or
control (PERSIST 2014). The phase 3 R117H trial (n = 69) lasted
for 24 weeks (KONDUCT 2015). Participants that completed 24
weeks of treatment were eligible to enrol into an open-label exten-
sion phase which lasted up to 104 weeks with an interim analysis
at 12 weeks (KONTINUE 2017). Data from KONTINUE were
not eligible for inclusion as participants were not re-randomised
(KONTINUE 2017).
All trials were conducted at multiple centres (Accurso 2010;
ENVISION 2013; DISCOVER 2011; KONDUCT 2015;
STRIVE 2011). The F508del trial was run across 34 sites in North
America (DISCOVER 2011). Although this trial recruited partic-
ipants with a class II mutation, we included it in the initial version
of the review on the basis that the trial evaluated ivacaftor and
its effect of the minimal amount of CFTR reaching the cell sur-
face in this mutation. The phase 2 G551D trial recruited partici-
pants from 13 sites in North America and Europe (Accurso 2010).
The paediatric G551D trial (65 sites) and the adult G551D trial
(29 sites) were conducted in North America, Europe and Aus-
tralia (ENVISION 2013; STRIVE 2011). The phase 3 R117H
trial was conducted at 31 sites across Europe and North America
(KONDUCT 2015).
Outcome data were reported at time frames ranging from 2 to
48 weeks (Accurso 2010; ENVISION 2013; DISCOVER 2011;
KONDUCT 2015; STRIVE 2011).
Participants
All 447 participants in the included trials had a confirmed diag-
nosis of CF. The F508del trial examined the effect of ivacaftor on
people homozygous for the F508del mutation (class II mutation)
(DISCOVER 2011). In the three G551D trials (class III muta-
tion), participants were required to possess at least one G551D-
CFTR allele (Accurso 2010; ENVISION 2013; STRIVE 2011).
TheR117H trial required participants to have at least one R117H-
CFTR allele (KONDUCT 2015).
Two trials recruited recruited participants aged 12 years and older
(DISCOVER 2011; STRIVE 2011); participants in the F508del
trial had a mean age of 25.5 years (DISCOVER 2011) and par-
ticipants in the adult G551D trial had a mean age of 23.2 years
(STRIVE 2011). The phase 2 G551D trial recruited participants
aged 18 years and over and participants had a median 21 age of
years (Accurso 2010). The paediatric phase 3G551D trial enrolled
participants aged 6 to 11 years of age and participants had a mean
age of 8.9 years (ENVISION 2013). The R117H trial recruited
those over 6 years of age and participants had a mean age of 31
years (KONDUCT 2015).
In the F508del trial 140 participants were allocated in a 4:1 ratio
to either intervention or placebo (DISCOVER 2011). Sample
sizes in the G551D trials ranged between 19 participants (Accurso
2010) and 167 participants (STRIVE 2011). The phase 2 G551D
trial allocated 19 participants in a 2:2:1 ratio to either one of
two intervention groups or a placebo group respectively (Accurso
2010). In the phase 3 G551D trials, 52 children and 167 adults
were allocated in a 1:1 ratio to either intervention or placebo
(ENVISION 2013; STRIVE 2011). During randomisation, the
adults were stratified according to age (less than 18 years versus
18 years and over) and pulmonary function (less than 70% versus
70% and over of the predicted FEV1) (STRIVE 2011). Similarly,
a 1:1 ratio was used to allocate participants to intervention or
placebo groups in the R117H trial; participants were stratified by
age (6 to 11 years, 12 to 17 years, and 18 years and over) and %
predicted FEV1 (< 70%, ≥ 70% to ≤ 90% and > 90%) during
randomisation (KONDUCT 2015).
All participants had a baseline FEV1 reading of 40% or over for
age, sex and height and where baseline information was avail-
able, similar characteristics were seen (Accurso 2010; ENVISION
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2013; DISCOVER 2011; KONDUCT 2015; STRIVE 2011).
Interventions
Ivacaftor was the intervention drug in all included trials (Accurso
2010; ENVISION2013; DISCOVER 2011; KONDUCT 2015;
STRIVE 2011). Four trials compared 150 mg of ivacaftor ev-
ery 12 hours to placebo (ENVISION 2013; DISCOVER 2011;
KONDUCT 2015; STRIVE 2011). The phase 2 G551D trial
compared 150 mg and 250 mg of ivacaftor every 12 hours to
placebo (Accurso 2010).
To determine the doses to be used, two G551D trials (the phase
2 trial and the paediatric phase 3 trial) conducted earlier inves-
tigations (Accurso 2010; ENVISION 2013). Ivacaftor dose lev-
els used in the phase 2 G551D trial were determined based on
pharmacokinetic modelling of data from a previous cross-over trial
(Accurso 2010). Pre-trial single-dose pharmacokinetic analysis and
phase 2a data were used to determine doses in the paediatric phase
3 G551D trial (ENVISION 2013).
Participants in four of the five included trials continued on pre-
scribed medications, that were approved for CF, during the trial
period (Accurso 2010; ENVISION 2013; DISCOVER 2011;
STRIVE 2011). No information was provided for the R117H
trial regarding how drug dosage was determined or whether par-
ticipants continued taking prescribed medications (KONDUCT
2015).
Outcomes
The primary end points in the trials were safety (Accurso 2010) or
absolute change in FEV1 (ENVISION 2013; KONDUCT 2015;
STRIVE 2011) or both (DISCOVER 2011).
All trials employed the CFQ-R respiratory domain to mea-
sure QoL (Accurso 2010; ENVISION 2013; DISCOVER 2011;
KONDUCT2015; STRIVE 2011). One trial reported data for all
domains (Accurso 2010). In the adult phase 3 G551D trial, data
for other CFQ-R domains were reported where improvements
were seen in the ivacaftor group (STRIVE 2011). Relative change
from baseline in FEV1 was reported in the full text by four trials
(Accurso 2010; DISCOVER 2011; KONDUCT 2015; STRIVE
2011) and in a conference abstract by the fifth trial (24-week in-
terim data only) (ENVISION 2013).
All trials reported on the safety profile of ivacaftor and the to-
tal number of participants who developed pulmonary exacer-
bations (Accurso 2010; ENVISION 2013; DISCOVER 2011;
KONDUCT 2015; STRIVE 2011). The adult G551D trial and
R117H trial also reported data for hospitalisation and number of
days of hospitalisation (KONDUCT 2015; STRIVE 2011). Three
trials reported on the number of participants who required ex-
tra courses of antibiotics (DISCOVER 2011; KONDUCT 2015;
STRIVE 2011).
All trials examined the effect of ivacaftor on absolute change
in FEV1 (Accurso 2010; ENVISION 2013; DISCOVER 2011;
KONDUCT 2015; STRIVE 2011). Two trials reported on ab-
solute change from baseline in FEV1 for subgroups, according to
pulmonary function, geographic region and gender (ENVISION
2013; STRIVE 2011).
Three trials reported on weight (change from baseline), BMI and
BMI as z score for age (ENVISION 2013; DISCOVER 2011;
STRIVE 2011) and one trial reported change in BMI from base-
line (KONDUCT 2015). Two trials reported on height z scores
(ENVISION 2013; STRIVE 2011).
All included trials reported on change from baseline in sweat
chloride concentration (Accurso 2010; ENVISION 2013;
DISCOVER 2011; KONDUCT 2015; STRIVE 2011).
Nasal potential difference, a primary outcome in the Accurso trial,
was not included in this review, as it is not yet a validated outcome
measure (Accurso 2010).
Excluded studies
A total of 62 trials (115 references) were listed as ex-
cluded. We excluded 12 trials which were of cross-over de-
sign (Altes 2011; Berkers 2017; Edgeworth 2017; Davies
2012; KONNECTION 2013; EudraCT Number: 2016-
001619-19; McGarry 2015; NCT01685801; NCT01784419;
NCT02709109; NCT02742519; NCT03068312) and one trial
which carried out secondary analysis on trials of cross-over
design (Accurso 2013). Eleven trials were excluded as they
used treatments to correct the molecular defect and were not
potentiators (ALBATROSS 2017; Chadwick 1998; Clancy
2012; FLAMINGO 2017; Horsley 2018; McCarty 2002;
NCT03474042; NCT02323100; Rubenstein 1998; Rubenstein
2006; Zeitlin 2002). Six trials were excluded as they exam-
ined stop codon therapies for class I mutations (Kerem 2014;
Pradal 2002; Romano 2000; Sermet-Gaudelus 2010; Wilschanski
2003; Wilschanski 2008). We excluded 12 trials due to an ob-
servational study design (EudraCT Number: 2016-001440-18;
Hubert 2018; NCT01549314; NCT01863238; NCT02039986;
NCT02141464; NCT02311140; NCT02445053;
NCT02722057; NCT03390985; NCT03652090; Seliger
2015) and a further 12 trials were excluded as they
had a single interventional arm with no comparator (
ARRIVAL 2018; Davies 2016; EudraCT Number: 2014-
000817-30; NCT01946412; NCT02310789; NCT02690519;
NCT02707562; NCT02934698;
NCT03256799; NCT03256968; NCT03277196; PERSIST
2014). Three trials used treatments to amplify or modify the
molecular defect rather than potentiate it (NCT02718495;
NCT02724527; NCT03258424). Four trials did not use mu-
tation-specific treatments e.g. antibiotic therapy (EUudraCT
Number: 2016-001785-29; NCT02443688; NCT02759562;
RIO-CF 2017). One trial excluded people with CF (TOPIC
2018).
We excluded 79 trials (110 references) comparing potentiator and
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corrector combination therapy to placebo, but these have not been
referenced within the list of excluded studies as a separate system-
atic review has been conducted which focuses on combination
therapy (Southern 2018).
Studies awaiting classification
Two trials are listed as awaiting classification (Kazani 2016;
Uttamsingh 2016), one of which has been terminated according
to the record on clinicaltrials.gov (Kazani 2016).
Trial design
Both trials are double-blind RCTs of parallel design, but one is a
phase 1 trial (Uttamsingh 2016) and the second is a phase 2 trial
(Kazani 2016). The phase 1 trial lasted for seven days with no
additional follow-up (Uttamsingh 2016). The phase 2 trial had a
duration of 14 days with a follow-up to 42 days (Kazani 2016).
Participants
In the phase 1 trial, investigators enrolled 40 participants with a
confirmed diagnosis of CF, but no details of participants’ baseline
characteristics are available (Uttamsingh 2016).
In the three-arm phase 2 trial, only the third phase of the trial
was eligible which randomised 49 adults with CF heterozygous
with one allele represented as any CFTR mutation and the other
allele must represent a class III, IV, V, VI CFTR mutation (Kazani
2016). In the phase 2 trial the mean age of participants was 31.7
years.With regards to gender split the trial randomisedmoremales
(n = 30) than females (n = 19).
Intervention
Investigators enrolled 40 participants and allocated them in a 4:1
ratio to either intervention or placebo (Uttamsingh 2016). CTP-
656 (a deuterated analogue of ivacaftor) was used as the interven-
tion drug. Participants received either 75mg, 150mg, or 225mg of
CTP-656. Dose escalation was initiated only after safety and tol-
erability were found to support proceeding to the higher dose. All
participants were dosed under fed conditions; a high-fat breakfast
was provided on Day 1 through Day 7 approximately 30 minutes
prior to dosing (Uttamsingh 2016). (Since this trial was under-
taken CTP-656 has been sold by its developers (Concert Pharma-
ceuticals Inc.) to Vertex and has been renamed VX-561.)
The phase 2 trial compared QBW251 (a membrane-associated
wild-type CFTR potentiator) at two doses - 150 mg twice daily
and 450 mg twice daily - to placebo. The 450 mg daily dose group
was split into participants with a number of different mutations
(n = 12) and a second group who were homozygous for F508del
(n = 19) (Kazani 2016).
Outcomes
The phase 1 trial’s main outcome was the pharmacokinetic (PK)
profile and PK blood samples were collected at several time points
post-dose on Day 1 and Day 7, and at 12 and 24 hours post-dose
on Day 2 through Day 6. The plasma concentrations of CTP-
656 and its metabolites, (D-M1 and D-M6) were analysed by a
combination of liquid chromatography with mass spectrometry
for all three dose cohorts (Uttamsingh 2016).
In the phase 2 trial, the primary outcomes were the change in LCI
and adverse events; secondary outcomes included the change in
FEV1, the change in CFQR reported outcomes and the change
in sweat chloride. Some limited results have been published on
clinicaltrials.gov (Kazani 2016).
Risk of bias in included studies
A summary of the risk of bias judgements can be found in the
figures (Figure 2; Figure 3).
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies. This Figure demonstrates the high proportion of trials that were
judged to have a high risk of attrition bias (incomplete outcome data addressed) and selective reporting bias.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Sequence generation
Four trials reported on random sequence generation; all four em-
ployed an unblinded statistician (not otherwise associated with
the trial) to produce the final randomisation list using a code pro-
duced by the trial sponsor and we judged these to have a low risk of
bias for sequence generation (Accurso 2010; DISCOVER 2011;
KONDUCT2015; STRIVE 2011).One phase 3G551D trial did
not report on how the children were randomised and we judged
this to have an unclear risk of bias (ENVISION 2013).
Allocation concealment
Four trials reported on allocation concealment (Accurso 2010;
DISCOVER 2011; KONDUCT 2015; STRIVE 2011). Partici-
pants were allocated to groups using an interactive voice response
system (IVRS) according to the concealed randomisation list and
we judged these to have a low risk of bias with regards to allocation
concealment (Accurso 2010; DISCOVER 2011; KONDUCT
2015; STRIVE 2011). The paediatric phase 3 G551D trial did
not report on allocation concealment and we judged this to have
an unclear risk of bias (ENVISION 2013).
Blinding
Three trials reported on the blinding of trial personnel (Accurso
2010; DISCOVER2011; STRIVE 2011). All trial personnel were
blinded to participant treatment assignments. Tasks requiring un-
blinded personnel were conducted by people not otherwise in-
volved in the trials; hence we judged these three trials to have a low
risk of bias for blinding of personnel (Accurso 2010; DISCOVER
2011; STRIVE 2011). Two trials stated that they were ’double-
blinded’ but did not provide sufficient information to allow a
clear judgement giving an unclear risk of bias (ENVISION 2013;
KONDUCT 2015).
With regards to the blinding of participants, none of the included
trials reported details of the oral tablets such as colour, size, con-
sistency or taste; therefore we judge them all to have an unclear
risk of bias with regards to the blinding of participants (Accurso
2010; DISCOVER 2011; ENVISION2013; KONDUCT 2015;
STRIVE 2011).
Incomplete outcome data
There was low attrition (less than 15%) in all included tri-
als (Accurso 2010; DISCOVER 2011; ENVISION 2013;
KONDUCT 2015; STRIVE 2011).
In the phase 2 G551D trial, one participant withdrew consent
prior to dosing, but all 19 remaining participants completed the
trial and were included in the analysis of reported outcomes; there-
fore, we judged this trial to have a low risk of attrition bias (Accurso
2010). In the R117H trial, two participants from the ivacaftor
group withdrew after dosing due to one participant becoming
pregnant and one for non-compliance. All 69 participants who
received at least one dose of the trial drug were included in the
analysis. We judged this trial to also have a low risk of attrition
bias (KONDUCT 2015).
In the remaining three trials, some participant data were excluded
from the analysis and these trials were judged to have a high risk
of attrition bias (DISCOVER 2011; ENVISION 2013; STRIVE
2011).
A total of 10 participants (7.1%) withdrew from the F508del
trial (DISCOVER 2011); eight out of 112 (7.1%) participants
withdrew from the ivacaftor group (three due to adverse events,
two for non-compliance, one refused medication, one was lost to
follow up; and one due to “early termination per sponsor deci-
sion”) and two participants out of 28 (7.1%) withdrew from the
placebo group due to adverse events (DISCOVER 2011). Partic-
ipant data were excluded from the analysis of the change from
baseline in sweat chloride concentration (one participant excluded
from the ivacaftor group) and the absolute change from base-
line in FEV1 (one participant excluded from the ivacaftor group).
The author was approached for information on these missing data
(DISCOVER 2011).
In the paediatric phase 3 G551D trial, 4 out of 52 children (7.7%)
withdrew from the placebo group, one for each of the following
reasons: adverse events; refusal of medication; withdrawal of con-
sent; andwrong genotype. Participant datawere excluded from the
analysis for absolute change from baseline in % predicted FEV1
(one child excluded from placebo group), change from baseline in
sweat chloride concentration (three children excluded from iva-
caftor group and three children excluded from the placebo group)
and CFQ-R respiratory domain paediatric version (one child ex-
cluded from placebo group). The author was approached for in-
formation on these missing data and revealed that a modified in-
tention-to-treat analysis (not per protocol) was employed, where
data were excluded from the analysis (ENVISION 2013).
In the adult phase 3 G551D trial, 10 out of 167 participants
(6.0%) withdrew from the placebo group; four due to adverse
events, one on the physician’s decision, two required prohibited
medication; one withdrew consent; one was the wrong genotype;
and one had “Increased Lab Draws/Difficult Lab Stick”. Six out of
167 participants (3.6%) withdrew from the ivacaftor group; one
due to adverse events; two for non-compliance; one became preg-
nant; one refused medication; and one withdrew consent. After
these 16 randomised participants (9.6%) withdrew, a total of 161
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participants (78 in the placebo group and83 in the ivacaftor group)
were included in the analysis. However, in the analysis of change
from baseline in CFQ-R respiratory domain scores, data from 10
participants (seven participants from the placebo group and three
participants from the ivacaftor group) were excluded; and data
from nine participants (four participants from the placebo group
and five participants from the ivacaftor group) were excluded from
the analysis of the change from baseline in sweat chloride con-
centration. The author was approached for information on these
missing data (STRIVE 2011).
Selective reporting
Trial protocols were available for the phase 2 G551D and the
adult phase 3 G551D trials (Accurso 2010; STRIVE 2011). In
the phase 2 trial, weight was measured at days 1, 3, 14, 21 and
28, but not reported. In such a trial, the change in weight of
participants from baseline is a key outcome and by not reporting
this outcome, the trial is at high risk of selective reporting bias
(Accurso 2010). In the adult trial, the following tertiary outcomes
were not reported in the full text: change from baseline in oxygen
saturation; change from baseline in EuroQol Questionnaire (EQ-
5D); and outpatient sick visits to the clinic or hospital for CF-
related complications. Also CFQ-R domain scores were reported
for domains where improvements were seen in the ivacaftor group
only.Hence, this trial was also judged tohave a high risk of selective
reporting bias (STRIVE 2011).
Full protocols were not available, either online or upon request, for
the remaining three trials (DISCOVER 2011; ENVISION 2013;
KONDUCT 2015). In the paediatric phase 3 G551D trial, FVC
was measured at days 1 and 15, then at weeks 8, 16, 24, 32, 40
and 48; but results were not reported in the full text; also, relative
change in FEV1 from baseline was reported at 24 weeks, but not
at any other time point (ENVISION 2013). In such trials, the
change from baseline in FVC and relative change from baseline in
FEV1 are key outcomes and by not reporting these outcomes, the
trial is at high risk of selective reporting (ENVISION 2013). In
the F508del trial, there weremissing data for change from baseline
in FEV1 score (at day 15 and week 8) and in change from base-
line in FVC or mid-forced expiratory flow (FEF25-75%) mea-
sured throughout the trial. Also, one withdrawal from the ivacaftor
group was due to “early termination per sponsor decision” and at-
tempts to illicit further information about this were unsuccessful;
we therefore found the risk of selective reporting in this trial to be
high (DISCOVER 2011). In the R117H trial, a protocol synopsis
was made available by the trial sponsor which reported a number
of tertiary outcomes; however, no results were made available for
these outcomes. We therefore judged the trial to be at high risk of
selective reporting bias (KONDUCT 2015).
Other potential sources of bias
The baseline characteristics of participants were similar in all
included trials (Accurso 2010; ENVISION 2013; DISCOVER
2011; KONDUCT 2015; STRIVE 2011).
In the phase 2 G551D trial, drug dosing was monitored by clinical
staff via returned dosage units and dosing diaries; an adherence
rate of 100% (range 92.6 to 100) was achieved (Accurso 2010).
In the paediatric phase 3 G551D trial, reviewing dosing with par-
ticipants and caregivers ensured correct doses were taken; mean
rates of compliance of 94.4% in the ivacaftor group and of 95.7%
in the placebo group were reported (ENVISION 2013). Two tri-
als ensured adherence by drug accountability (DISCOVER 2011;
STRIVE 2011). No information was provided regarding drug ad-
herence for the R117H trial (KONDUCT 2015).
In the R117H trial additional age subgroup analyses were per-
formed for participants aged 6 to 11 years and≥ 18 years, however,
there were only two participants between 12 to 17 years of age so
no statistical analysis was performed for this group (KONDUCT
2015). No reason was provided for the low numbers in 12 to 17
age group (KONDUCT 2015).
All trials were funded by a single company, Vertex Pharmaceuticals
Incorporated (Accurso 2010; DISCOVER 2011; ENVISION
2013; KONDUCT 2015; STRIVE 2011).
Effects of interventions
See: Summary of findings for themain comparison Summary of
findings - ivacaftor compared with placebo for cystic fibrosis with
the F508del CFTR mutation; Summary of findings 2 Summary
of findings - ivacaftor compared with placebo for cystic fibrosis
with at least one G551D CFTR mutation; Summary of findings
3Summary of findings - ivacaftor comparedwith placebo for cystic
fibrosis with at least one R117H CFTR mutation
In the summary of findings tables, the quality of the evidence has
been graded for pre-defined outcomes (see above) and definitions
of these gradings provided.
Ivacaftor versus placebo
Primary outcomes
1. Survival
No survival data or deaths were reported by any of the included
trials (n = 447) (Accurso 2010; DISCOVER 2011; ENVISION
2013; KONDUCT 2015; STRIVE 2011).
2. QoL
a. total QoL score
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None of the trials reported on total QoL scores (n = 447) (Accurso
2010; DISCOVER 2011; ENVISION2013; KONDUCT 2015;
STRIVE 2011).
b. different sub-domains
All five trials reported the CFQ-R respiratory domain scores (n
= 447) (Accurso 2010; DISCOVER 2011; ENVISION 2013;
KONDUCT 2015; STRIVE 2011). The phase 2 G551D trial
also reported scores for all other CFQ-R domains (Accurso 2010)
and the adult phase 3 G551D trial reported scores for CFQ-R
domainswhere improvements were reported in the ivacaftor group
(STRIVE 2011).
In the F508del trial, investigators reported lower scores on the
CFQ-R respiratory domain score in the ivacaftor group (MD -1.3)
at 16 weeks, but this difference was not significant (DISCOVER
2011) (moderate-quality evidence). Insufficient data for this out-
come were reported for inclusion in the analysis.
Data from both phase 3 G551D trials have not been combined as
the paediatric trial reported individual change from baseline respi-
ratory domain scores, for both children and parents or caregivers
(ENVISION2013), but the adult trial pooled theCFQ-R respira-
tory domain scores from adult and child questionnaires (STRIVE
2011). In the paediatric trial, at 24 weeks children in the ivacaftor
group reported higher CFQ-R respiratory domain scores, MD
6.10 (95% CI -1.35 to 13.55), but the difference between groups
was not significant (ENVISION 2013) (Analysis 2.1) (moderate-
quality evidence). In the same trial at 24 weeks, the parents or
caregivers of children in the ivacaftor group reported significantly
higher CFQ-R respiratory domain scores, MD 5.90 (95%CI 0.41
to 11.39) (Analysis 2.2) (moderate-quality evidence). In the adult
trial, at 24 weeks participants reported significantly higher CFQ-R
respiratory domain scores in the ivacaftor group, MD 8.10 (95%
CI 4.77 to 11.43) (STRIVE 2011) (Analysis 2.3) (moderate-qual-
ity evidence).
At 48 weeks, both children and and parents or caregivers reported
higher CFQ-R respiratory domain scores in the ivacaftor group,
MD 5.10 (95% CI -1.56 to 11.76) and MD 4.90 (95% CI -
0.39 to 10.19) respectively (Analysis 2.1; Analysis 2.2) (moderate-
quality evidence); in neither case were treatment differences sig-
nificant (ENVISION 2013). In the adult trial at 48 weeks, inves-
tigators reported significantly higher CFQ-R respiratory domain
scores in the ivacaftor group, MD 8.60 (95% CI 5.27 to 11.93)
(STRIVE 2011) (Analysis 2.3) (moderate-quality evidence). At
the same time-point, significantly higher CRQ-R scores in the
physical functioning scale (P < 0.001), social functioning scale (P
= 0.0026), eating disturbances scale (P = 0.0021) and treatment
burden scale (P = 0.0419) were observed (STRIVE 2011). Higher
scores for the body, emotion and digestive scales were also seen
but the treatment differences between groups for these domains
were not significant (STRIVE 2011).
Accurso reported on improvement in the respiratory domain score
at two weeks and four weeks using medians and ranges, preclud-
ing the analysis of these data in RevMan (Accurso 2010). At two
weeks, a median (range) increase of 5.6 (0.0 to 16.7) points was
achieved in the 150 mg ivacaftor group and 5.6 (-11.1 to 11.1)
in the 250 mg ivacaftor group. The median (range) change of 2.8
(-5.6 to 11.1) in the placebo group meant the difference between
the two treatment and the placebo groups was not significant. At
four weeks, there were no significant differences between treat-
ment groups and the placebo group; the 150 mg group reported a
median (range) improvement of 8.3 (0.0 to 16.7) points, the 250
mg group reported a median (range) improvement of 11.1 (-5.6
to 33.3) points and the placebo group reported a median (range)
improvement of 2.8 (-5.6 to 11.1) points (Accurso 2010). Accurso
also presentedmedian (range) scores for all other CFQ-R domains
which are shown in the additional tables (Table 2). None of the
improvements were significant (Accurso 2010) (moderate-quality
evidence).
In the R117H trial, investigators reported a significant improve-
ment in the CFQ-R respiratory domain scores in the ivacaftor
group, MD 8.40 (95% CI 2.17 to 14.63) (KONDUCT 2015)
(Analysis 3.1) (moderate-quality evidence). The treatment effect
was adjusted for continuous baseline values of age and % pre-
dicted FEV1 (KONDUCT 2015). The R117H trial conducted a
further subgroup analysis by age, which only showed a significant
improvement in the respiratory domain score for adults in the iva-
caftor group and not children (Table 3).
3. FEV1 (relative change from baseline)
All included trials reported this outcome (n = 447) (Accurso
2010; DISCOVER 2011; ENVISION 2013; KONDUCT 2015;
STRIVE 2011).
At 16 weeks investigators reported no significant difference in
the relative change from baseline in FEV1 between groups in the
F508del trial, MD 2.40% (95% CI -0.95 to 5.75) (DISCOVER
2011) (Analysis 1.1) (moderate-quality evidence).
At 24 weeks in the phase 3 G551D trials, both children and adults
in the ivacaftor group reported significant improvements in the rel-
ative change from baseline in FEV1 (ENVISION 2013; STRIVE
2011). For the paediatric trial, only interim data were reported in
a conference abstract which were insufficient for inclusion into the
meta-analysis, MD 17.4% (P < 0.0001) (ENVISION 2013); but
for the adult trial investigators reported MD 16.90% (95% CI
13.60 to 20.20) (Analysis 2.4). Data at 48 weeks were not reported
in the paediatric trial (ENVISION 2013); however, the adult trial
reported a significant improvement in the relative change from
baseline in FEV1 in the ivacaftor group at 48 weeks, MD 16.80%
(95% CI 13.50 to 20.10) (STRIVE 2011) (Analysis 2.4) (moder-
ate-quality evidence).
Again Accurso reported medians (range) from the phase 2 G551D
trial; at four weeks there was a relative improvement from baseline
in % predicted FEV1 of 8.7% (2.3 to 31.3) in the 150 mg group,
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4.4% (0.0 to 18.3) in the 250 mg group and 7.3% (5.2 to 8.2) in
the placebo group (Accurso 2010). Treatment differences between
ivacaftor arms and the placebo group were not significant (Accurso
2010) (moderate-quality evidence).
In the R117H trial, investigators included the relative change from
baseline in FEV1 data in a results table; however, the absolute
change in FEV1 was a primary outcome and this was the focus of
the text (KONDUCT 2015). At 24 weeks investigators reported
no significant difference in the relative change from baseline in
FEV1 between treatment groups MD 5.00% (95% CI -0.24 to
10.24) (Analysis 3.2) (moderate-quality evidence). Treatment ef-
fect was adjusted for continuous baseline values of age and % pre-
dicted FEV1 (KONDUCT 2015).
Secondary outcomes
1. Adverse effects
All included trials reported the number of participants who ex-
perienced adverse effects (n = 447) (Accurso 2010; DISCOVER
2011; ENVISION 2013; KONDUCT 2015; STRIVE 2011).
The F508del trial reported the number of participants who expe-
rienced adverse effects that occurred in at least 5% of participants
taking ivacaftor (DISCOVER 2011) (Analysis 1.2). Accurso re-
ported the number of participants who experienced any adverse
effect in the phase 2 G551D trial (Accurso 2010); we have pooled
data for the 150 mg group and 250 mg group and compared these
to the placebo group (Analysis 2.6). Both phase 3 G551D trials
reported the number of participants who experienced any serious
adverse effect and the number of participants who experienced all
adverse effects that occurred inmore than 5% of participants in ei-
ther treatment arm (ENVISION 2013; STRIVE 2011). We have
combined the data from both trials (Analysis 2.5). Serious adverse
effects were defined as life-threatening or debilitating, which is
consistent with our definition of severe. The R117H trial reported
the number of participants with any adverse event, serious adverse
events (the authors’ definition of a serious adverse event was not
present in the text), adverse events leading to discontinuation and
adverse events occurring in 15% of participants in any ivacaftor
treatment group (KONDUCT 2015) (Analysis 3.3; Analysis 3.4).
For the F508del trial, phase 3 G551D trials and the R117H trial,
we have reported on adverse effects that occurred more frequently
in either the ivacaftor or placebo groups where there was greater or
equal to 5% incidental difference between groups in the number
of participants affected (DISCOVER 2011; ENVISION 2013;
KONDUCT 2015; STRIVE 2011). Given the small sample size
in the phase 2 G551D trial by Accurso (n = 19), we have not
reported on the most common adverse effects from this trial (
Accurso 2010). For all trials we have present below the results that
were statistically significant in trial reports. Where numerical data
were not provided, we have discussed the results narratively.
a. mild (therapy does not need to be discontinued)
In the F508del trial, episodes of cough, nausea, rash and con-
tact dermatitis were experienced by more participants assigned
to ivacaftor compared to those assigned to placebo. Pulmonary
exacerbations were more common in participants in the placebo
group (DISCOVER 2011) (Analysis 1.2) (low-quality evidence).
In the adult phase 3 G551D trial, more adults in the placebo
group experienced episodes of pulmonary exacerbation, cough,
haemoptysis, and decreased pulmonary function in comparison
to participants in the ivacaftor group. Adverse effects that oc-
curred in more adults in the ivacaftor group were headache, upper
respiratory tract infection, nasal congestion, rash, and dizziness
(STRIVE 2011) (Analysis 2.5) (low-quality evidence). In the pae-
diatric phase 3 G551D trial, episodes of cough, productive cough,
vomiting, rales, and decreased pulmonary function were experi-
enced by more children in the placebo group in comparison to
children in the ivacaftor group. Episodes of oropharyngeal pain,
headache, nasopharyngitis, upper respiratory tract infection, otitis
media, diarrhoea, and an increased blood eosinophil count were
reported in more children in the ivacaftor group (ENVISION
2013) (Analysis 2.5) (low-quality evidence). In the R117H trial
more episodes of nasal congestion, oropharyngeal pain, abdom-
inal pain, wheeze and CF lung pathogen colonisation were ex-
perienced in the ivacaftor group compared to the placebo group
(KONDUCT 2015) (Analysis 3.4) (low-quality evidence).
There were no statistically significant differences at the 1% signif-
icance level to allow for multiple analyses related to adverse events
in any of the included trials (Analysis 2.5; Analysis 2.6, Analysis
1.2; Analysis 3.4).
b. moderate (therapy is discontinued and the adverse effect
ceases)
The F508del trial and both phase 3 G551D trials reported
the number of participants who experienced adverse effects that
required interruption of the intervention (DISCOVER 2011;
ENVISION 2013; STRIVE 2011). The R117H trial did not re-
port any participants requiring interruption of the intervention
(KONDUCT 2015).
In the F508del trial, two participants in the ivacaftor group (1.8%)
stopped receiving the interventiondue to elevated liver enzyme val-
ues; but the intervention was subsequently restarted as both cases
were found to be caused by concurrent pathology (DISCOVER
2011). No trial drug interruption occurred in the placebo group.
The difference between groups in number of participants who re-
quired trial interruption was not significant, OR 1.29 (95% CI
0.06 to 27.62) (Analysis 1.3) (low-quality evidence). In the pae-
diatric phase 3 G551D trial, three participants from the placebo
group experienced adverse effects requiring interruption of the in-
tervention compared to one participant in the ivacaftor group; but
the details of these adverse events were not reported (ENVISION
2013) (low-quality evidence). In the adult trial, 11 adverse events
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in the ivacaftor group (13.3%) compared to four in the placebo
group (5.1%) required trial drug interruption. Adverse events in
the ivacaftor group were: haemoptysis (n = 1); migraine (n = 1);
upper respiratory tract infection (n = 1); pulmonary exacerbation
(n = 1); increased hepatic enzyme (n = 2); pulmonary exacerbation
and anaphylactic shock (n = 1); lymph node pain and gynaeco-
mastia (n = 1); myalgia and diarrhoea (n = 1); decreased weight
and pulmonary exacerbation (n = 1); and vulvovaginal mycotic
infection, oral candidiasis and two episodes of pulmonary exac-
erbation (n = 1). Adverse events in the placebo group were: mi-
graine (n = 1); pulmonary exacerbation (n = 1); increased blood
lactate dehydrogenase and increased hepatic enzymes (n = 1); and
rash, nephrolithiasis and renal colic (n = 1). Investigators reported
that five participants in the placebo group required drug interrup-
tion; however, one of these participants subsequently withdrew
from the trial and will be discussed under ’severe’ adverse events
(STRIVE 2011) (low-quality evidence). Combined data for both
phase 3 G551D trials showed no significant difference between
treatment arms, OR 1.18 (95% CI 0.14 to 9.92) (Analysis 2.7)
(low-quality evidence). Heterogeneity was substantial (I² = 64%)
which is possibly due to the difference in ages between the adult
and paediatric trials.
c. severe (life-threatening or debilitating, or which persists
even after treatment is discontinued)
All included trials reported the number of participants who de-
veloped adverse effects that required discontinuation of the inter-
vention (Accurso 2010; DISCOVER 2011; ENVISION 2013;
KONDUCT 2015; STRIVE 2011).
In the F508del trial, three participants in the ivacaftor group
(2.7%) discontinued due to asthenia, fatigue and headache (n =
1), arthritis (n = 1) and myopathy (n = 1); a further participant
in this group developed fatigue, depression and suicidal ideation
that was considered to be life-threatening (DISCOVER 2011).
In comparison, two participants in the placebo group (7.1%) dis-
continued medication because of abnormal feelings of cognitive
disorder (n = 1) and elevated liver enzymes and increased lactate
dehydrogenase levels (n = 1). The abnormal liver enzyme profile
was considered to be caused by concomitant use of an anabolic
steroid like a nutritional supplement (DISCOVER 2011). The
number of participants requiring trial drug discontinuation be-
tween treatment arms was not significant, OR 0.36 (95% CI 0.06
to 2.25) (Analysis 1.3) (low-quality evidence).
In the paediatric phase 3 G551D trial, one participant from the
placebo group withdrew due to anxiety and psychological issues
(ENVISION 2013). In the adult trial, four participants from the
placebo group withdrew from the trial; one each due to increased
hepatic enzyme levels, atrioventricular block, panic attack and res-
piratory failure. There was one dropout from the ivacaftor group
due to increased hepatic enzymes (STRIVE 2011). Combined
data for the phase 3 G551D trials showed no significant difference
between treatment arms in the number of participants discontin-
uing the trial drug, OR 0.25 (95% CI 0.04 to 1.57) (Analysis 2.7)
(low-quality evidence). Likewise, combined data from the two tri-
als for serious adverse effects, did not show an increase with iva-
caftor compared with placebo (Analysis 2.8), with the exception
of pulmonary exacerbation which will be discussed under other
adverse effects of therapy (below).
No severe adverse effects were reported in any of the participants
in the phase 2 G551D trial and all adverse events resolved without
discontinuation of the intervention (Accurso 2010) (low-quality
evidence).
The R117H trial reported six (17%) severe adverse events in the
placebo group and four (12%) in the ivacaftor group with no
participants discontinuing the intervention due to adverse events
(KONDUCT 2015). There was no significant difference in the
number of serious adverse events between treatment arms, OR
0.64 (95% CI 0.16 to 2.52) (Analysis 3.3) (low-quality evidence).
d. other adverse effects of therapy (of any severity) that are
not classifiable according to these categories
The number of participants who experienced episodes of pul-
monary exacerbation was reported by all trials (Accurso 2010;
DISCOVER 2011; ENVISION 2013; KONDUCT 2015;
STRIVE 2011) (low-quality evidence). In all cases pulmonary ex-
acerbations were protocol-defined; both phase 3 G551D trials and
also the F508del trial employed the same definition (DISCOVER
2011; ENVISION 2013; STRIVE 2011), but this was different
to the definition employed by the phase 2 G551D trial (Accurso
2010). The R117H trial reported protocol-defined pulmonary ex-
acerbations, but the full protocol was not available to determine
this definition (KONDUCT 2015). Data for all G551D partic-
ipants in this review are shown separately (Analysis 2.9). In the
adult phase 3 G551D trial, there were minor differences in the
number of participants experiencing episodes of pulmonary exac-
erbations between the full text, supplementary appendix and an
online trials database ( clinicaltrials.gov).Datawere extracted from
the online trials database where data for serious and other cases of
pulmonary events were reported.
In the phase 2 G551D trial, one participant from each of the treat-
ment arms experienced an exacerbation compared to none in the
placebo group (Accurso 2010); when analysed, there was no sig-
nificant difference in the number of participants who experienced
pulmonary exacerbations between the ivacaftor group (combined
data from 150 mg and 250 mg groups) and the placebo group at
onemonth,OR1.67 (95%CI 0.07 to 41.64) (Analysis 2.9). In the
phase 3 G551D trials, at 48 weeks significantly fewer participants
in the ivacaftor group experienced serious episodes of pulmonary
exacerbations compared to participants in the placebo group, OR
0.34 (99% CI 0.13 to 0.88) (Analysis 2.8). Combined data for all
exacerbations in these trials was not significant between groups at
this time-point, OR 0.64; 95% CI 0.36 to 1.12) (Analysis 2.9). In
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the adult trial, the meta-analysis of all exacerbations shows signif-
icantly fewer participants in the ivacaftor group experienced exac-
erbations than in the placebo group, OR 0.54 (95% CI 0.29 to
1.01) (STRIVE 2011) (Analysis 2.9). In the F508del trial, inves-
tigators reported a non-significant lower frequency of pulmonary
exacerbations in the ivacaftor group, OR 0.44 (99% CI 0.14 to
1.41) (Analysis 1.2).
The adult phase 3 G551D trial reported data for the time-to-first
pulmonary exacerbation (STRIVE 2011). At 24 weeks, a signif-
icantly greater proportion of participants in the ivacaftor group
(78%) were exacerbation-free in comparison to participants in the
placebo group (51%). This corresponds to a hazard ratio (HR)
of 0.46 (95% CI 0.28 to 0.76) (P = 0.002) so within the first 24
weeks, adults receiving ivacaftor were 54% less likely to experience
an exacerbation than those assigned to placebo (Analysis 2.10).
At 48 weeks, 67% of participants in the ivacaftor group and 41%
of participants in the placebo group were exacerbation-free, HR
0.46 (95%CI 0.29 to 0.73), and the difference between groups re-
mained significant (P < 0.001) (Analysis 2.10) (moderate-quality
evidence). Therefore during the 48-week trial period, participants
receiving ivacaftor were 54% less likely to experience an exacerba-
tion than those assigned to placebo (STRIVE 2011).
The R117H trial reported that at 24 weeks there was no sig-
nificant difference between treatment groups for the time-to-
first pulmonary exacerbation, HR 0.93 (95% CI 0.42 to 2.08)
(KONDUCT 2015) (Analysis 3.6) (moderate-quality evidence).
Additionally, there was no significant difference between the iva-
caftor and placebo groups in the number of participants experi-
encing a pulmonary exacerbation, OR 0.81 (95%CI 0.30 to 2.19)
(Analysis 3.5).
There was no significant difference in the hepatic enzyme profile
between groups in either phase 3 G551D trial (Analysis 2.5;
Analysis 2.11). The majority of participants in the F508del trial
had aspartate aminotransferase (AST), alanine aminotransferase
(ALT) and bilirubin values less than or equal to two times ULN
(DISCOVER 2011).
2. Hospitalisation
The adult phase 3 G551D trial (n = 167) reported on the number
of hospitalisations for episodes of pulmonary exacerbation and also
on the number of days admitted (STRIVE 2011). The R117H
trial reported the number of hospital admissions for episodes of
pulmonary exacerbation (KONDUCT 2015).
a. number of days
In the G551D trial, of the episodes of pulmonary exacerbation
that required hospitalisations, those occurring in participants in
the ivacaftor group required less time in hospital, MD -0.23 days
(95% CI -3.74 to 3.28) (Analysis 2.12). We note this non-signifi-
cant summary statistic conflicts with the trial report. The Supple-
mentary table 2B of the supplementary appendix reports a P value
of 0.0275 for this difference; however, this has been calculated
from aWilcoxon rank-sum test, stratified by baseline % predicted
FEV1 severity and age group (STRIVE 2011). This is a non-para-
metric test used when data are skewed and where values are usually
given as medians and ranges. In this trial, however, mean and SDs
have been reported. As stated above, after entering these data into
Review Manager, we have calculated a different P value of 0.90
which was not significant (Analysis 2.12).
b. number of episodes
Similarly, in the G551D trial significantly fewer episodes of pul-
monary exacerbation required hospitalisation in participants in
the ivacaftor group, OR 0.37 (95% CI 0.16 to 0.81) (Analysis
2.13) (STRIVE 2011). The R117H trial did not show a signifi-
cant difference between treatment groups in the number of partic-
ipants requiring hospital admission for pulmonary exacerbations
(Analysis 3.5) (KONDUCT 2015).
3. School or work attendance
No individual data for school or work attendance was reported by
any trial (n =447) (Accurso 2010;DISCOVER2011; ENVISION
2013; KONDUCT 2015; STRIVE 2011).
4. Other physiological measures of lung function
a. FEV1 (absolute values)
All included trials reported on the absolute change frombaseline in
FEV1 (n = 447) (Accurso 2010; DISCOVER 2011; ENVISION
2013; KONDUCT 2015; STRIVE 2011). For the four phase
three trials, this outcome was a primary endpoint (DISCOVER
2011; ENVISION 2013; KONDUCT 2015; STRIVE 2011).
The data in the paediatric phase 3 G551D trial were adjusted
based on the continuous baseline value of % of predicted FEV1
(ENVISION 2013). Data in the R117H trial were adjusted
for continuous baseline values of age and % predicted FEV1
(KONDUCT 2015).
Investigators reported no significant differences between groups
in the F508del trial for change from baseline of % predicted FEV1
at 16 weeks, MD 1.70% (95% CI -0.65 to 4.05) (DISCOVER
2011) (Analysis 1.4) (moderate-quality evidence).
Both phase 3 G551D trials reported results early (day 15), but we
are unable to include these results in our analysis (ENVISION
2013; STRIVE 2011). At this time point, an estimated MD of
13.0% points can be deduced from the graph (Figure 2 in the
full paper) for the paediatric trial (ENVISION 2013) and the
adult trial reported a significant MD of 9.2% points (P < 0.001)
(STRIVE 2011). At 24 weeks combined data from both of these
trials show a significant increase in FEV1 (% predicted) from base-
line in the ivacaftor group, MD 10.80% (95% CI 8.91 to 12.69)
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(P < 0.00001) with no heterogeneity (I² = 0%) (Analysis 2.14)
(low-quality evidence). Combined data at 48 weeks still demon-
strate a significant change from baseline in FEV1 (% predicted),
MD10.44% (95%CI 8.56 to 12.32), again with no heterogeneity
(I² = 0%) (Analysis 2.14) (low-quality evidence). For the change
from baseline in FEV1 (L), combined data at 24 weeks show a
significant increase in in the ivacaftor group, MD 0.33 L (95%
CI 0.17 to 0.49), but with considerable heterogeneity (I² = 85%)
(Analysis 2.15) (low-quality evidence). At 48 weeks the combined
data still demonstrate a significant improvement,MD0.31L (95%
CI 0.11 to 0.50), but again with considerable heterogeneity (I²
= 90%) (Analysis 2.15) (low-quality evidence). We do not know
why the I² values are different between the meta-analyses of %
predicted FEV1 and FEV1 (L); we are not able to infer anything
from it as there are only two trials in the analysis (ENVISION
2013; STRIVE 2011).
At four weeks, in the phase 2 G551D trial, investigators reported
a median (range) change from baseline in FEV1 of 0.25 L (0.05
to 0.75) in the 150 mg group, 0.17 L (0 to 0.37) in the 250 mg
group and 0.20 L (0.12 to 0.33) in the placebo group (low-quality
evidence). Treatment differences between the ivacaftor arms and
the placebo arm were not significant (Accurso 2010).
Subgroup analysis of the G551D trials
Improvements in the absolute change from baseline in FEV1
amongst pre-defined subgroups were reported at 48 weeks by the
phase 3 G551D trials (ENVISION 2013; STRIVE 2011).
In the paediatric trial at 48 weeks, children in three subgroups
demonstrated significant improvements in the change from base-
line in % predicted FEV1 in the ivacaftor group compared to the
placebo group:
• a baseline % predicted FEV1 below 90%, MD 14.90 (95%
CI 7.30 to 22.50);
• were from Europe, MD 24.60 (95% CI 6.40 to 42.80); and
• were female, MD 13.80 (95% CI 4.20 to 23.40)
(ENVISION 2013).
However, there was no significant difference in the change from
baseline in % predicted FEV1 between treatment and placebo in
the following subgroups:
• baseline % predicted FEV1 over 90%, MD 6.90% (95% CI
-3.80 to 17.60);
• from North America, MD 5.80% (95% CI -2.60 to 14.20);
• from Australia, MD 4.20% (95% CI -3.70 to 12.10); and
• male, MD 5.20% (95% CI -2.20 to 12.60) (ENVISION
2013) (Analysis 2.16).
The adult phase 3 G551D trial reported significant improvements
in FEV1 % predicted favouring ivacaftor over placebo in all sub-
groups (Table 4); insufficient data precludes inclusion of these re-
sults in a meta-analysis (STRIVE 2011).
The R117H trial reported that at 24 weeks there was no significant
treatment differences in absolute % predicted FEV1 between the
ivacaftor and placebo groups, MD 2.10% (95% CI -1.13 to 5.33)
(Analysis 3.7) (KONDUCT 2015) (low-quality evidence).
b. FVC (absolute values and change from baseline)
Three trials reported on the change frombaseline in FVC (Accurso
2010; DISCOVER 2011; STRIVE 2011). None of the data were
included in ameta-analysis as theywere either non-parametric data
(reported as median and ranges) (Accurso 2010) or insufficient
data were provided (DISCOVER 2011; STRIVE 2011).
The F508del trial reported no significant differences between
groups in FVC, but no numerical data were provided (
DISCOVER 2011).
The phase 2 G551D trial reported a relative improvement from
baseline FVC at two weeks in all three groups; there was a 9.0%
improvement in the 150 mg ivacaftor group, a 7.4% improvement
in the 250 mg ivacaftor group and a 1.0% improvement in the
placebo group (Accurso 2010). Treatment differences between the
ivacaftor groups and the placebo group were not significant. At
four weeks a median (range) change from baseline of 0.18 L (-0.29
to 0.48) in the 150 mg group, 0.09 L (-0.09 to 0.43) in the 250
mg group and 0.10 L in the placebo group were reported. These
values corresponded to relative changes from baseline of 4.6% in
the 150 mg group, 2.6% in the 250 mg group and 2.3% in the
placebo group. Treatment differences between the ivacaftor groups
and the placebo group were not significant (Accurso 2010).
The adult phase 3 G551D trial reported on the absolute change
from baseline in FVC in the form of a graph (supplemental figure
4B of the supplementary appendix) (STRIVE 2011). From the
graph, an estimated MD between intervention and placebo arms
of 11.5% at 24weeks and 7.0% at 48weeks can be deduced. These
results should be interpreted with caution, as they are not accurate
(STRIVE 2011).
5. Extra courses of antibiotics
Three trials reported on extra courses of antibiotics required by
participants (n = 376) (DISCOVER 2011; KONDUCT 2015;
STRIVE 2011).
The F508del trial reported on the number of new sinopulmonary
signs or symptom events that required new or changed antibiotic
therapy; however, the route of administration was not stated (
DISCOVER 2011). Investigators reported proportionately fewer
episodes of new sinopulmonary signs or symptom events requiring
antibiotic treatment in the ivacaftor group, OR 0.56 (95% CI
0.24 to 1.30); however, the difference was not significant (Analysis
1.5).
The adult phase 3 G551D trial reported firstly the num-
ber of episodes of pulmonary exacerbation that required in-
travenous antibiotics and secondly the number of days on in-
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travenous antibiotics to treat pulmonary exacerbations (see be-
low) (STRIVE 2011). The R117H trial reported the number of
episodes of pulmonary exacerbation requiring intravenous antibi-
otics (KONDUCT 2015).
a. oral
This outcome was not reported in any trial.
b. intravenous
In the adult phase 3 G551D trial, Ramsey reported significantly
fewer episodes of pulmonary exacerbations requiring intravenous
antibiotics occurred inparticipants in the ivacaftor group,OR0.34
(95% CI 0.18 to 0.64) (P = 0.0009) (Analysis 2.17). In addition,
more days of intravenous antibiotic administration were required
for exacerbations occurring in participants in the placebo group,
MD -4.35 (95% CI -10.51 to 1.81) (Analysis 2.18). Supplemen-
tary table 2B of the supplementary appendix reports a P value of
0.0183 for this difference; however, this has been calculated from
aWilcoxon rank-sum test, stratified by baseline %predicted FEV1
severity and age group (STRIVE 2011). This is a non-parametric
test used when data are skewed and where values are usually given
as medians and ranges. In this trial however, mean and SDs have
been reported. After entering these data into Review Manager, we
have calculated a different P value of 0.17 which was not signifi-
cant (Analysis 2.18).
In the R117H trial, investigators reported fewer episodes of pul-
monary exacerbation requiring intravenous antibiotics in the iva-
caftor group, OR 0.30 (95% CI 0.06 to 1.62), however, this result
was not significant (P = 0.16) (Analysis 3.5) (KONDUCT 2015).
c. inhaled
This outcome was not reported in either trial.
6. Radiological measures of lung disease
No trials reported chest radiograph scores or CT scores.
7. Acquisition of respiratory pathogen
No trial reported on the acquisition of any respiratory pathogens
(e.g. P aeruginosa, S aureus, H influenzae).
8. Eradication of respiratory pathogens
No trial reported on the eradication of any respiratory pathogens
(e.g. P aeruginosa, S aureus, H influenzae).
9. Nutrition and growth
a. weight
Three trials (n = 359) reported the absolute change from baseline
in weight (kg) (DISCOVER 2011; ENVISION 2013; STRIVE
2011); one of these additionally reported on weight-for-age z score
(DISCOVER 2011).
The F508del trial, reported no significant difference inweight gain
between the ivacaftor group and the placebo group at 16 weeks,
MD -0.20 kg (95% CI -1.18 to 0.78) (Analysis 1.6). There was
also no significance difference between groups in weight-for-age
z scores (MD 0.43), but insufficient data prevented inclusion of
this outcome in the analysis (DISCOVER 2011).
Combineddata from the phase 3G551Dtrials at 24weeks demon-
strated significant weight gain in the ivacaftor group, MD 2.37 kg
(95% CI 1.68 to 3.06) with moderate heterogeneity (I² = 38%)
(ENVISION 2013; STRIVE 2011) (Analysis 2.19). Combined
data from the same trials at 48 weeks also demonstrated significant
weight gain in the ivacaftor group compared to placebo, MD 2.75
kg (95% CI 1.74 to 3.75), but with no heterogeneity (I² = 0%)
(ENVISION 2013; STRIVE 2011) (Analysis 2.19).
b. BMI
Four trials reported on the change from baseline in BMI
(DISCOVER 2011; ENVISION 2013; KONDUCT 2015;
STRIVE 2011) and three additionally reported BMI for age z score
(DISCOVER2011; ENVISION2013; STRIVE 2011), but none
of them provided sufficient information for inclusion into a meta-
analysis (DISCOVER 2011; ENVISION 2013; KONDUCT
2015; STRIVE 2011).
In the F508del trial, a lowerBMI scorewas reported in the ivacaftor
group in comparison to the placebo group at 16 weeks, MD -
0.04mg/m², but the difference between groups was not significant
(DISCOVER 2011). In the phase 3 G551D trials, both children
and adults in the ivacaftor group scored significantly higher BMI
values at 48weeks,MD1.09 kg/m² (P = 0.0003) andMD0.93 kg/
m² (P < 0.0001) respectively (ENVISION 2013; STRIVE 2011).
In the F508del trial, at 16 weeks there was no significant differ-
ence between the ivacaftor group and the placebo group in BMI-
for-age z score amongst a subgroup of participants aged 20 years
or below, MD 0.75 (DISCOVER 2011). The paediatric phase 3
G551D trial reported significantly higher BMI-for-age-z scores in
the ivacaftor group compared to placebo at 24 weeks, MD 0.34
(P ≤ 0.001), and 48 weeks, MD 0.45 (P < 0.001) (ENVISION
2013). At 48 weeks, the adult phase 3 G551D trial reported signif-
icantly higher BMI-for-age-z scores in the ivacaftor group amongst
a subgroup of 47 participants aged 12 to 20 years, MD 0.33 (P =
0.0490) (STRIVE 2011).
The R117H trial reported a higher BMI score in the ivacaftor
group compared to placebo at 24 weeks,MD 0.26 kg/m² (95%CI
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-1.57 to 2.09), but this was not significant (P = 0.1) (KONDUCT
2015) (Analysis 3.8). Treatment effect was adjusted for age and
categorical % predicted FEV1 at baseline (KONDUCT 2015).
c. height
Two trials reported onheight z scores (ENVISION 2013; STRIVE
2011). The paediatric phase 3 G551D trial reported improve-
ments in the ivacaftor group at both 24 weeks (MD 0.06) and
48 weeks (MD 0.12) (ENVISION 2013). In the adult phase 3
G551D trial reported improvements in the ivacaftor group at 24
weeks (MD 0.05) and 48 weeks (MD 0.06) amongst a subset of
47 participants aged 12 to 20 years (STRIVE 2011).
10. Sweat chloride (change from baseline)
The change from baseline in sweat chloride concentration was
reported by all trials (n = 447) (Accurso 2010; DISCOVER 2011;
ENVISION 2013; KONDUCT 2015; STRIVE 2011).
In the F508del trial, investigators reported significant reductions
in sweat chloride concentration at 16 weeks in the ivacaftor group
compared to the placebo group, MD -2.90 mmol/L (95% CI -
5.60 to -0.20) (DISCOVER 2011) (Analysis 1.7).
In the phase 2 G551D trial, at four weeks there was a significant
difference in the median (range) change from baseline in sweat
chloride concentration between the 150 mg group (within group
change -59.5 mmol/L (-66.0 to -19.0) and the placebo group
(within group change 5.0 mmol/L (-2.0 to 11.0) (P = 0.02); a
similar significant difference was seen between the 250 mg group
(within group change -38.0 mmol/L (-47.0 to -10.5) and placebo
group (within group change 5.0 mmol/L (-2.0 to 11.0) (P = 0.03)
(Accurso 2010).
In the phase 3 G551D trials, reduced sweat chloride concentra-
tions were reported early (day 15) in children, MD -50 mmol/L
(estimated from a graph) (ENVISION 2013) and in adults, MD
-47.1 mmol/L (P < 0.001) (STRIVE 2011). Combined data from
these trials demonstrated significant reductions in sweat chloride
concentration at 24weeks,MD-50.19mmol/L (95%CI -56.20 to
-44.18)with amoderate level of heterogeneity (I² = 57%) (Analysis
2.20), and at 48 weeks, MD -49.74 mmol/L (95% CI -54.61 to -
44.87) with a moderate level of heterogeneity (I² = 40%) (Analysis
2.20). Secondary analysis of combined data from these trials re-
ported that the number needed to treat (NNT) for a reduction of
20 mmol/L in sweat chloride concentration was 1.03. Data from
each phase 3 G551D trial demonstrated that significant changes
in sweat chloride were reported regardless of whether participants
were FEV1 responders (5% point improvement) or minimal re-
sponders (less than 5% point improvement) (ENVISION 2013;
STRIVE 2011) (Table 5).
In the R117H trial, at 24 weeks a significant reduction in sweat
chloride concentrations was reported in the ivacaftor group com-
pared to placebo group, MD -24.00 mmol/L (95% CI -28.01 to
-19.99) (P = <0.0001) (KONDUCT 2015) (Analysis 3.9). Treat-
ment effect was adjusted for continuous baseline values of age and
%predictedFEV1 (KONDUCT2015). In addition, age subgroup
analysis showed significant reductions in sweat chloride concen-
trations for both participants aged 6 to 11 years and 18 years and
over (Table 3).
11. Cost of treatment
No trials reported on the cost of ivacaftor treatment.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Ivacaftor compared with placebo for cystic fibrosis with at least one G551D CFTR mutation
Patient or population: adults and children with cyst ic f ibrosis and with at least one G551D CFTR mutat ion
Settings: outpat ients
Intervention: ivacaf tor
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Ivacaftor
Survival
Follow-up: 2 - 48 weeks
No deaths reported. No deaths reported. NA 238
(3 studies)
NA
QoL
Total score
Follow-up: NA
Not reported. NA NA NA
QoL (CFQ-R)
Respiratory domain
Follow-up: 2 - 48 weeks
See comment.1 See comment.1 NA 222
(3 studies)
⊕⊕⊕©
moderate2
A small phase 2 trial (n
= 19) showed no signif -
icant dif f erence at 2 or
4 weeks
A phase 3 trial (n = 151)
in adults showed sig-
nif icant ly higher qual-
ity of lif e in the iva-
caf tor group compared
to placebo at 48 weeks
A phase 3 trial (n = 52)
showed no signif icant
dif f erence at 24 or 48
weeks in the child ver-
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sion of the CFQ-R. The
same trial showed a sig-
nif icant ly higher qual-
ity of lif e in the iva-
caf tor group compared
to placebo at 48 weeks
in the parent / caregiver
version at 24 weeks but
not at 48 weeks.5
FEV1 %predicted Rela-
tive change from base-
line
Follow-up: 2 - 48 weeks
See comment.1 See comment.1 NA 232
(3 studies)
⊕⊕⊕©
moderate2
A small phase 2 trial (n
= 19) showed no signif -
icant dif f erence at 2 or
4 weeks
Two phase 3 trials (n
= 213) showed a sig-
nif icant improvement in
FEV1 at 24 weeks (MD
ranged between 16.9%
to 17.4%)
One phase 3 trial (n
= 161) showed a sig-
nif icant improvement in
FEV1 at 48 weeks (MD
16.8%). 6
FEV1 L and %predicted
Absolute change from
baseline
Follow-up: 2 to 48
weeks
See comment.1 See comment.1 NA 232
(3 studies)
⊕⊕©©
low2,3
A small phase 2 trial (n
= 19) showed no signif -
icant dif f erence at 2 or
4 weeks
Two phase 3 trials (n
= 213) showed a sig-
nif icant improvement in
FEV1 (L and % pre-
dicted) at 24 weeks and
48 weeks.7
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Adverse events
Follow-up: 2 - 48 weeks
The most commonly re-
ported adverse events
in the placebo group
were: pulmonary exac-
erbat ion, cough,
oropharyngeal pain and
headache
The most commonly re-
ported adverse events
in the ivacaf tor group
were: cough, pul-
monary exacerbat ion,
upper respiratory tract
infect ion and headache
NA 232
(3 studies)
⊕⊕©©
low2,4
Pulmonary exacerba-
t ions were signif i-
cant ly more common
in the placebo group.
There was no sig-
nif icant dif f erence be-
tween groups in terms
of any other adverse
events.8
Time to first pulmonary
exacerbation
Follow-up: 48 weeks
41% of the placebo
group were exacerba-
t ion f ree at 48 weeks.
67% of the ivacaf tor
group were exacerba-
t ion f ree at 48 weeks
HR 0.46 (95%CI 0.29 to
0.73)
161
(1 study)
⊕⊕⊕©
moderate2
There was also a stat is-
t ically signif icant dif f er-
ence between groups
at 24 weeks; 78% and
51% of the ivacaf tor
and placebo groups
were exacerbat ion f ree
respect ively; HR 0.46
(95% CI 0.28 to 0.76)
* The basis for the assumed risk is the mean placebo group risk across studies, unless otherwise stated. The corresponding risk (and its 95% CI) is based on the assumed
risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CFQ-R: Cyst ic Fibrosis Quest ionnaire-Revised; CFTR: cyst ic f ibrosis transmembrane regulator; CI: conf idence interval; FEV1: f orced expiratory volume at 1 second; HR: hazard
rat io; MD: mean dif ference; QoL: quality of lif e.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1. Presentat ion of the data prevented pooling the data f rom all three studies therefore results are summarised narrat ively.
2. Downgraded once due to risk of bias f rom incomplete outcome data and/ or select ive report ing in all of the included studies.
3. Downgraded once due to unexplained heterogeneity.
4. Downgraded once due to imprecision: few events occurred therefore CIs for occurrence of specif ic events are very wide
(also see Analysis 2.5, Analysis 2.6 and Analysis 2.8).
5. See analyses for numerical results (Analysis 2.1; Analysis 2.2; Analysis 2.3).
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6. See analysis for numerical results (Analysis 2.4).
7. See analyses for numerical results (Analysis 2.14; Analysis 2.15).
8. See analyses for numerical results (Analysis 2.5; Analysis 2.6; Analysis 2.8).
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Ivacaftor compared with placebo for cystic fibrosis with at least one R117H CFTR mutation
Patient or population: adults and children with cyst ic f ibrosis and with at least one R117H CFTR mutat ion
Settings: outpat ients
Intervention: ivacaf tor
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Ivacaftor
Survival
Follow-up: 2 - 24 weeks
No deaths reported. No deaths reported. NA 69
(1 study)
NA
QoL
Total score
Follow-up: NA
Not reported. NA NA NA
QoL (CFQ-R)
Respiratory domain
Follow-up: 2 - 24 weeks
Not reported. The mean adjusted
CFQ-R respiratory do-
main score was 8.40%
higher (2.17% higher to
14.63% higher) in the
ivacaf tor group
NA 69
(1 study)
⊕⊕⊕©
moderate2
There was a signif icant
improvement in CFQ-
R respiratory domain
scores at 24 weeks.3
FEV1 %predicted Rela-
tive change from base-
line
Follow-up: 2 - 24 weeks
See comment.1 The mean adjusted
FEV1 (% predicted) was
5.00% higher (0.24%
lower to 10.24%higher)
in the ivacaf tor group
NA 69
(1 study)
⊕⊕⊕©
moderate2
There was no sig-
nif icant dif f erence be-
tween groups at 24
weeks.3
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FEV1 L and
% predicted
Absolute change from
baseline
Follow-up: 2 - 24 weeks
See comment.1 The mean adjusted
FEV1 (% predicted) was
2.10% higher (1.13%
lower to 5.33% higher)
in the ivacaf tor group
NA 69
(1 study)
⊕⊕⊕©
moderate2
There was no sig-
nif icant dif f erence be-
tween groups at 24
weeks.3
Adverse events
Follow-up: 2 - 24 weeks
The most commonly re-
ported adverse events
in the placebo group
were: pulmonary exac-
erbat ion and cough
The most commonly re-
ported adverse events
in the ivacaf tor group
were: pulmonary exac-
erbat ion,
cough, headache, nasal
congest ion, oropharyn-
geal pain, diarrhoea and
increased sputum
NA 69
(1 study)
⊕⊕©©
low2,4
There was no
signif icant dif f erence
between groups in
terms of any other ad-
verse events
Time to first
pulmonary
exacerbation
Follow-up:
24 weeks
63% of the placebo
group were exacerba-
t ion f ree at 24 weeks.
68% of the ivacaf tor
group were exacerba-
t ion f ree at 24 weeks
HR 0.93 (95%CI 0.42 to
2.08)
69
(1 study)
⊕⊕⊕©
moderate2
There was no
signif icant dif f erence
between groups at 24
weeks.
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95%CI) is based on the assumed
risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CFQ-R: Cyst ic Fibrosis Quest ionnaire-Revised; CFTR: cyst ic f ibrosis transmembrane regulator; CI: conf idence interval; FEV1: f orced expiratory volume at 1 second; HR: hazard
rat io; MD: mean dif ference; QoL: quality of lif e.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1. Presentat ion of the data prevented including data in analysis therefore results are presented narrat ively.
2. Downgraded once due to risk of bias f rom select ive report ing.
3. Treatment ef fect was adjusted for baseline values of age and % predicted FEV1.
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4. Downgraded once due to imprecision: few events occurred therefore CIs for occurrence of specif ic events are very wide
(also see Analysis 3.4)
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D I S C U S S I O N
Summary of main results
The CFTR protein product of a class III mutation is transported
to the cell membrane, but displays defective chloride ion gating
and dysregulation of sodium channels resulting in a severe CF
phenotype; characterised by chronic airway infection and inflam-
mation and pancreatic insufficiency. Agents that repair the under-
lying gating defects (CFTR potentiators) restore CFTR function
for class III mutations and correct the abnormal transmembrane
salt transport in cell and animal models (Van Goor 2009). These
CFTR potentiators may also have a role in repairing the underly-
ing gating defect in the minimal amounts of class II CFTR that
are transported to the cell membrane and for the restrictive move-
ment of chloride ions in class IV CFTR.
This review examines whether CFTR potentiators improve clin-
ically relevant endpoints in CF. Five trials with 447 participants
met the inclusion criteria for this review; one compared 150
mg and 250 mg doses of ivacaftor (a potentiator) to placebo
(Accurso 2010) and four compared 150 mg of ivacaftor to
placebo (DISCOVER 2011; ENVISION 2013; KONDUCT
2015; STRIVE 2011). Three trials examined the impact of iva-
caftor on people with a class III mutation (G551D) (Accurso
2010; ENVISION 2013; STRIVE 2011). One trial enrolled par-
ticipants with a class II mutation (F508del) (DISCOVER 2011)
and one enrolled participants with a class IV mutation (R117H)
(KONDUCT 2015).
The trial that evaluated ivacaftor for people with F508del enrolled
participants aged 12 years or over (n = 140) for a duration of 16
weeks (DISCOVER 2011). The first G551D trial was a phase
2 trial enrolling participants 18 years and over and measuring a
number of outcomes at 14 and 28 days (Accurso 2010). This was
followed by two phase 3 trials, the first enrolling participants aged
12 years and older (n = 167) (STRIVE 2011) and the second
enrolled participants aged 6 to 11 years (n = 52) (ENVISION
2013). These trials reported outcomes at 24 and 48 weeks. The
R117H trial enrolled participants over six years of age (n = 69)
and measured outcomes at 24 weeks (KONDUCT 2015).
The primary end points for these trials were safety (Accurso
2010) or change in FEV1 (ENVISION2013; KONDUCT 2015;
STRIVE 2011) or both (DISCOVER 2011). With respect to this
review’s primary outcomes, there were no deaths reported in any
of the trials and the length and size of the trials precluded valid
assessment of the impact of ivacaftor on survival. For CFQ-R
scores, no significant difference was reported in the F508del trial
(DISCOVER 2011). The adults randomised to ivacaftor in the
phase 2 G551D trial did not report significantly higher CFQ-
R respiratory domain scores 28 days (Accurso 2010). However,
adults in the phase 3 G551D trial reported significantly higher
CFQ-R respiratory scores at 24 weeks, MD 8.10 (95% CI 4.63
to 11.57) and at 48 weeks, MD 8.70 (95% CI 5.51 to 11.89)
(Analysis 2.3). This finding was not reproduced in the paediatric
participants (ENVISION 2013). The R117H trial reported sig-
nificantly higher CFQ-R scores at 24 weeks in participants ran-
domised to ivacaftor, MD 8.40 (95% CI 2.17 to 14.63) (Analysis
3.1) (KONDUCT 2015). Again, for relative change in FEV1,
no significant improvement was reported in the F508del trial
(DISCOVER 2011). The phase 2 G551D trial did not report
treatment with ivacaftor resulted in a significant improvement in
relative change in FEV1 (Accurso 2010). However, in the adult
G551D phase 3 trial, significant improvements in relative change
in FEV1 were seen early (after 15 days) and maintained through
to 48 weeks, MD 16.80% (95% CI 13.50 to 20.10) (STRIVE
2011). Significant improvements in this outcome were also seen
at 24 weeks in the paediatric trial, MD 17.4% (P < 0.0001), but
results at 48 weeks were not published (ENVISION 2013). The
R117H did not report any significant improvement in relative
change in FEV1 (KONDUCT 2015).
We compared the number of participants experiencing adverse ef-
fects between the ivacaftor group and the placebo group. Com-
bined data from both G551D phase 3 trials demonstrated a re-
duced reporting of cough, OR 0.57 (95%CI 0.33 to 1.00) and re-
duced episodes of decreased pulmonary function, OR 0.29 (95%
CI 0.10 to 0.82) in the ivacaftor group (Analysis 2.5). Increased
reports of dizziness were recorded in participants receiving iva-
caftor in the adult G551D trial (STRIVE 2011), but this ad-
verse effect was not reported by any other trial (Accurso 2010;
DISCOVER 2011; ENVISION2013; KONDUCT 2015). Data
from the R117H trial showed increased reporting of adverse ef-
fects in the ivacaftor group except for pulmonary exacerbation,
OR 0.93 (95% CI 0.35 to 2.44), however, these results were not
significant (KONDUCT 2015) (Analysis 3.4). No trial reported
a significant increase in adverse effects leading to interruption or
termination of the trial drug (Accurso 2010; DISCOVER 2011;
ENVISION 2013; KONDUCT 2015; STRIVE 2011).
Combined data from the phase 3 G551D trials demonstrated
significantly fewer participants experienced ’serious’ cases of pul-
monary exacerbation in the ivacaftor group, OR 0.34 (95% CI
0.17 to 0.70) (Analysis 2.13). When considering all data for exac-
erbations, fewer adults in the ivacaftor group reported exacerba-
tions in the adult phase 3 G551D trial, OR 0.54 (95% CI 0.29 to
1.01) (Analysis 2.9); also, more participants in the placebo group
required hospitalisation and IV antibiotics for pulmonary exacer-
bations and a greater proportion of participants in the ivacaftor
group were exacerbation-free at the 24 and 48 week time points
(Analysis 2.10) (STRIVE 2011). In the R117H trial fewer par-
ticipants in the ivacaftor group experienced pulmonary exacerba-
tions, hospitalisation and IV antibiotics for the exacerbation, but
results were not significant (Analysis 3.5) (KONDUCT 2015).
This effect was not reported by the remaining three trials (Accurso
2010; DISCOVER 2011; ENVISION 2013).
The adverse effects profile of ivacaftor should be interpreted with
caution as it was based on small numbers of participants. Fur-
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thermore, none of the included trials were powered to assess this
outcome (Accurso 2010; DISCOVER 2011; ENVISION 2013;
KONDUCT 2015; STRIVE 2011).
No significant weight gain or change in BMI scores were reported
in the F508del or R117H trials (DISCOVER 2011; KONDUCT
2015). Participants in both phase 3 G551D trials demonstrated
significant weight gain on ivacaftor at 24weeks,MD2.37 kg (95%
CI 1.68 to 3.06) and 48 weeks, MD 2.75 kg (95% CI 1.74 to
3.75) (Analysis 2.19). These two trials also reported that signifi-
cantly higher BMI scores were achieved in the ivacaftor group; for
children, MD 1.09 kg/m² (P = 0.0003) and for adults, MD 0.93
kg/m² (P < 0.0001). Significantly higher BMI for age z scores were
reported for children in the ivacaftor group at 24 weeks, MD 0.34
(P≤ 0.001) and at 48 weeks, MD 0.45 (P < 0.001) (ENVISION
2013). In a subset of participants aged 12 to 20 years old from the
adult trial, a higher BMI for age Z score was reported at 48 weeks,
MD 0.33 (P = 0.0490) (STRIVE 2011).
All trials reported significant reductions in sweat chloride concen-
trations (Accurso 2010; DISCOVER 2011; ENVISION 2013;
KONDUCT 2015; STRIVE 2011). The F508del trial reported
a MD of -2.90 mmol/L (95% CI -5.60 to -0.20) (DISCOVER
2011). The phase 2 G551D trial reported median values at 28
days; in the 150 mg ivacaftor group, median -64.5 mmol/L (P =
0.02) and in the 250 mg ivacaftor group, median -43.0 mmol/L (P
= 0.03) (Accurso 2010). Combined data from the phase 3 G551D
trials demonstrated significant reductions in sweat chloride con-
centration in participants on ivacaftor at 24 weeks, MD -50.19
mmol/L (95% CI -56.20 to -44.18) and 48 weeks, MD -49.74
mmol/L (95% CI -54.61 to -44.87) (Analysis 2.20). Similarly, the
ivacaftor group in the R117H trial reported a significant reduction
in sweat chloride concentration at 24 weeks, MD -24.00 mmol/
L (95% CI -28.01 to -19.99) (Analysis 3.9).
Overall completeness and applicability of
evidence
The DISCOVER trial recruited 140 participants homozygous for
the F508del mutation, who were a representative sample for peo-
ple with this mutation aged from 12 years upwards. This trial was
included because it evaluated ivacaftor, although on a population
with class IImutations inwhich aminimal amount ofCFTR is able
to reach the cell surface. In light of the results that failed to reach
statistical significance in this population, trials with younger par-
ticipants with F508del are not appropriate (DISCOVER 2011).
Three trials recruited 238 participants with the G551D mutation
representing a significant proportion of all people with this mu-
tation in the countries where the trials were undertaken (Accurso
2010; ENVISION 2013; STRIVE 2011). It can be assumed that
the results are applicable to those with the G551D mutation not
included in the trials; however, current trials have not enrolled
children under six years of age or pregnant women. There are
insufficient data for some outcomes, which we considered to be
important for this review: school or work attendance; radiological
measures of lung disease; acquisition of respiratory pathogens; and
cost of treatment. One G551D trial reported on hospitalisations
and extra courses of antibiotics (STRIVE 2011).
The R117H trial recruited 69 participants with the R117H mu-
tation. Results are not applicable to individuals with other class IV
mutations and the small sample size reduces the applicability of
this evidence to people with cystic fibrosis who carry the R117H
mutation (KONDUCT 2015).
There is no current evidence to support the use of CFTR poten-
tiators in people with other class III to V mutations (not G551D).
While there are trials recruiting people with other class III to V
mutations, these have not be included in this review due to their
cross-over trial design (KONNECTION 2013; NCT01685801;
NCT01784419).
Quality of the evidence
All the included trials were RCTs which represent the highest
quality with regards to trial design.
The overall risk of bias across the included trials was judged
to be moderate. Random sequence generation, allocation con-
cealment and blinding of trial personnel were well-documented.
Blinding of participants was less clear, as details of ivacaftor and
placebo tablets (such as taste, colour and consistency) were not
provided. Participant data were excluded from the analysis in four
trials (DISCOVER 2011; ENVISION 2013; KONDUCT 2015;
STRIVE 2011). The risk of selective reporting was generally high
as trials did not always report on outcomes outlined in the pro-
tocol, or present data for all outcomes and report on outcomes
considered important by the review authors.
The quality of the evidence in this review is judged to be moder-
ate to low, mainly due to risk of bias from incomplete outcome
data and selective reporting and imprecision of results, particularly
where few individuals have experienced adverse events (Summary
of findings for the main comparison; Summary of findings 2;
Summary of findings 3).
Potential biases in the review process
The review authors conducted a comprehensive literature search
of online journal databases using the Cystic Fibrosis and Genetic
Disorders Review Group’s Cystic Fibrosis Trials Register and on-
line trials databases (Appendix 1) and also of manual searching of
journal conference abstracts. Two authors independently applied
the inclusion and exclusion criteria to the resultant literature and
extracted relevant trials. The authors independently extracted data
and assessed the risk of bias of the included trials. If they failed
to reach a consensus on the risk of bias in a trial, a third author
(KWS) arbitrated. The initial analyses were undertaken by one
review author (SP) and checked for appropriateness by the review
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statistician (KD). MS completed the analysis for the update of the
review. This methodological approach ensured that risks of bias in
the review process were kept to a minimum.
This review has assessed all available published trial data. Trial
authors were contacted for relevant unpublished information and
individual participant data. To date, a protocol synopsis and sum-
mary of product characteristics have been provided with regards to
information requested for the R117H trial (KONDUCT 2015).
We are not aware of any unpublished trials, although we have
highlighted issues with selective reporting in the included trials.
Agreements and disagreements with other
studies or reviews
We are aware of one other published review of ivacaftor for people
with CF which included the phase 3 G551D trials and data from
the open-label extensions to these trials (Whiting 2014). In line
with this Cochrane Review, the Whiting review also concluded
that ivacaftor has a clinically relevant impact on people with CF
with the G551D mutation. We identified disagreements between
the two reviews concerning the methodological quality and risk
of bias assessments for the phase 3 G551D trials, although both
reviews have used the Cochrane risk of bias tool. In the Whiting
review, the authors judged the risk of bias for all methodologi-
cal aspects of the adult phase 3 G551D trial to be low; whereas
we judged this trial to have an unclear risk of detection bias and
high risks of attrition bias and selective reporting bias (STRIVE
2011). With regards to the paediatric phase 3 G551D trial, dis-
agreements were identified for participant and outcome assessor
blinding, incomplete outcome data and selective reporting. The
Whiting review judged this trial to have a low risk of detection
bias, performance bias and selective outcome reporting bias and
an unclear risk of attrition bias; while we judged the trial to have
an unclear risk of detection and performance bias and a high risk
of attrition bias and selective outcome reporting bias (ENVISION
2013). The overall methodological quality of the phase 3 G551D
trials was assessed to be higher in the Whiting review than in this
review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The F508del trial demonstrated no evidence to support the use
of ivacaftor in those with the F508del mutation (DISCOVER
2011). The two G551D phase 3 trials demonstrated a clinically
relevant impact of ivacaftor on outcomes at 24 and 48 weeks in
children (over six years of age) and adults with cystic fibrosis (CF)
and the G551D mutation (ENVISION 2013; STRIVE 2011).
The R117H trial demonstrated an improvement in the respiratory
domain of theCFQ-Rbut no improvement in respiratory function
(KONDUCT 2015). These trials were judged to have a moderate
risk of bias.
Implications for research
Ivacaftor is the first intervention that corrects the underlying
molecular defect in CF. It has demonstrated effectiveness in people
with a class III mutation (G551D) and some effectiveness with
class IV mutations (R117H) and has the potential to be used for
other class III and IVmutations. Phase 3 trials examining ivacaftor
in combination with a CFTR corrector (lumacaftor) in class II
mutations (F508del) have been assessed in a separate Cochrane
Review (Southern 2018).
As new mutation-specific therapies emerge, it is important that
the lessons learnt from this review are taken on board, in particular
with respect to trial design (cross-over trials are not appropriate
given the potential for the therapies under consideration to fun-
damentally change the natural history of the condition), selective
reporting and the details of participant blinding. It is important
that these trials examine valid outcomes that are relevant to people
with CF and their families.
With novel therapies and approaches, such as ivacaftor, the report-
ing of adverse events is critical and this should be undertaken in
a robust and consistent manner. Valid post-market surveillance is
also essential.
In view of the cost implications for this therapy, ongoing health
economic evaluations are required.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Accurso 2010
Methods 3-arm RCT of parallel design.
Multicentre: 13 centres reported.
Duration: 28 days.
Participants Adults with CF with a G551D-CFTR mutation on at least 1 allele. Total of 19 partici-
pants were enrolled in Part 2 of this trial
Gender n (%)
Total cohort: 10 (53) males; Treatment group 1: 3 (38) males; Treatment group 2: 4 (57)
males; Control group: 3 (75) males
White race n (%)
Total cohort: 19 (100); Treatment group 1: 8 (100); Treatment group 2: 7 (100); Control
group: 4 (100)
Age median (range)
Total cohort: 21 (18 - 42) years; Treatment group 1: 23 (18 - 40) years; Treatment group
2: 21 (20 - 38) years; Control group: 24 (18 - 42) years
BMI median (range)
Total cohort: 22 (20 - 25); Treatment group 1: 22 (20 - 23); Treatment group 2: 23 (20
- 25); Control group: 22 (21 - 23)
CFTR Genotype n (%)
G551D/F508del
Total cohort: 16 (84); Treatment group 1: 7 (88); Treatment group 2: 5 (71); Control
group: 4 (100)
G551D/3849+10kbC→T
Total cohort: 1 (5); Treatment group 1: 0 (0); Treatment group 2: 1 (14) Control group:
0 (0)
G551D/621+1G→T
Total cohort: 1 (5); Treatment group 1: 1 (12); Treatment group 2: 0 (0); Control group:
0 (0)
G551D/G542X
Total cohort: 1 (5); Treatment group 1: 0 (0); Treatment group 2: 1 (14); Control group:
0 (0)
FEV1 % predicted
Median (range)
Total cohort: 69 (40 - 122); Treatment group 1: 65 (42 - 122); Treatment group 2: 76
(40 - 106); Control group: 77 (53 - 112)
40% to <70% n (%)
Total cohort: 10 (53); Treatment group 1: 5 (62); Treatment group 2: 3 (43); Control
group: 2 (50)
70% to <90% n (%)
Total cohort: 5 (26); Treatment group 1: 2 (25); Treatment group 2: 3 (43); Control
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Accurso 2010 (Continued)
group: 0 (0)
≥90% value n (%)
Total cohort: 4 (21); Treatment group 1: 1 (12); Treatment group 2: 1 (14); Control
group: 2 (50)
Sweat chloride (mmol/L) mean (range)
Total cohort: 95.5 (84.8 - 115.8); Treatment group 1: 100.1 (86.8 - 112.5); Treatment
group 2: 97.3 (84.8 - 115.8); Control group: 93.8 (88.0 - 109.5)
CFQ-R respiratory domain (points) mean (range)
Total cohort: 72.2 (16.7 - 88.9); Treatment group 1: 69.4 (16.7 - 88.9); Treatment group
2: 72.2 (61.1 - 83.3); Control group: 80.6 (38.9 - 83.3)
Interventions Treatment Group 1: VX-770 150 mg 2x daily (n = 8).
Treatment Group 2; VX-770 250 mg 2x daily (n = 7).
Control: placebo 2x daily (n = 4).
Outcomes Primary outcome:
1. Safety and adverse effects*
Secondary outcomes:
1. CFTR ion channel function.
2. Change in QoL from baseline*
3. Relative change from baseline in FEV1*
4. Relative change from baseline in FVC* and relative change from baseline in FEF25−75
5. Change from baseline in sweat chloride concentration.*
Notes This was a 2-part trial; part 1 was of cross-over design and so not included in this review.
We only present details of the second part which was of parallel design
The responsible funding body was Vertex Pharmaceuticals Incorporated
* These outcomes are presented in the review.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation list generated by a statisti-
cian not otherwise associated with the trial
Allocation concealment (selection bias) Low risk Participants assigned to a treatment arm
using an Interactive Voice Response sys-
tem according to a concealed randomisa-
tion list. This ensured the outcome asses-
sors and participants were unaware of their
allocation
Blinding (performance bias and detection
bias)
All outcomes
Low risk All trial personnel were blinded to partic-
ipants’ treatment. Exceptions to this were
the laboratory staff and clinical pharmacist
who prepared the medication. These trial
personnel were not otherwise involved in
the trial
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Accurso 2010 (Continued)
Blinding of participants Unclear risk All participants received the same number
of tablets to maintain trial and personnel
blinding. However, there is no report on
details of the tablets (e.g. colour, size, taste)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All together, 20 participants were ran-
domised. 1 of 5 placebo participants with-
drew due to withdrawal of consent prior to
dosing (5% of total participants). All other
participants were accounted for in the anal-
ysis
Selective reporting (reporting bias) High risk The change from baseline in weight, al-
though not reported as an outcome, was
measured at day 1, 3, 14, 21 and 28. It was
not reported in the publication
Other bias Low risk Similar baseline characteristics andhigh ad-
herence rate (100% [range, 92.6 - 100])
DISCOVER 2011
Methods 2-part RCT, both parts of parallel design. Participants who met set out criteria by the
end of part A were eligible to proceed to part B of the trial
In part A, participants were randomly assigned to the intervention or control group in
a 4:1 ratio respectively
Multicentre: 34 sites.
Duration: part A lasted 16 weeks with part B, an open label extension, lasting up to 96
weeks
Participants 140 participants randomised to treatment or placebo in a ratio of 4:1 (treatment group
n = 112; placebo n = 28)
Gender n (%)
Treatment group: 58 (52) males; Placebo group: 16 (57) males
Age years, mean (SD)/median (range)
Treatment group: 22.8 (10.3)/19.5 (12 - 52); Placebo group: 25.0 (8.4)/24.0 (12 - 39)
CFTR Genotype
All homozygous for the F508del-CFTR mutation.
Height cm, median (range)
Treatment group: 164.0 (139.0 - 189.6); Placebo group: 170.7 (145.6 - 184.0)
Weight kg, median (range)
Treatment group: 55.9 (35.1 - 99.8); Placebo group: 64.9 (44.2 - 100.3)
BMI kg/m², median (range)
Treatment group: 20.4 (15.7 - 31.6); Placebo group: 21.5 (17.9 - 40.8)
Sweat chloride mmol/L, mean (SD)/median (range)
Treatment group: 101.4 (10.3)/101.0 (79.5 - 135.5); Placebo group: 102.4 (7.9)/101.5
(91.0 - 122.0)
FEV1 % predicted, mean (SD)/median (range)
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DISCOVER 2011 (Continued)
Treatment group: 79.7 (22.7)/79.0 (40 - 129); Placebo group: 74.8 (24.1)/67.0 (43 -
127)
Interventions Part A
Treatment group: 150 mg of VX-770 (ivacaftor) 2x daily (n = 112)
Control group: placebo (n = 28).
Part B
Treatment group: 150 mg of VX-770 2x daily.
Control group: placebo.
Outcomes Primary outcomes
1. Adverse events, clinical laboratory values, ECGs, vital signs and physical examination.
*
2. Absolute change in FEV1 % predicted from baseline through 16 weeks.*
Secondary outcomes
1. Change from baseline through week 16 in sweat chloride concentration.*
2. Change from baseline through week 16 in weight.*
3. Participant reported health using the disease-specific CFQ-R through week 16.*
Notes The responsible funding body was Vertex Pharmaceuticals Incorporated
* These outcomes are presented in the review.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Eligible participants were randomised to a
treatment group (ivacaftor or placebo) in a
1:1 ratio using a randomisation code pro-
duced by Vertex
Allocation concealment (selection bias) Low risk 2 statisticians were involved. The trial
statistician was blinded whereas the other
was unblinded and not associated with the
trial. The unblinded statistician generated
the final randomisation list that was pro-
vided to the Interactive Voice Response/In-
teractive Web Response System
Blinding (performance bias and detection
bias)
All outcomes
Low risk All site personnel including the investiga-
tor, the trial monitor, and the Vertex trial
team were blinded. Laboratory personnel
or their designee were unblinded to the
bio-analysis results, but remained blinded
to treatment assignment. A clinical phar-
macologist not involved in the conduct of
the trial reviewed the bio-analysis results on
an ongoing basis, but remained blinded to
the participant’s identity number and treat-
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DISCOVER 2011 (Continued)
ment assignment
Blinding of participants Unclear risk The participantswere ’blinded.’ There is no
report on details of the tablets (e.g. colour,
size, taste)
Incomplete outcome data (attrition bias)
All outcomes
High risk 8withdrawalswere reported in the ivacaftor
group and 2 in the placebo group. Analyses
were performed on all randomised partic-
ipants who received at least 1 dose of the
trial drug (ivacaftor n = 112 and placebo
n = 28), as shown in table 3 of the full
paper. However, when assessing the results
on clinicaltrials.gov, the number in the iva-
caftor group is presented as 111 instead of
112 for the outcomes change from baseline
in sweat chloride and absolute change from
baseline in FEV1, suggesting an ITT anal-
ysis was not conducted.
Selective reporting (reporting bias) High risk The protocol for this trial was not available.
There are no data for the change from base-
line in FEV1 at day 15 or week 8. In addi-
tion no data were reported for the outcome
measures FVC or FEF25−75 at 16 weeks. 1
withdrawal from the trial was due to “early
termination per sponsor decision” and no
additional information was provided. The
author was approached for information on
these missing data
Other bias Low risk Similar baseline characteristics.
ENVISION 2013
Methods 2-arm RCT of parallel design. Participants were randomly assigned in a 1:1 ratio
Multicentre: 29 centres reported.
Duration: 48 weeks.
Participants 52 children enrolled onto this trial (control n = 26, intervention n = 26). Children aged
6 to 11 years were eligible for inclusion
Gender n (%)
Total cohort: 25 (48) males; Treatment group: 9 (35) males; Control group: 16 (62)
males
Age years, mean (range)
Total cohort: 8.9 (range 6 - 12); Treatment group: 8.9 (range 6 - 12); Control group: 8.
9 (range 6 - 12)
CFTR Genotype
NB Participants with at least one G551D allele were eligible.
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ENVISION 2013 (Continued)
44 participants had theG551D/F508del genotype. 8 participants had theG551D-CFTR
mutation on one allele and a non-F508del-CFTR mutation on the second allele
Height cm, mean (range)
Total cohort: 133.8 (110.5 - 168.6); Treatment group: 134.9 (115.0 - 168.6); Control
group: 132.6 (110.5 - 155.8)
Weight kg, mean (range)
Total cohort: 30.9 (17.8 - 62.6); Treatment group: 31.8 (18.8 - 62.6); Control group:
30.0 (17.8 - 46.3)
FEV1 % predicted
Participants with baseline FEV1 40% - 105% of the predicted value for persons of their age,
sex and height were eligible.
Mean (range)
Total cohort: 84.2 (44.0 - 133.8); Treatment group: 84.7 (52.4 - 133.8); Control group:
83.7 (44.0 - 116.3)
< 70%, n (%)
Total cohort: 12 (23); Treatment group: 4 (15); Control group: 8 (31)
> 70% to < 90%, n (%)
Total cohort: 18 (35); Treatment group: 12 (46); Control group: 6 (23)
> 90%, n (%)
Total cohort: 22 (42); Treatment group: 10 (38); Control group: 12 (46)
Sweat chloride mmol/L, mean (range)
Total cohort: 104.6 (54.0 - 128.0); Treatment group: 104.3 (54.0 - 128.0); Control
group: 104.8 (92.0 - 121.0)
CFQ-R score for respiratory domain, mean (range)
Child version
Total cohort: 79 (25.0 - 100.0); Treatment group: 78 (33.3 - 100.0); Control group: 80
(25.0 - 100.0)
Parent/caregiver version
Total cohort: 81 (33.3 - 100.0); Treatment group: 81 (33.3 - 100.0); Control group: 81
(38.9 - 100.0)
Interventions 48-week RCT
Treatment: VVX-770 also known as ivacaftor 150 mg 2x daily (n = 26)
Control: placebo (n = 26).
Open-label extension
Treatment: VVX-770 also known as ivacaftor 150 mg 2x daily.
Control: placebo.
Outcomes Primary Outcome
1. Absolute change from baseline through week 24 in % predicted FEV1*
Secondary outcomes
Absolute changes from baseline in:
1. % predicted FEV1 (through week 48);*
2. weight (at weeks 24 and 48);*
3. concentrations of sweat chloride (a measure of CFTR function) (at weeks 24 and 48)
;*
4. participant-reported respiratory symptoms as assessed by the respiratory domain of
the child version of the CFQ-R (at weeks 24 and 48);*
5. safety.*
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Notes The responsible funding body was Vertex Pharmaceuticals Incorporated.
* These outcomes are presented in the review.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants randomised in a 1:1 ratio,
however method not reported
Allocation concealment (selection bias) Unclear risk No description of allocation concealment.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Described as double blind. It is not stated
how attending researchers were blinded
Blinding of participants Unclear risk Described as double blind. It is not stated
how participants were blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk In the paediatric phase 3 G551D trial 4/52
participants (7.7%) withdrew from the to-
tal trial population. All 4 participants with-
drew from the placebo group
In the analysis of the following outcomes
participant data were excluded:
• absolute change from baseline in %
predicted FEV1 (1 participant excluded
from placebo group)
• change from baseline in sweat
chloride concentration (6 participants
excluded)
• CFQ-R respiratory domain child
version (1 participant excluded from
placebo group).
A modified intention-to-treat analysis
(not per protocol) was employed, where
data were excluded from the analysis (
ENVISION 2013).
Selective reporting (reporting bias) High risk At each visit (days 1, 15 andweeks 8, 16, 24,
32, 40 and 48) participant FVC measure-
ments were recorded. These results were
not published in the full text, nor made
available upon request
Data for the relative change from baseline
in FEV1 (an important outcome in such a
trial) were not reported at 48 weeks
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Other bias Low risk Similar baseline characteristics andhigh ad-
herence rate.
KONDUCT 2015
Methods Phase 3, double-blind, RCT of parallel design.
Multicentre: 31 centres reported.
Duration: 24 weeks with an open-label extension phase for up to 104 weeks. Participants
were not re-randomised for the extension phase
Participants 69 participants aged 6 years or older with CF with at least 1 allele of the R117H-CFTR
mutation were enrolled. Total: control n = 35, intervention n = 34; 6 - 11 years control
n = 8, intervention n = 9; ≥ 18 years control n = 26, intervention n = 24
Age years, mean (SD)
Overall: treatment group: 29.2 (16.6); placebo group: 32.7 (17.4)
6 - 11 years: treatment group 8.8 (1.9); placebo group 9 (1.6).
≥ 18 years: treatment group 37.5 (12.1); placebo group 40.6 (12.6)
Gender n (%)
Overall: treatment group 19 (56%) females; placebo group 20 (57%) females.
6 - 11 years: treatment group 5 (56%) females; placebo group 3 (38%) females
≥ 18 years: treatment group 13 (54%); placebo group 16 (62%)
Weight kg, mean (SD)
Overall: treatment group: 66.1 (25.5); placebo group: 62.8 (25.4)
6 - 11 years: treatment group 32.9 (13.3); placebo group 34.0 (9.1).
≥ 18 years: treatment group 77.9 (16.7); placebo group 71.7 (22.5)
BMI kg/m2, mean (SD)
Overall: treatment group: 24.5 (6.3); placebo group: 23.1 (6)
6 - 11 years: treatment group 17.6 (3.3); placebo group 17.1 (2.4).
≥ 18 years: treatment group 26.9 (5.2); placebo group 24.9 (5.7)
FEV1 % predicted, mean (SD)
Participants with baseline FEV1 40% to 90% (for participants aged 12 years or older) or
40% to 105% (for participants aged 6 to 11 years) of the predicted value for age, sex, and
height were eligible.
Overall: treatment group: 75.7 (19.3); placebo group: 70.2 (18.9)
6 - 11 years: treatment group 97.5 (8.6); placebo group 94.0 (8.4).
≥ 18 years: treatment group 67.0 (15.4); placebo group 62.3 (14.4)
FEV1 % predicted, n (%)
<70%
Overall: treatment group: 13 (38%); placebo group: 15 (43%).
6 - 11 years: treatment group 0; placebo group 0.
≥ 18 years: treatment group 13 (54%); placebo group 15 (58%)
≥ 70 to ≤ 90%
Overall: treatment group: 14 (41%); placebo group: 14 (40%).
6 - 11 years: treatment group 3 (33%); placebo group 2 (25%).
≥ 18 years: treatment group 10 (42%); placebo group 11 (42%)
> 90%
Overall: treatment group: 7 (21%); placebo group: 6 (17%).
6 - 11 years: treatment group 6 (67%); placebo group 6 (75%).
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≥ 18 years: treatment group 1 (4%); placebo group 0.
Sweat chloride n/mmol/l, mean (SD)
Overall: treatment group: 32/67.3 (23.5); placebo group: 35/73.4 (19.7)
6 - 11 years: treatment group 8/64.2 (22.6); placebo group 8/74.7 (28.6).
≥ 18 years: treatment group 23/69.3 (24.1); placebo group 26/73.0 (17.3)
CFQ-R score for respiratory domain, n/score, mean (SD)
Overall: treatment group: 33/75.3 (20.1); placebo group: 34/66.4 (24.4)
6 - 11 years: treatment group 8/92.7 (7.0); placebo group 7/91.7 (6.8).
≥ 18 years: treatment group 24/68.4 (19.1); placebo group 26/59.2 (23.2)
CFTR genotype (Arg117His/Phe508del), mean (SD)
Overall: treatment group: 28 (82%); placebo group: 25 (71%).
6 - 11 years: treatment group 8 (89%); placebo group 6 (75%).
≥ 18 years: treatment group 19 (79%); placebo group 19 (73%)
Interventions Ivacaftor 150 mg orally 2x daily for 24 weeks.
Outcomes Primary outcome:
1. absolute change from baseline in % predicted FEV1 (through 24 weeks).
Secondary outcomes:
1. change from baseline in BMI (through 24 weeks);
2. change from baseline in sweat chloride (through 24 weeks);
3. change from baseline in the respiratory domain of the CFQ-R (through 24 weeks);
4. time to first pulmonary exacerbation (through 24 weeks);
5. number of participants with adverse events and serious adverse events (through 24
weeks)
Notes The responsible funding body was Vertex Pharmaceuticals Incorporated
* These outcomes are presented in the review.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were assigned to receive
placebo or ivacaftor (1:1) via a randomisa-
tion specification and randomisation code.
The code list was sent to the IVRS
Allocation concealment (selection bias) Low risk A masked biostatistician created the ran-
domisation specification and dummy ran-
domisation code, thiswas then approvedby
an unmasked biostatistician not associated
with the trial, prior to generating the fi-
nal randomisation list. An unblinded qual-
ity check biostatistician reviewed and ap-
proved final randomisation list. The bio-
statistician not associatedwith the trial pro-
vided the final list to IVRS
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KONDUCT 2015 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Described as double blinded. Other than
the biostatisticians, it is not stated which
trial personnel were blinded or how they
were blinded
Blinding of participants Unclear risk Described as double blinded. There is no
report on details of the tablets (e.g. colour,
size, taste)
Incomplete outcome data (attrition bias)
All outcomes
Low risk In total, 69participantswere randomised. 2
withdrew from the intervention groupwith
reasons given. A full analysis set included
all randomised participants who received at
least 1 dose of trial drug
Selective reporting (reporting bias) High risk No protocol was available online to com-
pare outcomes in the protocol with those
published. The author was approached for
further information and a protocol synop-
sis provided.This showed the following ter-
tiary outcomes which were reported in the
protocol but no with no published results
1. PK parameter estimates of ivacaftor and
metabolites, M1 and M6, derived
from plasma concentration-time data
2. Change from baseline in nonrespiratory
domains of the CFQ-R
3. Change from baseline in weight
4. Change from baseline in height
5. CF-related complications (pancreatitis
or distal ileal obstruction syndrome
6. Change from baseline in inflammatory
mediators
7. Change from baseline in qualitative mi-
crobiological cultures
8. Change from baseline in IRT
9. Change from baseline in fecal elastase-1
Other bias Low risk Similar baseline characteristics.
There were only 2 participants between 12
- 17 years of age so no age subgroup statisti-
cal analysis were performed for this group.
They were included in overall analysis. No
comment was made regarding the reason
for low enrolment in this age group
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STRIVE 2011
Methods 2-arm RCT of parallel design.
Multicentre international trial with participants from Europe, North America and Aus-
tralia
Duration: up to 48 weeks.
Participants Total of 167 participants recruited: treatment group n = 84; control group n = 83
Participants (at least 12 years of age) were stratified according to age (< 18 years versus
≥18 years) and pulmonary function (under 70% versus 70% and over of the predicted
FEV1).
Gender, n (%)
Total cohort: 77 (48) males; Treatment group: 39 (47) males; Control group: 38 (49)
males
Non-Hispanic or white, n (%)
Total cohort: 158 (98); Treatment group: 81 (98); Control group: 77 (99)
Geographic distribution, n (%)
North America
Total cohort: 100 (62); Treatment group: 50 (60); Control group: 50 (64)
Europe
Total cohort: 42 (26); Treatment group: 23 (28); Control group: 19 (24)
Australia
Total cohort: 19 (12); Treatment group: 10 (12); Control group: 9 (12)
Age years, mean (range)
Total cohort: 25.5 (12 - 53); Treatment group: 26.2 (12 - 53); Control group: 24.7(12
- 53)
Age distribution, n (%)
Under 18 years
Total cohort: 36 (22); Treatment group: 19 (23); Control group: 17 (22)
18 years and over
Total cohort: 125 (78); Treatment group: 64 (77); Control group: 61 (78)
Height cm, mean (range)
Total cohort: 167.1 (142.2 - 189.8); Treatment group: 167.7 (142.8 - 185.0); Control
group: 166.5 (142.2 - 189.8)
Weight kg, mean (range)
Total cohort: 61.5 (30.2 - 109.9); Treatment group: 61.7(30.2 - 107.2); Control group:
61.2(31.9 - 109.9)
BMI, mean (range)
Total cohort: 21.8 (14.8 - 38.9); Treatment group: 21.7 (14.8 - 38.9); Control group:
21.9 (15.2 - 38.6)
Positive for Pseudomonas aeruginosa, n (%)
Total cohort: 122 (76); Treatment group: 64 (77); Control group: 57 (73)
CFTR Genotype
Non-G551D-CFTR allele n (%), NB Only participants with at least 1 G551D allele
were eligible.
Class I
Total cohort: 21 (13); Treatment group: 10 (12); Control group: 11 (14)
Class II
Total cohort: 132 (82); Treatment group: 70 (84); Control group: 62 (79)
Class III
Total cohort: 1 (1); Treatment group: 0; Control group: 1 (1)
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STRIVE 2011 (Continued)
Class IV
Total cohort: 4 (2); Treatment group: 2 (2); Control group: 2 (3)
Class V
Total cohort: 1 (1); Treatment group: 0; Control group: 1 (1)
Unknown
Total cohort: 2(1); Treatment group: 1(1); Control group: 1(1)
FEV1 % predicted, mean (range)
NB Only participants with baseline FEV1 40% - 90% of the predicted value for persons of
their age, sex and height were eligible.
Total cohort: 63.6 (31.6 - 98.2); Treatment group: 63.5 (37.3 - -98.2); Control group:
63.7 (31.6 - 97.1)
FEV1 distribution, n (%)
Under 70% of predicted value
Total cohort: 94 (58); Treatment group: 49 (59); Control group: 45 (58)
70% and over of predicted value
Total cohort: 67 (42); Treatment group: 34 (41); Control group: 33 (42)
Sweat chloride mmol/L, mean (range)
Total cohort: 100.2 (58.0 - 128.0); Treatment group: 100.4 (74.5 - 128.0); Control
group: 100.1 (58.0 - 121.5)
Interventions 48-week RCT
Treatment: VX-770 also known as ivacaftor 150 mg 2x daily (n = 83)
Control: placebo (n = 78).
Open-label extension
Treatment: VVX-770 also known as ivacaftor 150 mg 2x daily.
Control: placebo.
Outcomes Primary outcome
1. Absolute change from baseline through week 24 in % predicted FEV1.*
Secondary outcomes
1. Change from baseline through week 48 in % predicted FEV1.*
2. Time to the first pulmonary exacerbation through week 24 and week 48. *
3. Participant-reported health using the disease-specific CFQ-R.*
4. Change in weight from baseline to week 24 and week 48. *
5. Change from baseline in the concentration of sweat chloride through week 24 and
week 48.*
Tertiary endpoints
1. Number and duration of pulmonary exacerbations.*
2. Total number of days of hospitalisation for pulmonary exacerbations.*
3. Need for antibiotic therapy for sinopulmonary signs or symptoms.*
Notes * These outcomes are presented in the review.
Risk of bias
Bias Authors’ judgement Support for judgement
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STRIVE 2011 (Continued)
Random sequence generation (selection
bias)
Low risk Eligible participants were randomised to a
treatment group (ivacaftor or placebo) in a
1:1 ratio using a randomisation code pro-
duced by Vertex
Allocation concealment (selection bias) Low risk 2 biostatisticians involved in randomisa-
tion process; 1 blinded trial statistician and
1 unblinded statistician not involved in the
trial. The statistician not associated with
the trial generated the final randomisation
list that was provided to an Interactive
Voice Response System
Blinding (performance bias and detection
bias)
All outcomes
Low risk All site personnel including the investiga-
tor, the trial monitor, and the Vertex trial
team were blinded. Laboratory personnel
or their designee were unblinded to the
bio-analysis results, but remained blinded
to treatment assignment. A clinical phar-
macologist not involved in the conduct of
the trial reviewed the bio-analysis results on
an ongoing basis, but remained blinded to
the participant’s identity number and treat-
ment assignment
Blinding of participants Unclear risk All participants were stated to have been
blinded, however, details of the tablets have
not been provided (e.g. colour, size, taste)
Incomplete outcome data (attrition bias)
All outcomes
High risk 167 participants were randomised - 83 par-
ticipants to the placebo group and 84 par-
ticipants to the ivacaftor group. 10 partic-
ipants withdrew from the placebo group
and 6 participants withdrew from the iva-
caftor group. 78 participants in the placebo
group and 83 participants in the ivacaftor
group (total n = 161) were included in the
analysis. The review authors found a mi-
nor discrepancy in the number of partici-
pants analysed for the outcomes measures:
change from baseline in CFQ-R respira-
tory domain scores (total analysed n = 151)
and the change from baseline in sweat chlo-
ride concentration (total analysed n = 152)
(STRIVE 2011).
Selective reporting (reporting bias) High risk Protocol provided. The following tertiary
outcomes were reported in the protocol,
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STRIVE 2011 (Continued)
but results for these outcomes were not
published
1. Change from baseline in oxygen satura-
tion through weeks 24 and 48.
2. Change from baseline in EuroQol Ques-
tionnaire (EQ-5D) through weeks 24
and 48.
3.Outpatient sick visits to the clinic or hos-
pital for CF-related complications through
weeks 24 and 48
In addition to this, results were only re-
ported for CFQ-R domains where im-
provementswere seen in the ivacaftor group
Other bias Low risk Similar baseline characteristics.
The responsible funding body was Vertex
Pharmaceuticals Incorporated
ALT: alanine transaminase
AST: aspartate transaminase
BMI: body mass index
CF: cystic fibrosis
CFQ-R: cystic fibrosis questionnaire - revised
CFTR: cystic fibrosis transmembrane regulator
ECG: electro-cardiogram
FEF25−75: forced expiratory flow at 25-75% of the pulmonary volume
FEV1: forced expiratory volume at one second
FVC: forced vital capacity
IRT: immunoreactive trypsinogen
ITT: intention to treat
IVRS: interactive voice response system
MRI: magnetic resonance image
PK: pharmacokinetic
QoL: quality of life
RCT: randomised controlled trial
ULN: upper limit of normal
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Accurso 2013 Secondary analysis on trials of cross-over design.
ALBATROSS 2017 Intervention to correct molecular defect, not a potentiator.
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(Continued)
Altes 2011 Trial of cross-over design.
ARRIVAL 2018 Single-arm interventional study, no comparison to placebo.
Berkers 2017 Trial of cross-over design.
Chadwick 1998 Intervention to correct molecular defect, not a potentiator.
Clancy 2012 Intervention to correct molecular defect, not a potentiator.
Davies 2012 Trial of cross-over design.
Davies 2016 Single-arm interventional trial.
Edgeworth 2017 Trial of cross-over design.
EudraCT Number: 2014-000817-30 Single-arm interventional study. Intervention was not with CFTR potentiator
EudraCT Number: 2016-001440-18 Observational study. Intervention was not with CFTR potentiator
EudraCT Number: 2016-001619-19 Trial of cross-over design. Intervention was not CFTR potentiator
EUudraCT Number: 2016-001785-29 Intervention used antibiotic therapy rather than CFTR potentiator
FLAMINGO 2017 Intervention to correct molecular defect, not a potentiator.
Horsley 2018 Intervention to correct molecular defect, not a potentiator.
Hubert 2018 Retrospective cohort design.
Kerem 2014 Intervention for stop codon mutations.
KONNECTION 2013 Trial of cross-over design.
McCarty 2002 Intervention to correct molecular defect, not a potentiator.
McGarry 2015 Trial of cross-over design.
NCT01549314 Prospective cohort study design.
NCT01685801 Trial of cross-over design.
NCT01784419 Trial of cross-over design.
NCT01863238 Prospective cohort study design.
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(Continued)
NCT01946412 Single-arm interventional study.
NCT02039986 Prospective cohort study design.
NCT02141464 Prospective cohort study design.
NCT02310789 Single-arm interventional study. Enrolled healthy participants only
NCT02311140 Prospective cohort study design.
NCT02323100 Intervention was glycerol phenylbutyrate corrector therapy, not a potentiator
NCT02443688 Intervention was with anti-inflammatory drug rather than CFTR potentiator
NCT02445053 Prospective cohort study design.
NCT02690519 Single-arm interventional trial design.
NCT02707562 Single-arm interventional trial design.
NCT02709109 Trial of cross-over design.
NCT02718495 Intervention was with a CFTR amplifier versus placebo.
NCT02722057 Cohort study design.
NCT02724527 Compared another mutation-specific therapy (corrector) with placebo
NCT02742519 Trial of cross-over design.
NCT02759562 Intervention was with a monoclonal antibody rather than CFTR potentiator
NCT02934698 Single-arm interventional study.
NCT03068312 Trial of cross-over design.
NCT03256799 Single-arm interventional study. Intervention was not CFTR potentiator
NCT03256968 Single-arm interventional study. Intervention was not CFTR potentiator
NCT03258424 Intervention was with a CFTR amplifier versus placebo.
NCT03277196 Non-randomised, intervention compared to observational arm, not placebo
NCT03390985 Prospective cohort study design.
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(Continued)
NCT03474042 Intervention was with CFTR corrector versus placebo.
NCT03652090 Cohort study design. Intervention was a cell sampling procedure
PERSIST 2014 Single-arm interventional study.
Pradal 2002 Intervention for stop codon mutations.
RIO-CF 2017 Intervention was a soluble guanylase cyclase stimulator, not a potentiator
Romano 2000 Intervention for stop codon mutations.
Rubenstein 1998 Intervention to correct molecular defect, not a potentiator.
Rubenstein 2006 Intervention to correct molecular defect, not a potentiator.
Seliger 2015 Observational trial.
Sermet-Gaudelus 2010 Intervention for stop codon mutations.
TOPIC 2018 Participants with CF were excluded.
Wilschanski 2003 Intervention for stop codon mutations.
Wilschanski 2008 Intervention for stop codon mutations.
Zeitlin 2002 Intervention to correct molecular defect, not a potentiator.
CFTR: cystic fibrosis transmembrane regulator
Characteristics of studies awaiting assessment [ordered by study ID]
Kazani 2016
Methods RCT, double-blind.
Phase 2.
Parallel design.
Duration: 2 weeks (with follow-up to Day 42).
Participants Eligibility criteria (Part 3)
Confirmed diagnosis of CF.
Heterozygous with one allele represented as any CFTR mutation and the other allele must represent a class III, IV,
V, VI CFTR mutation
Aged over 18 years.
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Kazani 2016 (Continued)
BMI: 15 - 35 kg/m².
FEV1 40% - 100% .
Oxygen saturation > 90% on room air.
2016 abstract describes an interim analysis of 40 participants who were enrolled into Part 3 of the trial. According
to the clinicaltrials.gov record, 49 participants with CF with a class III, IV, V, or VI mutation on one allele and any
other CFTR mutation on the other allele were randomised and all completed the trial
Randomised: overall n = 49; intervention 1 n = 6; intervention 2 (multiple mutations) n = 12, intervention 2
(homozygous for F508del) n = 19; control group n = 12
Age, mean (SD): intervention 1 - 39.3 (5.47) years; intervention 2 (multiple mutations) - 32.7 (13.77) years,
intervention 2 (homozygous for F508del) - 27 (5.44) years; control - 27.9 (6.37) years
Gender split: overall - 30 males, 19 females; intervention 1 - 5 males, 1 female; intervention 2 (multiple mutations)
- 7 males, 5 females, intervention 2 (homozygous for F508del) - 10 males, 9 females; control - 8 males, 4 females
Interventions Intervention 1 (n = 4): QBW251 150 mg twice daily (oral capsule)
Intervention 2 (n = 12): QBW251 450 mg twice daily (oral capsule)
Control (n = 10): placebo (oral capsule).
Outcomes Primary outcomes
1. Change in LCI
2. Adverse events
Secondary outcomes
1. Change in FEV1
2. Change in CFQR reported outcomes
3. Change in sweat chloride
Notes Only part 3 of trial which includes people with CF is eligible to be included in review. Parts 1 and 2 enrolled healthy
participants
The trial has been terminated, but some results are posted on clinicaltrials.gov
Sponsor is Novartis.
Uttamsingh 2016
Methods RCT, double-blind.
Phase 1.
Parallel design.
Duration: 7 days.
Participants 40 participants (each cohort enrolled 10 new participants; 8 participants received active drug and 2 received placebo
(4:1 randomisation)
Interventions Intervention 1: CTP-656 75 mg once daily.
Intervention 2: CTP-656 150 mg once daily.
Intervention 3: CTP-656 225 mg once daily.
Control: placebo.
All participants were dosed under fed conditions; a high-fat breakfast was provided on Day 1 through Day 7
approximately 30 minutes prior to dosing. Dose escalation was initiated only after safety and tolerability were found
to support proceeding to the higher dose
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Uttamsingh 2016 (Continued)
Outcomes PK blood samples were collected at several time points post-dose on Day 1 and Day 7, and at 12 and 24 hours post-
dose on Day 2 through Day 6. The plasma concentrations of CTP-656 and its metabolites, D-M1 and D-M6 were
analysed by LC-MS/MS. The steady-state PK profiles for CTP-656, D-M1 and D-M6 were evaluated for the 3 dose
cohorts
Notes The author was approached for further information.
Drug initially developed by Concert Pharmaceuticals Inc. before being sold to Vertex for further development in
2017 and being re-named VX-561
BMI: body mass index
CF: cystic fibrosis
CFQ-R: cystic fibrosis questionnaire-revised
CFTR: cystic fibrosis transmembrane regulator
FEV1: forced expiratory volume at one second
LCI: lung clearance index
LC-MS/MS: liquid chromatography with mass spectrometry
PK: pharmacokinetic
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Ivacaftor (VX-770) versus placebo in people with the F508del CFTR mutation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV1 - relative change from
baseline
1 Mean Difference (Fixed, 95% CI) Subtotals only
1.1 At 16 weeks 1 140 Mean Difference (Fixed, 95% CI) 2.4 [-0.95, 5.75]
2 Adverse effects 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Pulmonary exacerbation 1 140 Odds Ratio (M-H, Fixed, 95% CI) 0.44 [0.14, 1.41]
2.2 Upper respiratory tract
infection
1 140 Odds Ratio (M-H, Fixed, 95% CI) 1.42 [0.18, 11.10]
2.3 Cough 1 140 Odds Ratio (M-H, Fixed, 95% CI) 2.62 [0.59, 11.59]
2.4 Productive cough 1 140 Odds Ratio (M-H, Fixed, 95% CI) 2.36 [0.15, 37.71]
2.5 Headache 1 140 Odds Ratio (M-H, Fixed, 95% CI) 1.42 [0.18, 11.10]
2.6 Nasal congestion 1 140 Odds Ratio (M-H, Fixed, 95% CI) 1.71 [0.22, 13.09]
2.7 Sinusitis 1 140 Odds Ratio (M-H, Fixed, 95% CI) 2.08 [0.13, 33.75]
2.8 Oropharyngeal pain 1 140 Odds Ratio (M-H, Fixed, 95% CI) 0.82 [0.14, 4.90]
2.9 Upper abdominal pain 1 140 Odds Ratio (M-H, Fixed, 95% CI) 1.8 [0.11, 29.87]
2.10 Nausea 1 140 Odds Ratio (M-H, Fixed, 95% CI) 2.65 [0.17, 41.76]
2.11 Diarrhea 1 140 Odds Ratio (M-H, Fixed, 95% CI) 0.74 [0.08, 6.49]
2.12 Contact dermatitis 1 140 Odds Ratio (M-H, Fixed, 95% CI) 3.48 [0.08, 158.51]
2.13 Rash 1 140 Odds Ratio (M-H, Fixed, 95% CI) 5.23 [0.12, 228.54]
2.14 Fatigue 1 140 Odds Ratio (M-H, Fixed, 95% CI) 0.73 [0.12, 4.45]
2.15 Pyrexia 1 140 Odds Ratio (M-H, Fixed, 95% CI) 1.14 [0.14, 9.20]
2.16 Increase in C-reactive
protein
1 140 Odds Ratio (M-H, Fixed, 95% CI) 1.53 [0.09, 26.08]
3 Severity of adverse effects of
therapy with regards to study
drug interruption (moderate)
or discontinuation (severe)
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Adverse effect requiring
study drug interruption
(moderate)
1 140 Odds Ratio (M-H, Fixed, 95% CI) 1.29 [0.06, 27.62]
3.2 Adverse effect requiring
study drug discontinuation
(severe)
1 140 Odds Ratio (M-H, Fixed, 95% CI) 0.36 [0.06, 2.25]
4 FEV1 % predicted - absolute
change from baseline
1 Mean Difference (Fixed, 95% CI) Subtotals only
4.1 At 16 weeks 1 140 Mean Difference (Fixed, 95% CI) 1.70 [-0.65, 4.05]
5 Antibiotic treatment of
sinopulmonary signs or
symptoms
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 At 16 weeks 1 140 Odds Ratio (M-H, Fixed, 95% CI) 0.56 [0.24, 1.30]
6 Weight (kg) - change from
baseline
1 Mean Difference (Fixed, 95% CI) Subtotals only
6.1 At 16 weeks 1 140 Mean Difference (Fixed, 95% CI) -0.2 [-1.18, 0.78]
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7 Sweat chloride concentration -
change from baseline
1 Mean Difference (Fixed, 95% CI) Subtotals only
7.1 At 16 weeks 1 140 Mean Difference (Fixed, 95% CI) -2.9 [-5.60, -0.20]
Comparison 2. Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR mutation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 CFQ-R score (respiratory
domain, child version) -
adjusted change from baseline
2 Mean Difference (Fixed, 95% CI) Subtotals only
1.1 At 24 weeks 2 51 Mean Difference (Fixed, 95% CI) 6.1 [-1.35, 13.55]
1.2 At 48 weeks 1 51 Mean Difference (Fixed, 95% CI) 5.1 [-1.56, 11.76]
2 CFQ-R score (respiratory
domain score, parent/caregiver
version) - adjusted change from
baseline
1 Mean Difference (Fixed, 95% CI) Subtotals only
2.1 At 24 weeks 1 52 Mean Difference (Fixed, 95% CI) 5.9 [0.41, 11.39]
2.2 At 48 weeks 1 52 Mean Difference (Fixed, 95% CI) 4.9 [-0.39, 10.19]
3 CFQ-R score (respiratory
domain score, pooled) -
absolute change from baseline
1 Mean Difference (Fixed, 95% CI) Subtotals only
3.1 At 24 weeks 1 151 Mean Difference (Fixed, 95% CI) 8.1 [4.77, 11.43]
3.2 At 48 weeks 1 151 Mean Difference (Fixed, 95% CI) 8.6 [5.27, 11.93]
4 FEV1 - mean relative change
from baseline
1 Mean Difference (Fixed, 95% CI) Subtotals only
4.1 24 weeks 1 161 Mean Difference (Fixed, 95% CI) 16.9 [13.60, 20.20]
4.2 48 weeks 1 161 Mean Difference (Fixed, 95% CI) 16.8 [13.50, 20.10]
5 Adverse events occurring in
greater than or equal to 5% of
trial participants
2 Odds Ratio (M-H, Fixed, 99% CI) Subtotals only
5.1 Pulmonary exacerbation 2 213 Odds Ratio (M-H, Fixed, 99% CI) 0.64 [0.30, 1.33]
5.2 Cough 2 213 Odds Ratio (M-H, Fixed, 99% CI) 0.57 [0.27, 1.19]
5.3 Productive Cough 2 213 Odds Ratio (M-H, Fixed, 99% CI) 0.81 [0.29, 2.24]
5.4 Pulmonary function test
decreased
2 213 Odds Ratio (M-H, Fixed, 99% CI) 0.29 [0.07, 1.14]
5.5 Wheezing 2 213 Odds Ratio (M-H, Fixed, 99% CI) 1.12 [0.28, 4.52]
5.6 Rales 2 213 Odds Ratio (M-H, Fixed, 99% CI) 0.86 [0.28, 2.69]
5.7 Oropharyngeal pain 2 213 Odds Ratio (M-H, Fixed, 99% CI) 1.26 [0.52, 3.05]
5.8 Nasal congestion 2 213 Odds Ratio (M-H, Fixed, 99% CI) 1.39 [0.55, 3.53]
5.9 Nasopharyngitis 2 213 Odds Ratio (M-H, Fixed, 99% CI) 1.32 [0.46, 3.76]
5.10 Upper respiratory tract
infection
2 213 Odds Ratio (M-H, Fixed, 99% CI) 1.91 [0.74, 4.90]
5.11 Bronchitis 1 52 Odds Ratio (M-H, Fixed, 99% CI) 1.57 [0.13, 18.48]
5.12 Otitis media 1 52 Odds Ratio (M-H, Fixed, 99% CI) 4.55 [0.23, 89.19]
5.13 Rhinorrhoea 2 213 Odds Ratio (M-H, Fixed, 99% CI) 0.65 [0.17, 2.45]
5.14 Sinusitis 2 213 Odds Ratio (M-H, Fixed, 99% CI) 0.75 [0.21, 2.68]
5.15 Ear Infection 1 52 Odds Ratio (M-H, Fixed, 99% CI) 0.18 [0.00, 10.67]
5.16 Pharyngitis streptococcal 1 52 Odds Ratio (M-H, Fixed, 99% CI) 5.41 [0.09, 312.04]
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5.17 Rhinitis 2 213 Odds Ratio (M-H, Fixed, 99% CI) 1.86 [0.40, 8.70]
5.18 Viral Infection 1 161 Odds Ratio (M-H, Fixed, 99% CI) 0.36 [0.04, 3.24]
5.19 Sinus Headache 1 161 Odds Ratio (M-H, Fixed, 99% CI) 1.44 [0.26, 8.01]
5.20 Headache 2 213 Odds Ratio (M-H, Fixed, 99% CI) 1.60 [0.66, 3.92]
5.21 Dizziness 1 161 Odds Ratio (M-H, Fixed, 99% CI) 10.55 [0.69, 162.40]
5.22 Pyrexia 2 213 Odds Ratio (M-H, Fixed, 99% CI) 0.96 [0.35, 2.60]
5.23 Fatigue 2 213 Odds Ratio (M-H, Fixed, 99% CI) 0.83 [0.23, 3.07]
5.24 Abdominal pain upper 2 213 Odds Ratio (M-H, Fixed, 99% CI) 0.87 [0.26, 2.91]
5.25 Abdominal pain 2 213 Odds Ratio (M-H, Fixed, 99% CI) 1.29 [0.46, 3.59]
5.26 Constipation 2 213 Odds Ratio (M-H, Fixed, 99% CI) 0.34 [0.06, 2.05]
5.27 Diarrhea 2 213 Odds Ratio (M-H, Fixed, 99% CI) 1.36 [0.45, 4.11]
5.28 Vomiting 2 213 Odds Ratio (M-H, Fixed, 99% CI) 0.58 [0.20, 1.68]
5.29 Nausea 2 213 Odds Ratio (M-H, Fixed, 99% CI) 1.13 [0.37, 3.40]
5.30 Gastrooesophageal reflux
disease
1 52 Odds Ratio (M-H, Fixed, 99% CI) 5.41 [0.09, 312.04]
5.31 Weight decreased 1 161 Odds Ratio (M-H, Fixed, 99% CI) 0.46 [0.05, 4.42]
5.32 Asparate
aminotransferase increased
2 213 Odds Ratio (M-H, Fixed, 99% CI) 2.02 [0.40, 10.31]
5.33 Alanine aminotransferase
increased
2 213 Odds Ratio (M-H, Fixed, 99% CI) 0.83 [0.21, 3.31]
5.34 Eosinophil count
increased
1 52 Odds Ratio (M-H, Fixed, 99% CI) 3.26 [0.15, 69.97]
5.35 C-reactive protein
increased
1 161 Odds Ratio (M-H, Fixed, 99% CI) 0.74 [0.12, 4.37]
5.36 Blood glucose increased 1 166 Odds Ratio (M-H, Fixed, 99% CI) 1.71 [0.25, 11.72]
5.37 Hypoglycaemia 1 161 Odds Ratio (M-H, Fixed, 99% CI) 0.69 [0.09, 5.18]
5.38 white blood cell count
decreased
1 52 Odds Ratio (M-H, Fixed, 99% CI) 5.41 [0.09, 312.04]
5.39 Bacteria sputum
Identified
2 213 Odds Ratio (M-H, Fixed, 99% CI) 2.02 [0.39, 10.32]
5.40 Joint Sprain 1 161 Odds Ratio (M-H, Fixed, 99% CI) 0.10 [0.00, 4.71]
5.41 Breath Sounds abnormal 2 213 Odds Ratio (M-H, Fixed, 99% CI) 0.35 [0.05, 2.49]
5.42 Arthralgia 1 161 Odds Ratio (M-H, Fixed, 99% CI) 1.34 [0.28, 6.44]
5.43 Myalgia 1 52 Odds Ratio (M-H, Fixed, 99% CI) 5.41 [0.09, 312.04]
5.44 Back pain 1 161 Odds Ratio (M-H, Fixed, 99% CI) 0.94 [0.17, 5.03]
5.45 Neck pain 1 52 Odds Ratio (M-H, Fixed, 99% CI) 5.41 [0.09, 312.04]
5.46 Haemoptysis 1 161 Odds Ratio (M-H, Fixed, 99% CI) 0.51 [0.16, 1.65]
5.47 Respiratory tract
congestion
2 213 Odds Ratio (M-H, Fixed, 99% CI) 0.71 [0.18, 2.86]
5.48 Sinus Congestion 1 161 Odds Ratio (M-H, Fixed, 99% CI) 1.97 [0.39, 10.10]
5.49 Dyspnoea 1 161 Odds Ratio (M-H, Fixed, 99% CI) 0.36 [0.04, 3.24]
5.50 Pleutiric pain 1 161 Odds Ratio (M-H, Fixed, 99% CI) 2.44 [0.27, 21.87]
5.51 Respiration abnormal 1 161 Odds Ratio (M-H, Fixed, 99% CI) 0.46 [0.05, 4.42]
5.52 Pharyngeal erythema 1 52 Odds Ratio (M-H, Fixed, 99% CI) 5.41 [0.09, 312.04]
5.53 Culture throat positive 1 51 Odds Ratio (M-H, Fixed, 99% CI) 2.17 [0.09, 55.58]
5.54 Rash 2 213 Odds Ratio (M-H, Fixed, 99% CI) 2.03 [0.58, 7.06]
5.55 Acne 1 161 Odds Ratio (M-H, Fixed, 99% CI) 1.95 [0.30, 12.62]
5.56 Lymphadenopathy 1 52 Odds Ratio (M-H, Fixed, 99% CI) 0.48 [0.02, 12.25]
5.57 Excoriation 1 52 Odds Ratio (M-H, Fixed, 99% CI) 0.48 [0.02, 12.25]
5.58 Neutrophil count
decreased
1 52 Odds Ratio (M-H, Fixed, 99% CI) 5.41 [0.09, 312.04]
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5.59 Forced expiratory
volume decreased
1 52 Odds Ratio (M-H, Fixed, 99% CI) 5.41 [0.09, 312.04]
5.60 Seasonal allergy 1 52 Odds Ratio (M-H, Fixed, 99% CI) 0.48 [0.02, 12.25]
5.61 Allergic rhinitis 1 52 Odds Ratio (M-H, Fixed, 99% CI) 5.41 [0.09, 312.04]
6 All adverse events 1 Odds Ratio (M-H, Fixed, 99% CI) Subtotals only
6.1 Cardiac Murmur 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.2 Chest discomfort 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.08 [0.00, 6.60]
6.3 Pulmonary exacerbation 1 19 Odds Ratio (M-H, Fixed, 99% CI) 1.67 [0.02, 114.48]
6.4 Upper respiratory tract
infection
1 19 Odds Ratio (M-H, Fixed, 99% CI) 1.67 [0.02, 114.48]
6.5 Respiratory tract
congestion
1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.6 Cough 1 19 Odds Ratio (M-H, Fixed, 99% CI) 1.09 [0.04, 30.57]
6.7 Cough decreased 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.8 Productive cough 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.21 [0.00, 11.63]
6.9 Sputum abnormal 1 19 Odds Ratio (M-H, Fixed, 99% CI) 1.67 [0.02, 114.48]
6.10 Sputum decreased 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.11 Sputum discolored 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.12 Increased upper airway
secretion
1 19 Odds Ratio (M-H, Fixed, 99% CI) 1.67 [0.02, 114.48]
6.13 Increased bronchial
secretion
1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.14 Rhonchi 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.15 Headache 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.16 Tension headache 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.17 Sinus headache 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.18 Sinusitis 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.19 Chronic sinusitis 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.08 [0.00, 6.60]
6.20 Sinus congestion 1 19 Odds Ratio (M-H, Fixed, 99% CI) 1.67 [0.02, 114.48]
6.21 Nasal congestion 1 19 Odds Ratio (M-H, Fixed, 99% CI) 1.67 [0.02, 114.48]
6.22 Nasal oedma 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.23 Nasal dryness 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.24 Nasal turbinate
abnormality
1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.25 Nasal septum disorder 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.26 Mucosal erosion 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.27 Epistaxis 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.28 Oral candidiasis 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.29 Pharyngeal oedema 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.30 Pharyngeal erythema 1 19 Odds Ratio (M-H, Fixed, 99% CI) 1.67 [0.02, 114.48]
6.31 Pharyngolaryngeal pain 1 19 Odds Ratio (M-H, Fixed, 99% CI) 1.67 [0.02, 114.48]
6.32 Tonsillar hypertrophy 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.08 [0.00, 6.60]
6.33 Abdominal distension 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.08 [0.00, 6.60]
6.34 Upper abdominal pain 1 19 Odds Ratio (M-H, Fixed, 99% CI) 1.67 [0.02, 114.48]
6.35 Decreased appetite 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.08 [0.00, 6.60]
6.36 Nausea 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.37 Vomiting 1 19 Odds Ratio (M-H, Fixed, 99% CI) 1.67 [0.02, 114.48]
6.38 Diarrhoea 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.46 [0.01, 16.23]
6.39 Flatulence 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.08 [0.00, 6.60]
6.40 Pyuria 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.41 White blood cells in
urine
1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
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6.42 Rash 1 19 Odds Ratio (M-H, Fixed, 99% CI) 1.67 [0.02, 114.48]
6.43 Contact dermatitis 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.08 [0.00, 6.60]
6.44 Erythema 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.45 Excoriation 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.46 Pruritis 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.47 Genital pruritis (female) 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.48 Vulvovaginal mycotic
infection
1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.49 Photosensitivity reaction 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.50 Allergy to arthropod bite 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.51 Skin laceration 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.52 Injection site oedema 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.53 Fatigue 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.54 Somnolence 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.55 Joint crepitation 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.56 Lymphadenopathy 1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
6.57 Blood creatinine
increased
1 19 Odds Ratio (M-H, Fixed, 99% CI) 0.93 [0.01, 78.14]
7 Severity of adverse effects of
therapy with regards to study
drug interruption (moderate)
or discontinuation (severe)
3 Odds Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Adverse effect requiring
study drug interruption
(moderate)
2 213 Odds Ratio (M-H, Random, 95% CI) 1.18 [0.14, 9.92]
7.2 Adverse effect requiring
study drug discontinuation
(severe)
3 232 Odds Ratio (M-H, Random, 95% CI) 0.25 [0.04, 1.57]
8 Serious adverse events 3 Odds Ratio (M-H, Fixed, 99% CI) Subtotals only
8.1 Haemoptysis 1 161 Odds Ratio (M-H, Fixed, 99% CI) 0.23 [0.01, 4.14]
8.2 Hypoglycaemia 1 161 Odds Ratio (M-H, Fixed, 99% CI) 0.18 [0.00, 10.12]
8.3 Complete atrioventricular
block
1 161 Odds Ratio (M-H, Fixed, 99% CI) 0.31 [0.00, 21.17]
8.4 Pulmonary exacerbation 2 213 Odds Ratio (M-H, Fixed, 99% CI) 0.34 [0.13, 0.88]
8.5 Gastrooesophageal reflux 1 161 Odds Ratio (M-H, Fixed, 99% CI) 0.31 [0.00, 21.17]
8.6 Pancreatic pseudocyst 1 161 Odds Ratio (M-H, Fixed, 99% CI) 2.85 [0.04, 195.35]
8.7 Pancreatitis 1 161 Odds Ratio (M-H, Fixed, 99% CI) 2.85 [0.04, 195.35]
8.8 Vomiting 1 161 Odds Ratio (M-H, Fixed, 99% CI) 0.31 [0.00, 21.17]
8.9 Abdominal pain 1 52 Odds Ratio (M-H, Fixed, 99% CI) 3.12 [0.04, 222.22]
8.10 Constipation 1 52 Odds Ratio (M-H, Fixed, 99% CI) 0.32 [0.00, 22.86]
8.11 Weight decreased 1 161 Odds Ratio (M-H, Fixed, 99% CI) 2.85 [0.04, 195.35]
8.12 Anaphylactic shock 1 161 Odds Ratio (M-H, Fixed, 99% CI) 2.85 [0.04, 195.35]
8.13 Catheter related
complication
1 161 Odds Ratio (M-H, Fixed, 99% CI) 0.31 [0.00, 21.17]
8.14 Implant site infection 1 161 Odds Ratio (M-H, Fixed, 99% CI) 0.31 [0.00, 21.17]
8.15 Influenza 1 161 Odds Ratio (M-H, Fixed, 99% CI) 2.85 [0.04, 195.35]
8.16 Pseudomonal lung
infection
2 213 Odds Ratio (M-H, Fixed, 99% CI) 0.31 [0.02, 6.34]
8.17 Pneumonia 1 161 Odds Ratio (M-H, Fixed, 99% CI) 2.85 [0.04, 195.35]
8.18 Sinusitis 1 161 Odds Ratio (M-H, Fixed, 99% CI) 2.85 [0.04, 195.35]
8.19 Cough 1 161 Odds Ratio (M-H, Fixed, 99% CI) 2.85 [0.04, 195.35]
8.20 Pleuritic pain 1 161 Odds Ratio (M-H, Fixed, 99% CI) 2.85 [0.04, 195.35]
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8.21 Pulmonary embolism 1 161 Odds Ratio (M-H, Fixed, 99% CI) 0.31 [0.00, 21.17]
8.22 Respiratory distress 1 161 Odds Ratio (M-H, Fixed, 99% CI) 0.31 [0.00, 21.17]
8.23 Productive cough 1 52 Odds Ratio (M-H, Fixed, 99% CI) 1.0 [0.02, 41.06]
8.24 Respiratory failure 1 161 Odds Ratio (M-H, Fixed, 99% CI) 0.31 [0.00, 21.17]
8.25 Pulmonary function test
decreased
1 52 Odds Ratio (M-H, Fixed, 99% CI) 0.32 [0.00, 22.86]
8.26 Lung consolidation 1 52 Odds Ratio (M-H, Fixed, 99% CI) 0.32 [0.00, 22.86]
8.27 Myringitis bullous 1 161 Odds Ratio (M-H, Fixed, 99% CI) 2.85 [0.04, 195.35]
8.28 Hepatic enzyme
increased
1 161 Odds Ratio (M-H, Fixed, 99% CI) 2.85 [0.04, 195.35]
8.29 Cervix carcinoma 1 161 Odds Ratio (M-H, Fixed, 99% CI) 2.85 [0.04, 195.35]
8.30 Musculoskeletal chest
pain
1 161 Odds Ratio (M-H, Fixed, 99% CI) 2.85 [0.04, 195.35]
8.31 Pain in extremity 1 161 Odds Ratio (M-H, Fixed, 99% CI) 0.31 [0.00, 21.17]
8.32 Spontaneous abortion 1 161 Odds Ratio (M-H, Fixed, 99% CI) 2.85 [0.04, 195.35]
8.33 Haematuria 1 161 Odds Ratio (M-H, Fixed, 99% CI) 2.85 [0.04, 195.35]
8.34 IgA nephropathy 1 161 Odds Ratio (M-H, Fixed, 99% CI) 2.85 [0.04, 195.35]
8.35 Nephrolithiasis 1 161 Odds Ratio (M-H, Fixed, 99% CI) 0.31 [0.00, 21.17]
8.36 Renal Colic 1 161 Odds Ratio (M-H, Fixed, 99% CI) 0.31 [0.00, 21.17]
8.37 Testicular torsion 1 161 Odds Ratio (M-H, Fixed, 99% CI) 0.31 [0.00, 21.17]
8.38 Pyrexia 1 52 Odds Ratio (M-H, Fixed, 99% CI) 3.12 [0.04, 222.22]
8.39 Muscle strain 1 52 Odds Ratio (M-H, Fixed, 99% CI) 3.12 [0.04, 222.22]
8.40 Hepatic enzyme
increased
1 52 Odds Ratio (M-H, Fixed, 99% CI) 3.12 [0.04, 222.22]
8.41 Adjustment disorder 1 52 Odds Ratio (M-H, Fixed, 99% CI) 0.32 [0.00, 22.86]
8.42 Anxiety 1 52 Odds Ratio (M-H, Fixed, 99% CI) 0.32 [0.00, 22.86]
8.43 Affective disorder 1 52 Odds Ratio (M-H, Fixed, 99% CI) 0.32 [0.00, 22.86]
8.44 Conversion disorder 1 52 Odds Ratio (M-H, Fixed, 99% CI) 3.12 [0.04, 222.22]
9 The number of G551D
participants who developed
episodes of pulmonary
exacerbation
3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 At 1 month 1 19 Odds Ratio (M-H, Fixed, 95% CI) 1.67 [0.07, 41.64]
9.2 At 48 weeks 2 213 Odds Ratio (M-H, Fixed, 95% CI) 0.64 [0.36, 1.12]
10 Time to first pulmonary
exacerbation
1 Hazard Ratio (Fixed, 95% CI) Subtotals only
10.1 At 24 weeks 1 161 Hazard Ratio (Fixed, 95% CI) 0.46 [0.28, 0.76]
10.2 At 48 weeks 1 161 Hazard Ratio (Fixed, 95% CI) 0.46 [0.29, 0.73]
11 Maximum liver function
test abnormalities in
adolescents/adults at 48 weeks
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
11.1 2x to 3x ULN AST 1 161 Odds Ratio (M-H, Fixed, 95% CI) 1.97 [0.57, 6.84]
11.2 2x to 3x ULN ALT 1 161 Odds Ratio (M-H, Fixed, 95% CI) 0.77 [0.23, 2.63]
11.3 2x to 3x ULN Bilirubin 1 161 Odds Ratio (M-H, Fixed, 95% CI) 1.90 [0.17, 21.39]
11.4 3x to 5x ULN AST 1 161 Odds Ratio (M-H, Fixed, 95% CI) 0.46 [0.04, 5.21]
11.5 3x to 5x ULN ALT 1 161 Odds Ratio (M-H, Fixed, 95% CI) 0.18 [0.01, 3.88]
11.6 3x to 5x ULN Bilirubin 1 161 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.7 5x to 8x ULN AST 1 161 Odds Ratio (M-H, Fixed, 95% CI) 2.85 [0.11, 71.12]
11.8 5x to 8x ULN ALT 1 161 Odds Ratio (M-H, Fixed, 95% CI) 0.31 [0.01, 7.71]
11.9 5x to 8x ULN Bilirubin 1 161 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.10 8x AST 1 161 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.06, 15.28]
11.11 8x ALT 1 161 Odds Ratio (M-H, Fixed, 95% CI) 6.83 [0.35, 134.32]
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11.12 8x Bilirubin 1 161 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Duration of hospitalisation for
pulmonary exacerbation
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
12.1 At 48 weeks 1 161 Mean Difference (IV, Fixed, 95% CI) -0.23 [-3.74, 3.28]
13 Number of hospitalisations for
pulmonary exacerbations
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
13.1 At 48 weeks 1 161 Odds Ratio (M-H, Fixed, 95% CI) 0.37 [0.16, 0.81]
14 FEV1 (% predicted) - mean
absolute change from baseline
2 Mean Difference (Fixed, 95% CI) Subtotals only
14.1 24 weeks 2 213 Mean Difference (Fixed, 95% CI) 10.80 [8.91, 12.69]
14.2 48 weeks 2 213 Mean Difference (Fixed, 95% CI) 10.44 [8.56, 12.32]
15 FEV1 (litres) - mean absolute
change from baseline
2 Mean Difference (Random, 95% CI) Subtotals only
15.1 24 weeks 2 212 Mean Difference (Random, 95% CI) 0.33 [0.17, 0.49]
15.2 48 weeks 2 212 Mean Difference (Random, 95% CI) 0.31 [0.11, 0.50]
16 Change from baseline through
week 24 in percent of predicted
FEV1 according to subgroup
1 Mean Difference (Fixed, 95% CI) Subtotals only
16.1 Subgroup 1: Baseline
FEV1 of less than or equal to
90% predicted
1 30 Mean Difference (Fixed, 95% CI) 14.9 [7.30, 22.50]
16.2 Subgroup 2: Baseline
FEV1 of more than 90%
predicted
1 21 Mean Difference (Fixed, 95% CI) 6.9 [-3.80, 17.60]
16.3 Subgroup 3: North
America
1 26 Mean Difference (Fixed, 95% CI) 5.8 [-2.60, 14.20]
16.4 Subgroup 4: Europe 1 11 Mean Difference (Fixed, 95% CI) 24.60 [6.40, 42.80]
16.5 Subgroup 5: Australia 1 14 Mean Difference (Fixed, 95% CI) 4.2 [-3.70, 12.10]
16.6 Subgroup 6: Male 1 24 Mean Difference (Fixed, 95% CI) 5.2 [-2.20, 12.60]
16.7 Subgroup 7: Female 1 27 Mean Difference (Fixed, 95% CI) 13.8 [4.20, 23.40]
17 Number of pulmonary
exacerbations requiring
intravenous antibiotics
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
17.1 At 48 weeks 1 161 Odds Ratio (M-H, Fixed, 95% CI) 0.34 [0.18, 0.64]
18 Days with intravenous
antibiotics administered for
pulmonary exacerbations
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
18.1 At 48 weeks 1 161 Mean Difference (IV, Fixed, 95% CI) -4.35 [-10.51, 1.81]
19 Weight - change from baseline
(kg)
2 Mean Difference (Fixed, 95% CI) Subtotals only
19.1 At 24 weeks 2 213 Mean Difference (Fixed, 95% CI) 2.37 [1.68, 3.06]
19.2 at 48 weeks 2 213 Mean Difference (Fixed, 95% CI) 2.75 [1.74, 3.75]
20 Sweat chloride level - change
from baseline
2 Mean Difference (Random, 95% CI) Subtotals only
20.1 At 24 weeks 2 213 Mean Difference (Random, 95% CI) -50.19 [-56.20, -44.
18]
20.2 At 48 weeks 2 213 Mean Difference (Random, 95% CI) -49.74 [-54.61, -44.
87]
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Comparison 3. Ivacaftor (VX-770) versus placebo in people with at least one R117H CFTR mutation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 CFQ-R score (respiratory
domain score, pooled) -
absolute change from baseline
1 Mean Difference (Fixed, 95% CI) Subtotals only
1.1 At 24 weeks 1 69 Mean Difference (Fixed, 95% CI) 8.4 [2.17, 14.63]
2 FEV1 relative change from
baseline
1 Mean Difference (Fixed, 95% CI) Subtotals only
2.1 At 24 weeks 1 69 Mean Difference (Fixed, 95% CI) 5.0 [-0.24, 10.24]
3 Adverse events 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Any adverse event 1 69 Odds Ratio (M-H, Fixed, 95% CI) 0.18 [0.01, 3.96]
3.2 Serious adverse event 1 69 Odds Ratio (M-H, Fixed, 95% CI) 0.64 [0.16, 2.52]
3.3 Adverse event leading to
discontinuation
1 69 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Adverse events in > 15% of
participants
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Pulmonary exacerbation 1 69 Odds Ratio (M-H, Fixed, 95% CI) 0.93 [0.35, 2.44]
4.2 Cough 1 69 Odds Ratio (M-H, Fixed, 95% CI) 1.20 [0.42, 3.47]
4.3 Headache 1 69 Odds Ratio (M-H, Fixed, 95% CI) 1.29 [0.35, 4.69]
4.4 Increased sputum 1 69 Odds Ratio (M-H, Fixed, 95% CI) 1.34 [0.33, 5.47]
4.5 Nasal congestion 1 69 Odds Ratio (M-H, Fixed, 95% CI) 1.34 [0.33, 5.47]
4.6 Oropharyhgeal pain 1 69 Odds Ratio (M-H, Fixed, 95% CI) 2.84 [0.51, 15.79]
4.7 Diarrhoea 1 69 Odds Ratio (M-H, Fixed, 95% CI) 1.34 [0.33, 5.47]
4.8 Abdominal pain 1 69 Odds Ratio (M-H, Fixed, 95% CI) 10.48 [0.54, 202.47]
4.9 Wheezing 1 69 Odds Ratio (M-H, Fixed, 95% CI) 4.53 [0.48, 42.82]
4.10 Cystic fibrosis lung
pathogen colonisation
1 69 Odds Ratio (M-H, Fixed, 95% CI) 3.29 [0.32, 33.31]
5 Summary of pulmonary
exacerbations
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 All pulmonary
exacerbations
1 69 Odds Ratio (M-H, Fixed, 95% CI) 0.81 [0.30, 2.19]
5.2Number of hospitalisations
for pulmonary exacerbation
1 69 Odds Ratio (M-H, Fixed, 95% CI) 0.30 [0.06, 1.62]
5.3 Number of pulmonary
exacerbations requiring
intravenous antibiotics
1 69 Odds Ratio (M-H, Fixed, 95% CI) 0.30 [0.06, 1.62]
6 Time to first pulmonary
exacerbation
1 Hazard Ratio (Fixed, 95% CI) Subtotals only
6.1 At 24 weeks 1 69 Hazard Ratio (Fixed, 95% CI) 0.93 [0.42, 2.08]
7 FEV1 predicted % absolute
change from baseline
1 Mean Difference (Fixed, 95% CI) Subtotals only
7.1 At 24 weeks 1 69 Mean Difference (Fixed, 95% CI) 2.1 [-1.13, 5.33]
8 BMI absolute change from
baseline
1 Mean Difference (Fixed, 95% CI) Subtotals only
8.1 At 24 weeks 1 69 Mean Difference (Fixed, 95% CI) 0.26 [-1.57, 2.09]
9 Sweat chloride concentration -
change from baseline
1 Mean Difference (Fixed, 95% CI) Subtotals only
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9.1 At 24 weeks 1 69 Mean Difference (Fixed, 95% CI) -22.00 [-28.01, -19.
99]
Analysis 1.1. Comparison 1 Ivacaftor (VX-770) versus placebo in people with the F508del CFTR mutation,
Outcome 1 FEV1 - relative change from baseline.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 1 Ivacaftor (VX-770) versus placebo in people with the F508del CFTR mutation
Outcome: 1 FEV1 - relative change from baseline
Study or subgroup Ivacaftor Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 At 16 weeks
DISCOVER 2011 112 28 2.4 (1.70918367) 100.0 % 2.40 [ -0.95, 5.75 ]
Subtotal (95% CI) 112 28 100.0 % 2.40 [ -0.95, 5.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
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Analysis 1.2. Comparison 1 Ivacaftor (VX-770) versus placebo in people with the F508del CFTR mutation,
Outcome 2 Adverse effects.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 1 Ivacaftor (VX-770) versus placebo in people with the F508del CFTR mutation
Outcome: 2 Adverse effects
Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pulmonary exacerbation
DISCOVER 2011 25/112 11/28 100.0 % 0.44 [ 0.18, 1.07 ]
Subtotal (99% CI) 112 28 100.0 % 0.44 [ 0.14, 1.41 ]
Total events: 25 (Ivacaftor), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.070)
2 Upper respiratory tract infection
DISCOVER 2011 11/112 2/28 100.0 % 1.42 [ 0.30, 6.79 ]
Subtotal (99% CI) 112 28 100.0 % 1.42 [ 0.18, 11.10 ]
Total events: 11 (Ivacaftor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.66)
3 Cough
DISCOVER 2011 34/112 4/28 100.0 % 2.62 [ 0.84, 8.12 ]
Subtotal (99% CI) 112 28 100.0 % 2.62 [ 0.59, 11.59 ]
Total events: 34 (Ivacaftor), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.096)
4 Productive cough
DISCOVER 2011 9/112 1/28 100.0 % 2.36 [ 0.29, 19.44 ]
Subtotal (99% CI) 112 28 100.0 % 2.36 [ 0.15, 37.71 ]
Total events: 9 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.43)
5 Headache
DISCOVER 2011 11/112 2/28 100.0 % 1.42 [ 0.30, 6.79 ]
Subtotal (99% CI) 112 28 100.0 % 1.42 [ 0.18, 11.10 ]
Total events: 11 (Ivacaftor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.66)
6 Nasal congestion
DISCOVER 2011 13/112 2/28 100.0 % 1.71 [ 0.36, 8.04 ]
Subtotal (99% CI) 112 28 100.0 % 1.71 [ 0.22, 13.09 ]
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Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 13 (Ivacaftor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
7 Sinusitis
DISCOVER 2011 8/112 1/28 100.0 % 2.08 [ 0.25, 17.33 ]
Subtotal (99% CI) 112 28 100.0 % 2.08 [ 0.13, 33.75 ]
Total events: 8 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
8 Oropharyngeal pain
DISCOVER 2011 10/112 3/28 100.0 % 0.82 [ 0.21, 3.19 ]
Subtotal (99% CI) 112 28 100.0 % 0.82 [ 0.14, 4.90 ]
Total events: 10 (Ivacaftor), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
9 Upper abdominal pain
DISCOVER 2011 7/112 1/28 100.0 % 1.80 [ 0.21, 15.26 ]
Subtotal (99% CI) 112 28 100.0 % 1.80 [ 0.11, 29.87 ]
Total events: 7 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
10 Nausea
DISCOVER 2011 10/112 1/28 100.0 % 2.65 [ 0.32, 21.59 ]
Subtotal (99% CI) 112 28 100.0 % 2.65 [ 0.17, 41.76 ]
Total events: 10 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
11 Diarrhea
DISCOVER 2011 6/112 2/28 100.0 % 0.74 [ 0.14, 3.86 ]
Subtotal (99% CI) 112 28 100.0 % 0.74 [ 0.08, 6.49 ]
Total events: 6 (Ivacaftor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
12 Contact dermatitis
DISCOVER 2011 6/112 0/28 100.0 % 3.48 [ 0.19, 63.61 ]
Subtotal (99% CI) 112 28 100.0 % 3.48 [ 0.08, 158.51 ]
Total events: 6 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
13 Rash
DISCOVER 2011 9/112 0/28 100.0 % 5.23 [ 0.30, 92.63 ]
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Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (99% CI) 112 28 100.0 % 5.23 [ 0.12, 228.54 ]
Total events: 9 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
14 Fatigue
DISCOVER 2011 9/112 3/28 100.0 % 0.73 [ 0.18, 2.89 ]
Subtotal (99% CI) 112 28 100.0 % 0.73 [ 0.12, 4.45 ]
Total events: 9 (Ivacaftor), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
15 Pyrexia
DISCOVER 2011 9/112 2/28 100.0 % 1.14 [ 0.23, 5.58 ]
Subtotal (99% CI) 112 28 100.0 % 1.14 [ 0.14, 9.20 ]
Total events: 9 (Ivacaftor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.88)
16 Increase in C-reactive protein
DISCOVER 2011 6/112 1/28 100.0 % 1.53 [ 0.18, 13.24 ]
Subtotal (99% CI) 112 28 100.0 % 1.53 [ 0.09, 26.08 ]
Total events: 6 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
0.01 0.1 1 10 100
Favours ivacaftor Favours placebo
78Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.3. Comparison 1 Ivacaftor (VX-770) versus placebo in people with the F508del CFTR mutation,
Outcome 3 Severity of adverse effects of therapy with regards to study drug interruption (moderate) or
discontinuation (severe).
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 1 Ivacaftor (VX-770) versus placebo in people with the F508del CFTR mutation
Outcome: 3 Severity of adverse effects of therapy with regards to study drug interruption (moderate) or discontinuation (severe)
Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adverse effect requiring study drug interruption (moderate)
DISCOVER 2011 2/112 0/28 100.0 % 1.29 [ 0.06, 27.62 ]
Subtotal (95% CI) 112 28 100.0 % 1.29 [ 0.06, 27.62 ]
Total events: 2 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
2 Adverse effect requiring study drug discontinuation (severe)
DISCOVER 2011 3/112 2/28 100.0 % 0.36 [ 0.06, 2.25 ]
Subtotal (95% CI) 112 28 100.0 % 0.36 [ 0.06, 2.25 ]
Total events: 3 (Ivacaftor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
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Analysis 1.4. Comparison 1 Ivacaftor (VX-770) versus placebo in people with the F508del CFTR mutation,
Outcome 4 FEV1 % predicted - absolute change from baseline.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 1 Ivacaftor (VX-770) versus placebo in people with the F508del CFTR mutation
Outcome: 4 FEV1 % predicted - absolute change from baseline
Study or subgroup Ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 At 16 weeks
DISCOVER 2011 112 28 1.7 (1.2) 100.0 % 1.70 [ -0.65, 4.05 ]
Subtotal (95% CI) 112 28 100.0 % 1.70 [ -0.65, 4.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
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Analysis 1.5. Comparison 1 Ivacaftor (VX-770) versus placebo in people with the F508del CFTR mutation,
Outcome 5 Antibiotic treatment of sinopulmonary signs or symptoms.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 1 Ivacaftor (VX-770) versus placebo in people with the F508del CFTR mutation
Outcome: 5 Antibiotic treatment of sinopulmonary signs or symptoms
Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 16 weeks
DISCOVER 2011 48/112 16/28 100.0 % 0.56 [ 0.24, 1.30 ]
Subtotal (95% CI) 112 28 100.0 % 0.56 [ 0.24, 1.30 ]
Total events: 48 (Ivacaftor), 16 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
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Analysis 1.6. Comparison 1 Ivacaftor (VX-770) versus placebo in people with the F508del CFTR mutation,
Outcome 6 Weight (kg) - change from baseline.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 1 Ivacaftor (VX-770) versus placebo in people with the F508del CFTR mutation
Outcome: 6 Weight (kg) - change from baseline
Study or subgroup Ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 At 16 weeks
DISCOVER 2011 112 28 -0.2 (0.5) 100.0 % -0.20 [ -1.18, 0.78 ]
Subtotal (95% CI) 112 28 100.0 % -0.20 [ -1.18, 0.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
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Analysis 1.7. Comparison 1 Ivacaftor (VX-770) versus placebo in people with the F508del CFTR mutation,
Outcome 7 Sweat chloride concentration - change from baseline.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 1 Ivacaftor (VX-770) versus placebo in people with the F508del CFTR mutation
Outcome: 7 Sweat chloride concentration - change from baseline
Study or subgroup Ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 At 16 weeks
DISCOVER 2011 112 28 -2.9 (1.38) 100.0 % -2.90 [ -5.60, -0.20 ]
Subtotal (95% CI) 112 28 100.0 % -2.90 [ -5.60, -0.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.10 (P = 0.036)
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Analysis 2.1. Comparison 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR
mutation, Outcome 1 CFQ-R score (respiratory domain, child version) - adjusted change from baseline.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR mutation
Outcome: 1 CFQ-R score (respiratory domain, child version) - adjusted change from baseline
Study or subgroup Ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 At 24 weeks
ENVISION 2013 26 25 6.1 (3.8) 100.0 % 6.10 [ -1.35, 13.55 ]
KONDUCT 2015 0 0 0 (0) Not estimable
Subtotal (95% CI) 26 25 100.0 % 6.10 [ -1.35, 13.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
2 At 48 weeks
ENVISION 2013 26 25 5.1 (3.4) 100.0 % 5.10 [ -1.56, 11.76 ]
Subtotal (95% CI) 26 25 100.0 % 5.10 [ -1.56, 11.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
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Analysis 2.2. Comparison 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR
mutation, Outcome 2 CFQ-R score (respiratory domain score, parent/caregiver version) - adjusted change
from baseline.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR mutation
Outcome: 2 CFQ-R score (respiratory domain score, parent/caregiver version) - adjusted change from baseline
Study or subgroup Ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 At 24 weeks
ENVISION 2013 26 26 5.9 (2.8) 100.0 % 5.90 [ 0.41, 11.39 ]
Subtotal (95% CI) 26 26 100.0 % 5.90 [ 0.41, 11.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
2 At 48 weeks
ENVISION 2013 26 26 4.9 (2.7) 100.0 % 4.90 [ -0.39, 10.19 ]
Subtotal (95% CI) 26 26 100.0 % 4.90 [ -0.39, 10.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.070)
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Analysis 2.3. Comparison 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR
mutation, Outcome 3 CFQ-R score (respiratory domain score, pooled) - absolute change from baseline.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR mutation
Outcome: 3 CFQ-R score (respiratory domain score, pooled) - absolute change from baseline
Study or subgroup Ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 At 24 weeks
STRIVE 2011 80 71 8.1 (1.7) 100.0 % 8.10 [ 4.77, 11.43 ]
Subtotal (95% CI) 80 71 100.0 % 8.10 [ 4.77, 11.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.76 (P < 0.00001)
2 At 48 weeks
STRIVE 2011 80 71 8.6 (1.7) 100.0 % 8.60 [ 5.27, 11.93 ]
Subtotal (95% CI) 80 71 100.0 % 8.60 [ 5.27, 11.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.06 (P < 0.00001)
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Analysis 2.4. Comparison 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR
mutation, Outcome 4 FEV1 - mean relative change from baseline.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR mutation
Outcome: 4 FEV1 - mean relative change from baseline
Study or subgroup Ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 24 weeks
STRIVE 2011 83 78 16.9 (1.68367347) 100.0 % 16.90 [ 13.60, 20.20 ]
Subtotal (95% CI) 83 78 100.0 % 16.90 [ 13.60, 20.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 10.04 (P < 0.00001)
2 48 weeks
STRIVE 2011 83 78 16.8 (1.68367347) 100.0 % 16.80 [ 13.50, 20.10 ]
Subtotal (95% CI) 83 78 100.0 % 16.80 [ 13.50, 20.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.98 (P < 0.00001)
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Analysis 2.5. Comparison 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR
mutation, Outcome 5 Adverse events occurring in greater than or equal to 5% of trial participants.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR mutation
Outcome: 5 Adverse events occurring in greater than or equal to 5% of trial participants
Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Pulmonary exacerbation
ENVISION 2013 7/26 6/26 14.4 % 1.23 [ 0.23, 6.42 ]
STRIVE 2011 29/83 39/78 85.6 % 0.54 [ 0.23, 1.23 ]
Subtotal (99% CI) 109 104 100.0 % 0.64 [ 0.30, 1.33 ]
Total events: 36 (Ivacaftor), 45 (Placebo)
Heterogeneity: Chi2 = 1.32, df = 1 (P = 0.25); I2 =25%
Test for overall effect: Z = 1.58 (P = 0.11)
2 Cough
ENVISION 2013 13/26 19/26 29.3 % 0.37 [ 0.08, 1.69 ]
STRIVE 2011 27/83 33/78 70.7 % 0.66 [ 0.28, 1.53 ]
Subtotal (99% CI) 109 104 100.0 % 0.57 [ 0.27, 1.19 ]
Total events: 40 (Ivacaftor), 52 (Placebo)
Heterogeneity: Chi2 = 0.73, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 1.95 (P = 0.051)
3 Productive Cough
ENVISION 2013 2/26 5/26 32.2 % 0.35 [ 0.04, 3.45 ]
STRIVE 2011 12/83 11/78 67.8 % 1.03 [ 0.32, 3.29 ]
Subtotal (99% CI) 109 104 100.0 % 0.81 [ 0.29, 2.24 ]
Total events: 14 (Ivacaftor), 16 (Placebo)
Heterogeneity: Chi2 = 1.17, df = 1 (P = 0.28); I2 =15%
Test for overall effect: Z = 0.53 (P = 0.59)
4 Pulmonary function test decreased
ENVISION 2013 2/26 4/26 25.2 % 0.46 [ 0.04, 4.84 ]
STRIVE 2011 3/83 11/78 74.8 % 0.23 [ 0.04, 1.29 ]
Subtotal (99% CI) 109 104 100.0 % 0.29 [ 0.07, 1.14 ]
Total events: 5 (Ivacaftor), 15 (Placebo)
Heterogeneity: Chi2 = 0.38, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 2.33 (P = 0.020)
5 Wheezing
ENVISION 2013 3/26 4/26 54.9 % 0.72 [ 0.09, 5.93 ]
STRIVE 2011 5/83 3/78 45.1 % 1.60 [ 0.23, 11.00 ]
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Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Subtotal (99% CI) 109 104 100.0 % 1.12 [ 0.28, 4.52 ]
Total events: 8 (Ivacaftor), 7 (Placebo)
Heterogeneity: Chi2 = 0.52, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
6 Rales
ENVISION 2013 2/26 4/26 33.4 % 0.46 [ 0.04, 4.84 ]
STRIVE 2011 9/83 8/78 66.6 % 1.06 [ 0.28, 4.00 ]
Subtotal (99% CI) 109 104 100.0 % 0.86 [ 0.28, 2.69 ]
Total events: 11 (Ivacaftor), 12 (Placebo)
Heterogeneity: Chi2 = 0.64, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.74)
7 Oropharyngeal pain
ENVISION 2013 7/26 4/26 19.2 % 2.03 [ 0.33, 12.32 ]
STRIVE 2011 17/83 15/78 80.8 % 1.08 [ 0.39, 3.00 ]
Subtotal (99% CI) 109 104 100.0 % 1.26 [ 0.52, 3.05 ]
Total events: 24 (Ivacaftor), 19 (Placebo)
Heterogeneity: Chi2 = 0.61, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.50)
8 Nasal congestion
ENVISION 2013 5/26 4/26 24.7 % 1.31 [ 0.20, 8.74 ]
STRIVE 2011 17/83 12/78 75.3 % 1.42 [ 0.49, 4.13 ]
Subtotal (99% CI) 109 104 100.0 % 1.39 [ 0.55, 3.53 ]
Total events: 22 (Ivacaftor), 16 (Placebo)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
9 Nasopharyngitis
ENVISION 2013 6/26 2/26 14.5 % 3.60 [ 0.38, 33.92 ]
STRIVE 2011 10/83 10/78 85.5 % 0.93 [ 0.27, 3.19 ]
Subtotal (99% CI) 109 104 100.0 % 1.32 [ 0.46, 3.76 ]
Total events: 16 (Ivacaftor), 12 (Placebo)
Heterogeneity: Chi2 = 1.86, df = 1 (P = 0.17); I2 =46%
Test for overall effect: Z = 0.68 (P = 0.50)
10 Upper respiratory tract infection
ENVISION 2013 6/26 2/26 13.9 % 3.60 [ 0.38, 33.92 ]
STRIVE 2011 19/83 12/78 86.1 % 1.63 [ 0.57, 4.67 ]
Subtotal (99% CI) 109 104 100.0 % 1.91 [ 0.74, 4.90 ]
Total events: 25 (Ivacaftor), 14 (Placebo)
Heterogeneity: Chi2 = 0.68, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 1.76 (P = 0.078)
11 Bronchitis
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Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
ENVISION 2013 3/26 2/26 100.0 % 1.57 [ 0.13, 18.48 ]
Subtotal (99% CI) 26 26 100.0 % 1.57 [ 0.13, 18.48 ]
Total events: 3 (Ivacaftor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
12 Otitis media
ENVISION 2013 4/26 1/26 100.0 % 4.55 [ 0.23, 89.19 ]
Subtotal (99% CI) 26 26 100.0 % 4.55 [ 0.23, 89.19 ]
Total events: 4 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
13 Rhinorrhoea
ENVISION 2013 3/26 4/26 37.5 % 0.72 [ 0.09, 5.93 ]
STRIVE 2011 4/83 6/78 62.5 % 0.61 [ 0.11, 3.38 ]
Subtotal (99% CI) 109 104 100.0 % 0.65 [ 0.17, 2.45 ]
Total events: 7 (Ivacaftor), 10 (Placebo)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
14 Sinusitis
ENVISION 2013 2/26 3/26 29.3 % 0.64 [ 0.05, 7.54 ]
STRIVE 2011 6/83 7/78 70.7 % 0.79 [ 0.18, 3.52 ]
Subtotal (99% CI) 109 104 100.0 % 0.75 [ 0.21, 2.68 ]
Total events: 8 (Ivacaftor), 10 (Placebo)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.55)
15 Ear Infection
ENVISION 2013 0/26 2/26 100.0 % 0.18 [ 0.00, 10.67 ]
Subtotal (99% CI) 26 26 100.0 % 0.18 [ 0.00, 10.67 ]
Total events: 0 (Ivacaftor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
16 Pharyngitis streptococcal
ENVISION 2013 2/26 0/26 100.0 % 5.41 [ 0.09, 312.04 ]
Subtotal (99% CI) 26 26 100.0 % 5.41 [ 0.09, 312.04 ]
Total events: 2 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
17 Rhinitis
ENVISION 2013 2/26 0/26 10.6 % 5.41 [ 0.09, 312.04 ]
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Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
STRIVE 2011 6/83 4/78 89.4 % 1.44 [ 0.26, 8.01 ]
Subtotal (99% CI) 109 104 100.0 % 1.86 [ 0.40, 8.70 ]
Total events: 8 (Ivacaftor), 4 (Placebo)
Heterogeneity: Chi2 = 0.61, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
18 Viral Infection
STRIVE 2011 2/83 5/78 100.0 % 0.36 [ 0.04, 3.24 ]
Subtotal (99% CI) 83 78 100.0 % 0.36 [ 0.04, 3.24 ]
Total events: 2 (Ivacaftor), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
19 Sinus Headache
STRIVE 2011 6/83 4/78 100.0 % 1.44 [ 0.26, 8.01 ]
Subtotal (99% CI) 83 78 100.0 % 1.44 [ 0.26, 8.01 ]
Total events: 6 (Ivacaftor), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
20 Headache
ENVISION 2013 7/26 4/26 22.0 % 2.03 [ 0.33, 12.32 ]
STRIVE 2011 19/83 13/78 78.0 % 1.48 [ 0.53, 4.17 ]
Subtotal (99% CI) 109 104 100.0 % 1.60 [ 0.66, 3.92 ]
Total events: 26 (Ivacaftor), 17 (Placebo)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.36 (P = 0.17)
21 Dizziness
STRIVE 2011 10/83 1/78 100.0 % 10.55 [ 0.69, 162.40 ]
Subtotal (99% CI) 83 78 100.0 % 10.55 [ 0.69, 162.40 ]
Total events: 10 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.22 (P = 0.026)
22 Pyrexia
ENVISION 2013 6/26 7/26 39.8 % 0.81 [ 0.16, 4.26 ]
STRIVE 2011 10/83 9/78 60.2 % 1.05 [ 0.30, 3.70 ]
Subtotal (99% CI) 109 104 100.0 % 0.96 [ 0.35, 2.60 ]
Total events: 16 (Ivacaftor), 16 (Placebo)
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.91)
23 Fatigue
ENVISION 2013 1/26 2/26 22.5 % 0.48 [ 0.02, 12.25 ]
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Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
STRIVE 2011 7/83 7/78 77.5 % 0.93 [ 0.22, 3.95 ]
Subtotal (99% CI) 109 104 100.0 % 0.83 [ 0.23, 3.07 ]
Total events: 8 (Ivacaftor), 9 (Placebo)
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
24 Abdominal pain upper
ENVISION 2013 6/26 5/26 39.5 % 1.26 [ 0.22, 7.29 ]
STRIVE 2011 4/83 6/78 60.5 % 0.61 [ 0.11, 3.38 ]
Subtotal (99% CI) 109 104 100.0 % 0.87 [ 0.26, 2.91 ]
Total events: 10 (Ivacaftor), 11 (Placebo)
Heterogeneity: Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
25 Abdominal pain
ENVISION 2013 4/26 3/26 22.6 % 1.39 [ 0.17, 11.52 ]
STRIVE 2011 13/83 10/78 77.4 % 1.26 [ 0.39, 4.06 ]
Subtotal (99% CI) 109 104 100.0 % 1.29 [ 0.46, 3.59 ]
Total events: 17 (Ivacaftor), 13 (Placebo)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.52)
26 Constipation
ENVISION 2013 2/26 3/26 35.2 % 0.64 [ 0.05, 7.54 ]
STRIVE 2011 1/83 5/78 64.8 % 0.18 [ 0.01, 3.08 ]
Subtotal (99% CI) 109 104 100.0 % 0.34 [ 0.06, 2.05 ]
Total events: 3 (Ivacaftor), 8 (Placebo)
Heterogeneity: Chi2 = 0.77, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 1.55 (P = 0.12)
27 Diarrhea
ENVISION 2013 3/26 0/26 4.6 % 7.89 [ 0.15, 414.95 ]
STRIVE 2011 11/83 10/78 95.4 % 1.04 [ 0.31, 3.47 ]
Subtotal (99% CI) 109 104 100.0 % 1.36 [ 0.45, 4.11 ]
Total events: 14 (Ivacaftor), 10 (Placebo)
Heterogeneity: Chi2 = 1.64, df = 1 (P = 0.20); I2 =39%
Test for overall effect: Z = 0.71 (P = 0.48)
28 Vomiting
ENVISION 2013 2/26 7/26 41.3 % 0.23 [ 0.02, 2.07 ]
STRIVE 2011 9/83 10/78 58.7 % 0.83 [ 0.23, 2.92 ]
Subtotal (99% CI) 109 104 100.0 % 0.58 [ 0.20, 1.68 ]
Total events: 11 (Ivacaftor), 17 (Placebo)
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Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Heterogeneity: Chi2 = 1.73, df = 1 (P = 0.19); I2 =42%
Test for overall effect: Z = 1.32 (P = 0.19)
29 Nausea
ENVISION 2013 0/26 2/26 23.9 % 0.18 [ 0.00, 10.67 ]
STRIVE 2011 13/83 9/78 76.1 % 1.42 [ 0.43, 4.72 ]
Subtotal (99% CI) 109 104 100.0 % 1.13 [ 0.37, 3.40 ]
Total events: 13 (Ivacaftor), 11 (Placebo)
Heterogeneity: Chi2 = 1.57, df = 1 (P = 0.21); I2 =36%
Test for overall effect: Z = 0.28 (P = 0.78)
30 Gastrooesophageal reflux disease
ENVISION 2013 2/26 0/26 100.0 % 5.41 [ 0.09, 312.04 ]
Subtotal (99% CI) 26 26 100.0 % 5.41 [ 0.09, 312.04 ]
Total events: 2 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
31 Weight decreased
STRIVE 2011 2/83 4/78 100.0 % 0.46 [ 0.05, 4.42 ]
Subtotal (99% CI) 83 78 100.0 % 0.46 [ 0.05, 4.42 ]
Total events: 2 (Ivacaftor), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
32 Asparate aminotransferase increased
ENVISION 2013 3/26 2/26 47.7 % 1.57 [ 0.13, 18.48 ]
STRIVE 2011 5/83 2/78 52.3 % 2.44 [ 0.27, 21.87 ]
Subtotal (99% CI) 109 104 100.0 % 2.02 [ 0.40, 10.31 ]
Total events: 8 (Ivacaftor), 4 (Placebo)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.11 (P = 0.27)
33 Alanine aminotransferase increased
ENVISION 2013 2/26 3/26 36.4 % 0.64 [ 0.05, 7.54 ]
STRIVE 2011 5/83 5/78 63.6 % 0.94 [ 0.17, 5.03 ]
Subtotal (99% CI) 109 104 100.0 % 0.83 [ 0.21, 3.31 ]
Total events: 7 (Ivacaftor), 8 (Placebo)
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
34 Eosinophil count increased
ENVISION 2013 3/26 1/26 100.0 % 3.26 [ 0.15, 69.97 ]
Subtotal (99% CI) 26 26 100.0 % 3.26 [ 0.15, 69.97 ]
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Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Total events: 3 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
35 C-reactive protein increased
STRIVE 2011 4/83 5/78 100.0 % 0.74 [ 0.12, 4.37 ]
Subtotal (99% CI) 83 78 100.0 % 0.74 [ 0.12, 4.37 ]
Total events: 4 (Ivacaftor), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
36 Blood glucose increased
STRIVE 2011 5/83 3/83 100.0 % 1.71 [ 0.25, 11.72 ]
Subtotal (99% CI) 83 83 100.0 % 1.71 [ 0.25, 11.72 ]
Total events: 5 (Ivacaftor), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
37 Hypoglycaemia
STRIVE 2011 3/83 4/78 100.0 % 0.69 [ 0.09, 5.18 ]
Subtotal (99% CI) 83 78 100.0 % 0.69 [ 0.09, 5.18 ]
Total events: 3 (Ivacaftor), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
38 white blood cell count decreased
ENVISION 2013 2/26 0/26 100.0 % 5.41 [ 0.09, 312.04 ]
Subtotal (99% CI) 26 26 100.0 % 5.41 [ 0.09, 312.04 ]
Total events: 2 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
39 Bacteria sputum Identified
ENVISION 2013 2/26 3/26 74.3 % 0.64 [ 0.05, 7.54 ]
STRIVE 2011 6/83 1/78 25.7 % 6.00 [ 0.36, 99.96 ]
Subtotal (99% CI) 109 104 100.0 % 2.02 [ 0.39, 10.32 ]
Total events: 8 (Ivacaftor), 4 (Placebo)
Heterogeneity: Chi2 = 2.43, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 1.11 (P = 0.27)
40 Joint Sprain
STRIVE 2011 0/83 4/78 100.0 % 0.10 [ 0.00, 4.71 ]
Subtotal (99% CI) 83 78 100.0 % 0.10 [ 0.00, 4.71 ]
Total events: 0 (Ivacaftor), 4 (Placebo)
Heterogeneity: not applicable
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Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Test for overall effect: Z = 1.54 (P = 0.12)
41 Breath Sounds abnormal
ENVISION 2013 0/26 2/26 37.9 % 0.18 [ 0.00, 10.67 ]
STRIVE 2011 2/83 4/78 62.1 % 0.46 [ 0.05, 4.42 ]
Subtotal (99% CI) 109 104 100.0 % 0.35 [ 0.05, 2.49 ]
Total events: 2 (Ivacaftor), 6 (Placebo)
Heterogeneity: Chi2 = 0.25, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.37 (P = 0.17)
42 Arthralgia
STRIVE 2011 7/83 5/78 100.0 % 1.34 [ 0.28, 6.44 ]
Subtotal (99% CI) 83 78 100.0 % 1.34 [ 0.28, 6.44 ]
Total events: 7 (Ivacaftor), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.63)
43 Myalgia
ENVISION 2013 2/26 0/26 100.0 % 5.41 [ 0.09, 312.04 ]
Subtotal (99% CI) 26 26 100.0 % 5.41 [ 0.09, 312.04 ]
Total events: 2 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
44 Back pain
STRIVE 2011 5/83 5/78 100.0 % 0.94 [ 0.17, 5.03 ]
Subtotal (99% CI) 83 78 100.0 % 0.94 [ 0.17, 5.03 ]
Total events: 5 (Ivacaftor), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
45 Neck pain
ENVISION 2013 2/26 0/26 100.0 % 5.41 [ 0.09, 312.04 ]
Subtotal (99% CI) 26 26 100.0 % 5.41 [ 0.09, 312.04 ]
Total events: 2 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
46 Haemoptysis
STRIVE 2011 9/83 15/78 100.0 % 0.51 [ 0.16, 1.65 ]
Subtotal (99% CI) 83 78 100.0 % 0.51 [ 0.16, 1.65 ]
Total events: 9 (Ivacaftor), 15 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
47 Respiratory tract congestion
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Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
ENVISION 2013 0/26 2/26 29.9 % 0.18 [ 0.00, 10.67 ]
STRIVE 2011 6/83 6/78 70.1 % 0.94 [ 0.20, 4.39 ]
Subtotal (99% CI) 109 104 100.0 % 0.71 [ 0.18, 2.86 ]
Total events: 6 (Ivacaftor), 8 (Placebo)
Heterogeneity: Chi2 = 0.94, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
48 Sinus Congestion
STRIVE 2011 8/83 4/78 100.0 % 1.97 [ 0.39, 10.10 ]
Subtotal (99% CI) 83 78 100.0 % 1.97 [ 0.39, 10.10 ]
Total events: 8 (Ivacaftor), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
49 Dyspnoea
STRIVE 2011 2/83 5/78 100.0 % 0.36 [ 0.04, 3.24 ]
Subtotal (99% CI) 83 78 100.0 % 0.36 [ 0.04, 3.24 ]
Total events: 2 (Ivacaftor), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
50 Pleutiric pain
STRIVE 2011 5/83 2/78 100.0 % 2.44 [ 0.27, 21.87 ]
Subtotal (99% CI) 83 78 100.0 % 2.44 [ 0.27, 21.87 ]
Total events: 5 (Ivacaftor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
51 Respiration abnormal
STRIVE 2011 2/83 4/78 100.0 % 0.46 [ 0.05, 4.42 ]
Subtotal (99% CI) 83 78 100.0 % 0.46 [ 0.05, 4.42 ]
Total events: 2 (Ivacaftor), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
52 Pharyngeal erythema
ENVISION 2013 2/26 0/26 100.0 % 5.41 [ 0.09, 312.04 ]
Subtotal (99% CI) 26 26 100.0 % 5.41 [ 0.09, 312.04 ]
Total events: 2 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
53 Culture throat positive
ENVISION 2013 2/25 1/26 100.0 % 2.17 [ 0.09, 55.58 ]
Subtotal (99% CI) 25 26 100.0 % 2.17 [ 0.09, 55.58 ]
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Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Total events: 2 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
54 Rash
ENVISION 2013 2/26 3/26 44.0 % 0.64 [ 0.05, 7.54 ]
STRIVE 2011 12/83 4/78 56.0 % 3.13 [ 0.67, 14.69 ]
Subtotal (99% CI) 109 104 100.0 % 2.03 [ 0.58, 7.06 ]
Total events: 14 (Ivacaftor), 7 (Placebo)
Heterogeneity: Chi2 = 1.97, df = 1 (P = 0.16); I2 =49%
Test for overall effect: Z = 1.47 (P = 0.14)
55 Acne
STRIVE 2011 6/83 3/78 100.0 % 1.95 [ 0.30, 12.62 ]
Subtotal (99% CI) 83 78 100.0 % 1.95 [ 0.30, 12.62 ]
Total events: 6 (Ivacaftor), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
56 Lymphadenopathy
ENVISION 2013 1/26 2/26 100.0 % 0.48 [ 0.02, 12.25 ]
Subtotal (99% CI) 26 26 100.0 % 0.48 [ 0.02, 12.25 ]
Total events: 1 (Ivacaftor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
57 Excoriation
ENVISION 2013 1/26 2/26 100.0 % 0.48 [ 0.02, 12.25 ]
Subtotal (99% CI) 26 26 100.0 % 0.48 [ 0.02, 12.25 ]
Total events: 1 (Ivacaftor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
58 Neutrophil count decreased
ENVISION 2013 2/26 0/26 100.0 % 5.41 [ 0.09, 312.04 ]
Subtotal (99% CI) 26 26 100.0 % 5.41 [ 0.09, 312.04 ]
Total events: 2 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
59 Forced expiratory volume decreased
ENVISION 2013 2/26 0/26 100.0 % 5.41 [ 0.09, 312.04 ]
Subtotal (99% CI) 26 26 100.0 % 5.41 [ 0.09, 312.04 ]
Total events: 2 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
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Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Test for overall effect: Z = 1.07 (P = 0.28)
60 Seasonal allergy
ENVISION 2013 1/26 2/26 100.0 % 0.48 [ 0.02, 12.25 ]
Subtotal (99% CI) 26 26 100.0 % 0.48 [ 0.02, 12.25 ]
Total events: 1 (Ivacaftor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
61 Allergic rhinitis
ENVISION 2013 2/26 0/26 100.0 % 5.41 [ 0.09, 312.04 ]
Subtotal (99% CI) 26 26 100.0 % 5.41 [ 0.09, 312.04 ]
Total events: 2 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
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Analysis 2.6. Comparison 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR
mutation, Outcome 6 All adverse events.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR mutation
Outcome: 6 All adverse events
Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Cardiac Murmur
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
2 Chest discomfort
Accurso 2010 0/15 1/4 100.0 % 0.08 [ 0.00, 6.60 ]
Subtotal (99% CI) 15 4 100.0 % 0.08 [ 0.00, 6.60 ]
Total events: 0 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
3 Pulmonary exacerbation
Accurso 2010 2/15 0/4 100.0 % 1.67 [ 0.02, 114.48 ]
Subtotal (99% CI) 15 4 100.0 % 1.67 [ 0.02, 114.48 ]
Total events: 2 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
4 Upper respiratory tract infection
Accurso 2010 2/15 0/4 100.0 % 1.67 [ 0.02, 114.48 ]
Subtotal (99% CI) 15 4 100.0 % 1.67 [ 0.02, 114.48 ]
Total events: 2 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
5 Respiratory tract congestion
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
6 Cough
Accurso 2010 4/15 1/4 100.0 % 1.09 [ 0.04, 30.57 ]
Subtotal (99% CI) 15 4 100.0 % 1.09 [ 0.04, 30.57 ]
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Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Total events: 4 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
7 Cough decreased
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
8 Productive cough
Accurso 2010 1/15 1/4 100.0 % 0.21 [ 0.00, 11.63 ]
Subtotal (99% CI) 15 4 100.0 % 0.21 [ 0.00, 11.63 ]
Total events: 1 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
9 Sputum abnormal
Accurso 2010 2/15 0/4 100.0 % 1.67 [ 0.02, 114.48 ]
Subtotal (99% CI) 15 4 100.0 % 1.67 [ 0.02, 114.48 ]
Total events: 2 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
10 Sputum decreased
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
11 Sputum discolored
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
12 Increased upper airway secretion
Accurso 2010 2/15 0/4 100.0 % 1.67 [ 0.02, 114.48 ]
Subtotal (99% CI) 15 4 100.0 % 1.67 [ 0.02, 114.48 ]
Total events: 2 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
13 Increased bronchial secretion
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
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Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
14 Rhonchi
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
15 Headache
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
16 Tension headache
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
17 Sinus headache
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
18 Sinusitis
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
19 Chronic sinusitis
Accurso 2010 0/15 1/4 100.0 % 0.08 [ 0.00, 6.60 ]
Subtotal (99% CI) 15 4 100.0 % 0.08 [ 0.00, 6.60 ]
Total events: 0 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
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Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
20 Sinus congestion
Accurso 2010 2/15 0/4 100.0 % 1.67 [ 0.02, 114.48 ]
Subtotal (99% CI) 15 4 100.0 % 1.67 [ 0.02, 114.48 ]
Total events: 2 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
21 Nasal congestion
Accurso 2010 2/15 0/4 100.0 % 1.67 [ 0.02, 114.48 ]
Subtotal (99% CI) 15 4 100.0 % 1.67 [ 0.02, 114.48 ]
Total events: 2 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
22 Nasal oedma
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
23 Nasal dryness
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
24 Nasal turbinate abnormality
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
25 Nasal septum disorder
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
26 Mucosal erosion
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
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Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
27 Epistaxis
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
28 Oral candidiasis
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
29 Pharyngeal oedema
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
30 Pharyngeal erythema
Accurso 2010 2/15 0/4 100.0 % 1.67 [ 0.02, 114.48 ]
Subtotal (99% CI) 15 4 100.0 % 1.67 [ 0.02, 114.48 ]
Total events: 2 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
31 Pharyngolaryngeal pain
Accurso 2010 2/15 0/4 100.0 % 1.67 [ 0.02, 114.48 ]
Subtotal (99% CI) 15 4 100.0 % 1.67 [ 0.02, 114.48 ]
Total events: 2 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
32 Tonsillar hypertrophy
Accurso 2010 0/15 1/4 100.0 % 0.08 [ 0.00, 6.60 ]
Subtotal (99% CI) 15 4 100.0 % 0.08 [ 0.00, 6.60 ]
Total events: 0 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
0.001 0.01 0.1 1 10 100 1000
Favours ivacaftor Favours placebo
(Continued . . . )
101Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
33 Abdominal distension
Accurso 2010 0/15 1/4 100.0 % 0.08 [ 0.00, 6.60 ]
Subtotal (99% CI) 15 4 100.0 % 0.08 [ 0.00, 6.60 ]
Total events: 0 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
34 Upper abdominal pain
Accurso 2010 2/15 0/4 100.0 % 1.67 [ 0.02, 114.48 ]
Subtotal (99% CI) 15 4 100.0 % 1.67 [ 0.02, 114.48 ]
Total events: 2 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
35 Decreased appetite
Accurso 2010 0/15 1/4 100.0 % 0.08 [ 0.00, 6.60 ]
Subtotal (99% CI) 15 4 100.0 % 0.08 [ 0.00, 6.60 ]
Total events: 0 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
36 Nausea
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
37 Vomiting
Accurso 2010 2/15 0/4 100.0 % 1.67 [ 0.02, 114.48 ]
Subtotal (99% CI) 15 4 100.0 % 1.67 [ 0.02, 114.48 ]
Total events: 2 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
38 Diarrhoea
Accurso 2010 2/15 1/4 100.0 % 0.46 [ 0.01, 16.23 ]
Subtotal (99% CI) 15 4 100.0 % 0.46 [ 0.01, 16.23 ]
Total events: 2 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
39 Flatulence
Accurso 2010 0/15 1/4 100.0 % 0.08 [ 0.00, 6.60 ]
Subtotal (99% CI) 15 4 100.0 % 0.08 [ 0.00, 6.60 ]
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Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Total events: 0 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
40 Pyuria
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
41 White blood cells in urine
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
42 Rash
Accurso 2010 2/15 0/4 100.0 % 1.67 [ 0.02, 114.48 ]
Subtotal (99% CI) 15 4 100.0 % 1.67 [ 0.02, 114.48 ]
Total events: 2 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
43 Contact dermatitis
Accurso 2010 0/15 1/4 100.0 % 0.08 [ 0.00, 6.60 ]
Subtotal (99% CI) 15 4 100.0 % 0.08 [ 0.00, 6.60 ]
Total events: 0 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
44 Erythema
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
45 Excoriation
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
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Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
46 Pruritis
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
47 Genital pruritis (female)
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
48 Vulvovaginal mycotic infection
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
49 Photosensitivity reaction
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
50 Allergy to arthropod bite
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
51 Skin laceration
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
52 Injection site oedema
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
0.001 0.01 0.1 1 10 100 1000
Favours ivacaftor Favours placebo
(Continued . . . )
104Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
53 Fatigue
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
54 Somnolence
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
55 Joint crepitation
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
56 Lymphadenopathy
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
57 Blood creatinine increased
Accurso 2010 1/15 0/4 100.0 % 0.93 [ 0.01, 78.14 ]
Subtotal (99% CI) 15 4 100.0 % 0.93 [ 0.01, 78.14 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
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Analysis 2.7. Comparison 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR
mutation, Outcome 7 Severity of adverse effects of therapy with regards to study drug interruption
(moderate) or discontinuation (severe).
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR mutation
Outcome: 7 Severity of adverse effects of therapy with regards to study drug interruption (moderate) or discontinuation (severe)
Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Adverse effect requiring study drug interruption (moderate)
ENVISION 2013 1/26 3/26 39.4 % 0.31 [ 0.03, 3.16 ]
STRIVE 2011 11/83 4/78 60.6 % 2.83 [ 0.86, 9.29 ]
Subtotal (95% CI) 109 104 100.0 % 1.18 [ 0.14, 9.92 ]
Total events: 12 (Ivacaftor), 7 (Placebo)
Heterogeneity: Tau2 = 1.58; Chi2 = 2.77, df = 1 (P = 0.10); I2 =64%
Test for overall effect: Z = 0.15 (P = 0.88)
2 Adverse effect requiring study drug discontinuation (severe)
Accurso 2010 0/15 0/4 Not estimable
ENVISION 2013 0/26 1/26 31.7 % 0.32 [ 0.01, 8.24 ]
STRIVE 2011 1/83 4/78 68.3 % 0.23 [ 0.02, 2.06 ]
Subtotal (95% CI) 124 108 100.0 % 0.25 [ 0.04, 1.57 ]
Total events: 1 (Ivacaftor), 5 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.48 (P = 0.14)
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Analysis 2.8. Comparison 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR
mutation, Outcome 8 Serious adverse events.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR mutation
Outcome: 8 Serious adverse events
Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Haemoptysis
STRIVE 2011 1/83 4/78 100.0 % 0.23 [ 0.01, 4.14 ]
Subtotal (99% CI) 83 78 100.0 % 0.23 [ 0.01, 4.14 ]
Total events: 1 (Ivacaftor), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
2 Hypoglycaemia
STRIVE 2011 0/83 2/78 100.0 % 0.18 [ 0.00, 10.12 ]
Subtotal (99% CI) 83 78 100.0 % 0.18 [ 0.00, 10.12 ]
Total events: 0 (Ivacaftor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
3 Complete atrioventricular block
Accurso 2010 0/83 1/78 100.0 % 0.31 [ 0.00, 21.17 ]
Subtotal (99% CI) 83 78 100.0 % 0.31 [ 0.00, 21.17 ]
Total events: 0 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
4 Pulmonary exacerbation
ENVISION 2013 2/26 3/26 10.6 % 0.64 [ 0.05, 7.54 ]
STRIVE 2011 11/83 26/78 89.4 % 0.31 [ 0.11, 0.86 ]
Subtotal (99% CI) 109 104 100.0 % 0.34 [ 0.13, 0.88 ]
Total events: 13 (Ivacaftor), 29 (Placebo)
Heterogeneity: Chi2 = 0.50, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 2.91 (P = 0.0037)
5 Gastrooesophageal reflux
STRIVE 2011 0/83 1/78 100.0 % 0.31 [ 0.00, 21.17 ]
Subtotal (99% CI) 83 78 100.0 % 0.31 [ 0.00, 21.17 ]
Total events: 0 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
6 Pancreatic pseudocyst
STRIVE 2011 1/83 0/78 100.0 % 2.85 [ 0.04, 195.35 ]
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Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Subtotal (99% CI) 83 78 100.0 % 2.85 [ 0.04, 195.35 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
7 Pancreatitis
STRIVE 2011 1/83 0/78 100.0 % 2.85 [ 0.04, 195.35 ]
Subtotal (99% CI) 83 78 100.0 % 2.85 [ 0.04, 195.35 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
8 Vomiting
STRIVE 2011 0/83 1/78 100.0 % 0.31 [ 0.00, 21.17 ]
Subtotal (99% CI) 83 78 100.0 % 0.31 [ 0.00, 21.17 ]
Total events: 0 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
9 Abdominal pain
ENVISION 2013 1/26 0/26 100.0 % 3.12 [ 0.04, 222.22 ]
Subtotal (99% CI) 26 26 100.0 % 3.12 [ 0.04, 222.22 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
10 Constipation
ENVISION 2013 0/26 1/26 100.0 % 0.32 [ 0.00, 22.86 ]
Subtotal (99% CI) 26 26 100.0 % 0.32 [ 0.00, 22.86 ]
Total events: 0 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
11 Weight decreased
STRIVE 2011 1/83 0/78 100.0 % 2.85 [ 0.04, 195.35 ]
Subtotal (99% CI) 83 78 100.0 % 2.85 [ 0.04, 195.35 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
12 Anaphylactic shock
STRIVE 2011 1/83 0/78 100.0 % 2.85 [ 0.04, 195.35 ]
Subtotal (99% CI) 83 78 100.0 % 2.85 [ 0.04, 195.35 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
13 Catheter related complication
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Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
STRIVE 2011 0/83 1/78 100.0 % 0.31 [ 0.00, 21.17 ]
Subtotal (99% CI) 83 78 100.0 % 0.31 [ 0.00, 21.17 ]
Total events: 0 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
14 Implant site infection
STRIVE 2011 0/83 1/78 100.0 % 0.31 [ 0.00, 21.17 ]
Subtotal (99% CI) 83 78 100.0 % 0.31 [ 0.00, 21.17 ]
Total events: 0 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
15 Influenza
STRIVE 2011 1/83 0/78 100.0 % 2.85 [ 0.04, 195.35 ]
Subtotal (99% CI) 83 78 100.0 % 2.85 [ 0.04, 195.35 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
16 Pseudomonal lung infection
ENVISION 2013 0/26 1/26 48.9 % 0.32 [ 0.00, 22.86 ]
STRIVE 2011 0/83 1/78 51.1 % 0.31 [ 0.00, 21.17 ]
Subtotal (99% CI) 109 104 100.0 % 0.31 [ 0.02, 6.34 ]
Total events: 0 (Ivacaftor), 2 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
17 Pneumonia
STRIVE 2011 1/83 0/78 100.0 % 2.85 [ 0.04, 195.35 ]
Subtotal (99% CI) 83 78 100.0 % 2.85 [ 0.04, 195.35 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
18 Sinusitis
STRIVE 2011 1/83 0/78 100.0 % 2.85 [ 0.04, 195.35 ]
Subtotal (99% CI) 83 78 100.0 % 2.85 [ 0.04, 195.35 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
19 Cough
STRIVE 2011 1/83 0/78 100.0 % 2.85 [ 0.04, 195.35 ]
Subtotal (99% CI) 83 78 100.0 % 2.85 [ 0.04, 195.35 ]
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Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
20 Pleuritic pain
STRIVE 2011 1/83 0/78 100.0 % 2.85 [ 0.04, 195.35 ]
Subtotal (99% CI) 83 78 100.0 % 2.85 [ 0.04, 195.35 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
21 Pulmonary embolism
STRIVE 2011 0/83 1/78 100.0 % 0.31 [ 0.00, 21.17 ]
Subtotal (99% CI) 83 78 100.0 % 0.31 [ 0.00, 21.17 ]
Total events: 0 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
22 Respiratory distress
STRIVE 2011 0/83 1/78 100.0 % 0.31 [ 0.00, 21.17 ]
Subtotal (99% CI) 83 78 100.0 % 0.31 [ 0.00, 21.17 ]
Total events: 0 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
23 Productive cough
ENVISION 2013 1/26 1/26 100.0 % 1.00 [ 0.02, 41.06 ]
Subtotal (99% CI) 26 26 100.0 % 1.00 [ 0.02, 41.06 ]
Total events: 1 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
24 Respiratory failure
STRIVE 2011 0/83 1/78 100.0 % 0.31 [ 0.00, 21.17 ]
Subtotal (99% CI) 83 78 100.0 % 0.31 [ 0.00, 21.17 ]
Total events: 0 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
25 Pulmonary function test decreased
ENVISION 2013 0/26 1/26 100.0 % 0.32 [ 0.00, 22.86 ]
Subtotal (99% CI) 26 26 100.0 % 0.32 [ 0.00, 22.86 ]
Total events: 0 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
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Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
26 Lung consolidation
ENVISION 2013 0/26 1/26 100.0 % 0.32 [ 0.00, 22.86 ]
Subtotal (99% CI) 26 26 100.0 % 0.32 [ 0.00, 22.86 ]
Total events: 0 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
27 Myringitis bullous
STRIVE 2011 1/83 0/78 100.0 % 2.85 [ 0.04, 195.35 ]
Subtotal (99% CI) 83 78 100.0 % 2.85 [ 0.04, 195.35 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
28 Hepatic enzyme increased
STRIVE 2011 1/83 0/78 100.0 % 2.85 [ 0.04, 195.35 ]
Subtotal (99% CI) 83 78 100.0 % 2.85 [ 0.04, 195.35 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
29 Cervix carcinoma
STRIVE 2011 1/83 0/78 100.0 % 2.85 [ 0.04, 195.35 ]
Subtotal (99% CI) 83 78 100.0 % 2.85 [ 0.04, 195.35 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
30 Musculoskeletal chest pain
STRIVE 2011 1/83 0/78 100.0 % 2.85 [ 0.04, 195.35 ]
Subtotal (99% CI) 83 78 100.0 % 2.85 [ 0.04, 195.35 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
31 Pain in extremity
STRIVE 2011 0/83 1/78 100.0 % 0.31 [ 0.00, 21.17 ]
Subtotal (99% CI) 83 78 100.0 % 0.31 [ 0.00, 21.17 ]
Total events: 0 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
32 Spontaneous abortion
STRIVE 2011 1/83 0/78 100.0 % 2.85 [ 0.04, 195.35 ]
Subtotal (99% CI) 83 78 100.0 % 2.85 [ 0.04, 195.35 ]
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Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
33 Haematuria
STRIVE 2011 1/83 0/78 100.0 % 2.85 [ 0.04, 195.35 ]
Subtotal (99% CI) 83 78 100.0 % 2.85 [ 0.04, 195.35 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
34 IgA nephropathy
STRIVE 2011 1/83 0/78 100.0 % 2.85 [ 0.04, 195.35 ]
Subtotal (99% CI) 83 78 100.0 % 2.85 [ 0.04, 195.35 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
35 Nephrolithiasis
STRIVE 2011 0/83 1/78 100.0 % 0.31 [ 0.00, 21.17 ]
Subtotal (99% CI) 83 78 100.0 % 0.31 [ 0.00, 21.17 ]
Total events: 0 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
36 Renal Colic
STRIVE 2011 0/83 1/78 100.0 % 0.31 [ 0.00, 21.17 ]
Subtotal (99% CI) 83 78 100.0 % 0.31 [ 0.00, 21.17 ]
Total events: 0 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
37 Testicular torsion
STRIVE 2011 0/83 1/78 100.0 % 0.31 [ 0.00, 21.17 ]
Subtotal (99% CI) 83 78 100.0 % 0.31 [ 0.00, 21.17 ]
Total events: 0 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
38 Pyrexia
ENVISION 2013 1/26 0/26 100.0 % 3.12 [ 0.04, 222.22 ]
Subtotal (99% CI) 26 26 100.0 % 3.12 [ 0.04, 222.22 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
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Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
39 Muscle strain
ENVISION 2013 1/26 0/26 100.0 % 3.12 [ 0.04, 222.22 ]
Subtotal (99% CI) 26 26 100.0 % 3.12 [ 0.04, 222.22 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
40 Hepatic enzyme increased
ENVISION 2013 1/26 0/26 100.0 % 3.12 [ 0.04, 222.22 ]
Subtotal (99% CI) 26 26 100.0 % 3.12 [ 0.04, 222.22 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
41 Adjustment disorder
ENVISION 2013 0/26 1/26 100.0 % 0.32 [ 0.00, 22.86 ]
Subtotal (99% CI) 26 26 100.0 % 0.32 [ 0.00, 22.86 ]
Total events: 0 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
42 Anxiety
ENVISION 2013 0/26 1/26 100.0 % 0.32 [ 0.00, 22.86 ]
Subtotal (99% CI) 26 26 100.0 % 0.32 [ 0.00, 22.86 ]
Total events: 0 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
43 Affective disorder
ENVISION 2013 0/26 1/26 100.0 % 0.32 [ 0.00, 22.86 ]
Subtotal (99% CI) 26 26 100.0 % 0.32 [ 0.00, 22.86 ]
Total events: 0 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
44 Conversion disorder
ENVISION 2013 1/26 0/26 100.0 % 3.12 [ 0.04, 222.22 ]
Subtotal (99% CI) 26 26 100.0 % 3.12 [ 0.04, 222.22 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
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Analysis 2.9. Comparison 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR
mutation, Outcome 9 The number of G551D participants who developed episodes of pulmonary exacerbation.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR mutation
Outcome: 9 The number of G551D participants who developed episodes of pulmonary exacerbation
Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 1 month
Accurso 2010 2/15 0/4 100.0 % 1.67 [ 0.07, 41.64 ]
Subtotal (95% CI) 15 4 100.0 % 1.67 [ 0.07, 41.64 ]
Total events: 2 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
2 At 48 weeks
ENVISION 2013 7/26 6/26 14.4 % 1.23 [ 0.35, 4.32 ]
STRIVE 2011 29/83 39/78 85.6 % 0.54 [ 0.29, 1.01 ]
Subtotal (95% CI) 109 104 100.0 % 0.64 [ 0.36, 1.12 ]
Total events: 36 (Ivacaftor), 45 (Placebo)
Heterogeneity: Chi2 = 1.32, df = 1 (P = 0.25); I2 =25%
Test for overall effect: Z = 1.58 (P = 0.11)
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Analysis 2.10. Comparison 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR
mutation, Outcome 10 Time to first pulmonary exacerbation.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR mutation
Outcome: 10 Time to first pulmonary exacerbation
Study or subgroup Ivacaftor Placebo log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 24 weeks
STRIVE 2011 83 78 -0.7765 (0.2533) 100.0 % 0.46 [ 0.28, 0.76 ]
Subtotal (95% CI) 83 78 100.0 % 0.46 [ 0.28, 0.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.07 (P = 0.0022)
2 At 48 weeks
STRIVE 2011 83 78 -0.7765 (0.2356) 100.0 % 0.46 [ 0.29, 0.73 ]
Subtotal (95% CI) 83 78 100.0 % 0.46 [ 0.29, 0.73 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.30 (P = 0.00098)
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Analysis 2.11. Comparison 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR
mutation, Outcome 11 Maximum liver function test abnormalities in adolescents/adults at 48 weeks.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR mutation
Outcome: 11 Maximum liver function test abnormalities in adolescents/adults at 48 weeks
Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2x to 3x ULN AST
STRIVE 2011 8/83 4/78 100.0 % 1.97 [ 0.57, 6.84 ]
Subtotal (95% CI) 83 78 100.0 % 1.97 [ 0.57, 6.84 ]
Total events: 8 (Ivacaftor), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
2 2x to 3x ULN ALT
STRIVE 2011 5/83 6/78 100.0 % 0.77 [ 0.23, 2.63 ]
Subtotal (95% CI) 83 78 100.0 % 0.77 [ 0.23, 2.63 ]
Total events: 5 (Ivacaftor), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
3 2x to 3x ULN Bilirubin
STRIVE 2011 2/83 1/78 100.0 % 1.90 [ 0.17, 21.39 ]
Subtotal (95% CI) 83 78 100.0 % 1.90 [ 0.17, 21.39 ]
Total events: 2 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
4 3x to 5x ULN AST
STRIVE 2011 1/83 2/78 100.0 % 0.46 [ 0.04, 5.21 ]
Subtotal (95% CI) 83 78 100.0 % 0.46 [ 0.04, 5.21 ]
Total events: 1 (Ivacaftor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
5 3x to 5x ULN ALT
STRIVE 2011 0/83 2/78 100.0 % 0.18 [ 0.01, 3.88 ]
Subtotal (95% CI) 83 78 100.0 % 0.18 [ 0.01, 3.88 ]
Total events: 0 (Ivacaftor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
6 3x to 5x ULN Bilirubin
STRIVE 2011 0/83 0/78 Not estimable
Subtotal (95% CI) 83 78 Not estimable
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(. . . Continued)
Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 0 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
7 5x to 8x ULN AST
STRIVE 2011 1/83 0/78 100.0 % 2.85 [ 0.11, 71.12 ]
Subtotal (95% CI) 83 78 100.0 % 2.85 [ 0.11, 71.12 ]
Total events: 1 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
8 5x to 8x ULN ALT
STRIVE 2011 0/83 1/78 100.0 % 0.31 [ 0.01, 7.71 ]
Subtotal (95% CI) 83 78 100.0 % 0.31 [ 0.01, 7.71 ]
Total events: 0 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
9 5x to 8x ULN Bilirubin
STRIVE 2011 0/83 0/78 Not estimable
Subtotal (95% CI) 83 78 Not estimable
Total events: 0 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
10 8x AST
STRIVE 2011 1/83 1/78 100.0 % 0.94 [ 0.06, 15.28 ]
Subtotal (95% CI) 83 78 100.0 % 0.94 [ 0.06, 15.28 ]
Total events: 1 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.96)
11 8x ALT
STRIVE 2011 3/83 0/78 100.0 % 6.83 [ 0.35, 134.32 ]
Subtotal (95% CI) 83 78 100.0 % 6.83 [ 0.35, 134.32 ]
Total events: 3 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
12 8x Bilirubin
STRIVE 2011 0/83 0/78 Not estimable
Subtotal (95% CI) 83 78 Not estimable
Total events: 0 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 2.12. Comparison 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR
mutation, Outcome 12 Duration of hospitalisation for pulmonary exacerbation.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR mutation
Outcome: 12 Duration of hospitalisation for pulmonary exacerbation
Study or subgroup Ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 48 weeks
STRIVE 2011 83 3.92 (13.62) 78 4.15 (8.71) 100.0 % -0.23 [ -3.74, 3.28 ]
Subtotal (95% CI) 83 78 100.0 % -0.23 [ -3.74, 3.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
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Analysis 2.13. Comparison 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR
mutation, Outcome 13 Number of hospitalisations for pulmonary exacerbations.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR mutation
Outcome: 13 Number of hospitalisations for pulmonary exacerbations
Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 48 weeks
STRIVE 2011 11/83 23/78 100.0 % 0.37 [ 0.16, 0.81 ]
Subtotal (95% CI) 83 78 100.0 % 0.37 [ 0.16, 0.81 ]
Total events: 11 (Ivacaftor), 23 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.47 (P = 0.014)
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Analysis 2.14. Comparison 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR
mutation, Outcome 14 FEV1 (% predicted) - mean absolute change from baseline.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR mutation
Outcome: 14 FEV1 (% predicted) - mean absolute change from baseline
Study or subgroup Ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 24 weeks
ENVISION 2013 26 26 12.5 (2.98) 10.5 % 12.50 [ 6.66, 18.34 ]
STRIVE 2011 83 78 10.6 (1.02) 89.5 % 10.60 [ 8.60, 12.60 ]
Subtotal (95% CI) 109 104 100.0 % 10.80 [ 8.91, 12.69 ]
Heterogeneity: Chi2 = 0.36, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 11.19 (P < 0.00001)
2 48 weeks
ENVISION 2013 26 26 10 (2.81) 11.6 % 10.00 [ 4.49, 15.51 ]
STRIVE 2011 83 78 10.5 (1.02) 88.4 % 10.50 [ 8.50, 12.50 ]
Subtotal (95% CI) 109 104 100.0 % 10.44 [ 8.56, 12.32 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 10.89 (P < 0.00001)
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Analysis 2.15. Comparison 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR
mutation, Outcome 15 FEV1 (litres) - mean absolute change from baseline.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR mutation
Outcome: 15 FEV1 (litres) - mean absolute change from baseline
Study or subgroup Ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 24 weeks
ENVISION 2013 26 25 0.236 (0.05765306) 45.0 % 0.24 [ 0.12, 0.35 ]
STRIVE 2011 83 78 0.4 (0.0255102) 55.0 % 0.40 [ 0.35, 0.45 ]
Subtotal (95% CI) 109 103 100.0 % 0.33 [ 0.17, 0.49 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 6.77, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 4.00 (P = 0.000064)
2 48 weeks
ENVISION 2013 26 25 0.2 (0.0566) 46.8 % 0.20 [ 0.09, 0.31 ]
STRIVE 2011 83 78 0.4 (0.0255102) 53.2 % 0.40 [ 0.35, 0.45 ]
Subtotal (95% CI) 109 103 100.0 % 0.31 [ 0.11, 0.50 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 10.38, df = 1 (P = 0.001); I2 =90%
Test for overall effect: Z = 3.07 (P = 0.0021)
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Analysis 2.16. Comparison 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR
mutation, Outcome 16 Change from baseline through week 24 in percent of predicted FEV1 according to
subgroup.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR mutation
Outcome: 16 Change from baseline through week 24 in percent of predicted FEV1 according to subgroup
Study or subgroup Ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Subgroup 1: Baseline FEV1 of less than or equal to 90% predicted
ENVISION 2013 16 14 14.9 (3.8776) 100.0 % 14.90 [ 7.30, 22.50 ]
Subtotal (95% CI) 16 14 100.0 % 14.90 [ 7.30, 22.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.84 (P = 0.00012)
2 Subgroup 2: Baseline FEV1 of more than 90% predicted
ENVISION 2013 10 11 6.9 (5.4593) 100.0 % 6.90 [ -3.80, 17.60 ]
Subtotal (95% CI) 10 11 100.0 % 6.90 [ -3.80, 17.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
3 Subgroup 3: North America
ENVISION 2013 12 14 5.8 (4.2858) 100.0 % 5.80 [ -2.60, 14.20 ]
Subtotal (95% CI) 12 14 100.0 % 5.80 [ -2.60, 14.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
4 Subgroup 4: Europe
ENVISION 2013 6 5 24.6 (9.2859) 100.0 % 24.60 [ 6.40, 42.80 ]
Subtotal (95% CI) 6 5 100.0 % 24.60 [ 6.40, 42.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.65 (P = 0.0081)
5 Subgroup 5: Australia
ENVISION 2013 8 6 4.2 (4.0307) 100.0 % 4.20 [ -3.70, 12.10 ]
Subtotal (95% CI) 8 6 100.0 % 4.20 [ -3.70, 12.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
6 Subgroup 6: Male
ENVISION 2013 9 15 5.2 (3.7756) 100.0 % 5.20 [ -2.20, 12.60 ]
Subtotal (95% CI) 9 15 100.0 % 5.20 [ -2.20, 12.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
7 Subgroup 7: Female
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(. . . Continued)
Study or subgroup Ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
ENVISION 2013 17 10 13.8 (4.898) 100.0 % 13.80 [ 4.20, 23.40 ]
Subtotal (95% CI) 17 10 100.0 % 13.80 [ 4.20, 23.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.82 (P = 0.0048)
-50 -25 0 25 50
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Analysis 2.17. Comparison 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR
mutation, Outcome 17 Number of pulmonary exacerbations requiring intravenous antibiotics.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR mutation
Outcome: 17 Number of pulmonary exacerbations requiring intravenous antibiotics
Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 48 weeks
STRIVE 2011 28/83 47/78 100.0 % 0.34 [ 0.18, 0.64 ]
Subtotal (95% CI) 83 78 100.0 % 0.34 [ 0.18, 0.64 ]
Total events: 28 (Ivacaftor), 47 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.33 (P = 0.00087)
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Analysis 2.18. Comparison 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR
mutation, Outcome 18 Days with intravenous antibiotics administered for pulmonary exacerbations.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR mutation
Outcome: 18 Days with intravenous antibiotics administered for pulmonary exacerbations
Study or subgroup Ivacaftor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 48 weeks
STRIVE 2011 83 6.68 (19.43) 78 11.03 (20.36) 100.0 % -4.35 [ -10.51, 1.81 ]
Subtotal (95% CI) 83 78 100.0 % -4.35 [ -10.51, 1.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.17)
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Analysis 2.19. Comparison 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR
mutation, Outcome 19 Weight - change from baseline (kg).
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR mutation
Outcome: 19 Weight - change from baseline (kg)
Study or subgroup Ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 At 24 weeks
ENVISION 2013 26 26 1.9 (0.51) 48.0 % 1.90 [ 0.90, 2.90 ]
STRIVE 2011 83 78 2.8 (0.49) 52.0 % 2.80 [ 1.84, 3.76 ]
Subtotal (95% CI) 109 104 100.0 % 2.37 [ 1.68, 3.06 ]
Heterogeneity: Chi2 = 1.62, df = 1 (P = 0.20); I2 =38%
Test for overall effect: Z = 6.70 (P < 0.00001)
2 at 48 weeks
ENVISION 2013 26 26 2.8 (0.74) 47.9 % 2.80 [ 1.35, 4.25 ]
STRIVE 2011 83 78 2.7 (0.71) 52.1 % 2.70 [ 1.31, 4.09 ]
Subtotal (95% CI) 109 104 100.0 % 2.75 [ 1.74, 3.75 ]
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 5.36 (P < 0.00001)
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Analysis 2.20. Comparison 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR
mutation, Outcome 20 Sweat chloride level - change from baseline.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 2 Ivacaftor (VX-770) versus placebo in people with at least one G551D CFTR mutation
Outcome: 20 Sweat chloride level - change from baseline
Study or subgroup Ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 At 24 weeks
ENVISION 2013 26 26 -54.3 (3.83) 35.7 % -54.30 [ -61.81, -46.79 ]
STRIVE 2011 83 78 -47.9 (1.73) 64.3 % -47.90 [ -51.29, -44.51 ]
Subtotal (95% CI) 109 104 100.0 % -50.19 [ -56.20, -44.18 ]
Heterogeneity: Tau2 = 11.65; Chi2 = 2.32, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 16.36 (P < 0.00001)
2 At 48 weeks
ENVISION 2013 26 26 -53.5 (3.8) 30.4 % -53.50 [ -60.95, -46.05 ]
STRIVE 2011 83 78 -48.1 (1.73) 69.6 % -48.10 [ -51.49, -44.71 ]
Subtotal (95% CI) 109 104 100.0 % -49.74 [ -54.61, -44.87 ]
Heterogeneity: Tau2 = 5.86; Chi2 = 1.67, df = 1 (P = 0.20); I2 =40%
Test for overall effect: Z = 20.03 (P < 0.00001)
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Analysis 3.1. Comparison 3 Ivacaftor (VX-770) versus placebo in people with at least one R117H CFTR
mutation, Outcome 1 CFQ-R score (respiratory domain score, pooled) - absolute change from baseline.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 3 Ivacaftor (VX-770) versus placebo in people with at least one R117H CFTR mutation
Outcome: 1 CFQ-R score (respiratory domain score, pooled) - absolute change from baseline
Study or subgroup Ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 At 24 weeks
KONDUCT 2015 34 35 8.4 (3.1786) 100.0 % 8.40 [ 2.17, 14.63 ]
Subtotal (95% CI) 34 35 100.0 % 8.40 [ 2.17, 14.63 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.64 (P = 0.0082)
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Analysis 3.2. Comparison 3 Ivacaftor (VX-770) versus placebo in people with at least one R117H CFTR
mutation, Outcome 2 FEV1 relative change from baseline.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 3 Ivacaftor (VX-770) versus placebo in people with at least one R117H CFTR mutation
Outcome: 2 FEV1 relative change from baseline
Study or subgroup Ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 At 24 weeks
KONDUCT 2015 34 35 5 (2.6735) 100.0 % 5.00 [ -0.24, 10.24 ]
Subtotal (95% CI) 34 35 100.0 % 5.00 [ -0.24, 10.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.87 (P = 0.061)
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Analysis 3.3. Comparison 3 Ivacaftor (VX-770) versus placebo in people with at least one R117H CFTR
mutation, Outcome 3 Adverse events.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 3 Ivacaftor (VX-770) versus placebo in people with at least one R117H CFTR mutation
Outcome: 3 Adverse events
Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any adverse event
KONDUCT 2015 32/34 35/35 100.0 % 0.18 [ 0.01, 3.96 ]
Subtotal (95% CI) 34 35 100.0 % 0.18 [ 0.01, 3.96 ]
Total events: 32 (Ivacaftor), 35 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
2 Serious adverse event
KONDUCT 2015 4/34 6/35 100.0 % 0.64 [ 0.16, 2.52 ]
Subtotal (95% CI) 34 35 100.0 % 0.64 [ 0.16, 2.52 ]
Total events: 4 (Ivacaftor), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
3 Adverse event leading to discontinuation
KONDUCT 2015 0/34 0/35 Not estimable
Subtotal (95% CI) 34 35 Not estimable
Total events: 0 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.54, df = 1 (P = 0.46), I2 =0.0%
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Analysis 3.4. Comparison 3 Ivacaftor (VX-770) versus placebo in people with at least one R117H CFTR
mutation, Outcome 4 Adverse events in > 15% of participants.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 3 Ivacaftor (VX-770) versus placebo in people with at least one R117H CFTR mutation
Outcome: 4 Adverse events in > 15% of participants
Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pulmonary exacerbation
KONDUCT 2015 13/34 14/35 100.0 % 0.93 [ 0.35, 2.44 ]
Subtotal (95% CI) 34 35 100.0 % 0.93 [ 0.35, 2.44 ]
Total events: 13 (Ivacaftor), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
2 Cough
KONDUCT 2015 10/34 9/35 100.0 % 1.20 [ 0.42, 3.47 ]
Subtotal (95% CI) 34 35 100.0 % 1.20 [ 0.42, 3.47 ]
Total events: 10 (Ivacaftor), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
3 Headache
KONDUCT 2015 6/34 5/35 100.0 % 1.29 [ 0.35, 4.69 ]
Subtotal (95% CI) 34 35 100.0 % 1.29 [ 0.35, 4.69 ]
Total events: 6 (Ivacaftor), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.70)
4 Increased sputum
KONDUCT 2015 5/34 4/35 100.0 % 1.34 [ 0.33, 5.47 ]
Subtotal (95% CI) 34 35 100.0 % 1.34 [ 0.33, 5.47 ]
Total events: 5 (Ivacaftor), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
5 Nasal congestion
KONDUCT 2015 5/34 4/35 100.0 % 1.34 [ 0.33, 5.47 ]
Subtotal (95% CI) 34 35 100.0 % 1.34 [ 0.33, 5.47 ]
Total events: 5 (Ivacaftor), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
6 Oropharyhgeal pain
KONDUCT 2015 5/34 2/35 100.0 % 2.84 [ 0.51, 15.79 ]
Subtotal (95% CI) 34 35 100.0 % 2.84 [ 0.51, 15.79 ]
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(. . . Continued)
Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 5 (Ivacaftor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
7 Diarrhoea
KONDUCT 2015 5/34 4/35 100.0 % 1.34 [ 0.33, 5.47 ]
Subtotal (95% CI) 34 35 100.0 % 1.34 [ 0.33, 5.47 ]
Total events: 5 (Ivacaftor), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
8 Abdominal pain
KONDUCT 2015 4/34 0/35 100.0 % 10.48 [ 0.54, 202.47 ]
Subtotal (95% CI) 34 35 100.0 % 10.48 [ 0.54, 202.47 ]
Total events: 4 (Ivacaftor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
9 Wheezing
KONDUCT 2015 4/34 1/35 100.0 % 4.53 [ 0.48, 42.82 ]
Subtotal (95% CI) 34 35 100.0 % 4.53 [ 0.48, 42.82 ]
Total events: 4 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
10 Cystic fibrosis lung pathogen colonisation
KONDUCT 2015 3/34 1/35 100.0 % 3.29 [ 0.32, 33.31 ]
Subtotal (95% CI) 34 35 100.0 % 3.29 [ 0.32, 33.31 ]
Total events: 3 (Ivacaftor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Chi2 = 4.78, df = 9 (P = 0.85), I2 =0.0%
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Analysis 3.5. Comparison 3 Ivacaftor (VX-770) versus placebo in people with at least one R117H CFTR
mutation, Outcome 5 Summary of pulmonary exacerbations.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 3 Ivacaftor (VX-770) versus placebo in people with at least one R117H CFTR mutation
Outcome: 5 Summary of pulmonary exacerbations
Study or subgroup Ivacaftor Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 All pulmonary exacerbations
KONDUCT 2015 11/34 13/35 100.0 % 0.81 [ 0.30, 2.19 ]
Subtotal (95% CI) 34 35 100.0 % 0.81 [ 0.30, 2.19 ]
Total events: 11 (Ivacaftor), 13 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
2 Number of hospitalisations for pulmonary exacerbation
KONDUCT 2015 2/34 6/35 100.0 % 0.30 [ 0.06, 1.62 ]
Subtotal (95% CI) 34 35 100.0 % 0.30 [ 0.06, 1.62 ]
Total events: 2 (Ivacaftor), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
3 Number of pulmonary exacerbations requiring intravenous antibiotics
KONDUCT 2015 2/34 6/35 100.0 % 0.30 [ 0.06, 1.62 ]
Subtotal (95% CI) 34 35 100.0 % 0.30 [ 0.06, 1.62 ]
Total events: 2 (Ivacaftor), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Chi2 = 1.56, df = 2 (P = 0.46), I2 =0.0%
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Analysis 3.6. Comparison 3 Ivacaftor (VX-770) versus placebo in people with at least one R117H CFTR
mutation, Outcome 6 Time to first pulmonary exacerbation.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 3 Ivacaftor (VX-770) versus placebo in people with at least one R117H CFTR mutation
Outcome: 6 Time to first pulmonary exacerbation
Study or subgroup Ivacaftor Placebo log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 24 weeks
KONDUCT 2015 34 35 -0.0726 (0.4115) 100.0 % 0.93 [ 0.42, 2.08 ]
Subtotal (95% CI) 34 35 100.0 % 0.93 [ 0.42, 2.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours ivacaftor Favours placebo
Analysis 3.7. Comparison 3 Ivacaftor (VX-770) versus placebo in people with at least one R117H CFTR
mutation, Outcome 7 FEV1 predicted % absolute change from baseline.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 3 Ivacaftor (VX-770) versus placebo in people with at least one R117H CFTR mutation
Outcome: 7 FEV1 predicted % absolute change from baseline
Study or subgroup Ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 At 24 weeks
KONDUCT 2015 34 35 2.1 (1.648) 100.0 % 2.10 [ -1.13, 5.33 ]
Subtotal (95% CI) 34 35 100.0 % 2.10 [ -1.13, 5.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
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Analysis 3.8. Comparison 3 Ivacaftor (VX-770) versus placebo in people with at least one R117H CFTR
mutation, Outcome 8 BMI absolute change from baseline.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 3 Ivacaftor (VX-770) versus placebo in people with at least one R117H CFTR mutation
Outcome: 8 BMI absolute change from baseline
Study or subgroup Ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 At 24 weeks
KONDUCT 2015 34 35 0.26 (0.9337) 100.0 % 0.26 [ -1.57, 2.09 ]
Subtotal (95% CI) 34 35 100.0 % 0.26 [ -1.57, 2.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
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Analysis 3.9. Comparison 3 Ivacaftor (VX-770) versus placebo in people with at least one R117H CFTR
mutation, Outcome 9 Sweat chloride concentration - change from baseline.
Review: Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
Comparison: 3 Ivacaftor (VX-770) versus placebo in people with at least one R117H CFTR mutation
Outcome: 9 Sweat chloride concentration - change from baseline
Study or subgroup Ivacaftor Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 At 24 weeks
KONDUCT 2015 34 35 -24 (2.046) 100.0 % -24.00 [ -28.01, -19.99 ]
Subtotal (95% CI) 34 35 100.0 % -24.00 [ -28.01, -19.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 11.73 (P < 0.00001)
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A D D I T I O N A L T A B L E S
Table 1. Classes of mutations affecting CFTR production, structure, and function
Class Example mutation Impact on CFTR structure and function
I G542X Synthesis of CFTR is critically impaired, and no functional protein is produced. This is due to the
presence of a premature stop codon in the nucleotide sequence. Individuals have minimal CFTR
function
II 1F508 A full length of CFTR is produced, but this is structurally abnormal and destroyed by the cell before
it reaches the cell membrane. This is called a defect in the intracellular trafficking pathway. Minimal
amounts of CFTR can escape being destroyed and be transported to the cell membrane. However here,
class II CFTR products display defective ion transport. Individuals have minimal CFTR function
III G551D CFTR is produced and embedded in the cell membrane, but the chloride channel does not respond
(‘switch on’) to normal stimulation from the cell. This means there is no significant ion transport
across the protein. Individuals have some residual CFTR function
IV R347P CFTR is transported to the outer cell membrane, and responds to normal stimulation, but functions
at a low level because chloride ions do not cross the channel appropriately. Individuals have some
residual CFTR function
V A455E Normal CFTR is produced, but the amount of protein is reduced. Individuals have some residual
CFTR function
CFTR: cystic fibrosis transmembrane conductance regulator
Table 2. CFQ-R domain scores in the phase 2 G551D study at 4 weeks (median (range))
Domain Day 14 Day 28
Placebo (n = 4) VX-770 150 mg
(n = 8)
VX-770 250 mg
(n = 7)
Placebo (n = 4) VX-770 150 mg
(n = 8)
VX-770 250 mg
(n = 7)
Body image 0 (-11.1 to 22.2) 0
(-22.2 to 0)
0
(-11.1 to 22.2)
-5.6
(-11.1 to 22.2)
0
(-22.2 to 11.1)
0
(-11.1 to 44.4)
Digestive symp-
toms
-5.6
(-22.2 to 0)
0
(0 to 22.2)
0
(-11.1 to 22.2)
0
(-22.0 to 0)
5.6
(0 to 22.2)
0
(-11.1 to 33.3)
Eating
disturbances
0
(-11.1 to 11.1)
0
(0 to 11.1)
0
(-11.1 to 0)
-5.6
(-11.1 to 0)
0
(0 to 0)
0
(-11.1 to 0)
Emotional func-
tioning
13.3
(-6.7 to 20.0)
0
(-26.7 to 0)
0
(-20.0 to 26.7)
3.3
(0 to 20.0)
0
(-6.7 to 6.7)
6.7
(-6.7 to 20.0)
Health
perceptions
5.6
(-11.1 to 11.1)
0
(-22.2 to 22.2)
0
(-33.3 to 11.1)
0
(-11.1 to 11.1)
0
(-22.2 to 22.2)
0
(-11.1 to 11.1)
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Table 2. CFQ-R domain scores in the phase 2 G551D study at 4 weeks (median (range)) (Continued)
Physical
functioning
0
(0 to 4.2)
2.1
(-4.2 to 16.7)
4.2
(0 to 8.3)
2.1
(0 to 4.2)
4.2
(-8.3 to 25.0)
0
(0 to 12.5)
Respiratory
symptoms
2.8
(-5.6 to 11.1)
5.6
(0 to 16.7)
5.6
(-11.1 to 11.1)
2.8
(-5.6 to 11.1)
8.3
(0 to 16.7)
11.1
(-5.6 to 33.3)
Role 0
(0 to 8.3)
0
(-8.3 to 8.3)
0
(0 to 8.3)
0
(0 to 0)
0
(-8.3 to 8.3)
0
(-8.3 to 8.3)
Social 2.8
(-5.6 to 5.6)
0
(-44.4 to 11.1)
-5.6
(-16.7 to 5.6)
2.8
(-11.1 to 5.6)
0
(-11.1 to 5.6)
0
(-16.7 to 11.1)
Treatment bur-
den
0
(-11.1 to 11.1)
-5.6
(-22.2 to 11.1)
0
(-22.2 to 22.2)
0
(0 to 0)
-5.6
(-22.2 to 11.1)
0
(-22.2 to 11.1)
Vitality 4.2
(-16.7 to 8.3)
4.2
(-8.3 to 16.7)
0
(-8.3 to 16.7)
-8.3
(-16.7 to 0)
0
(-16.7 to 25.0)
0
(0 to 16.7)
Weight 0
(0 to 33.3)
0
(0 to 33.3)
0
(-33.3 to 33.3)
0
(0 to 33.3)
0
(0 to 33.3)
0
(-33.3 to 33.3)
CFQ-R: Cystic Fibrosis Questionnaire-Revised
Table 3. Outcomes for age subgroups in R117H study at 24 weeks
Overall 6 - 11 years ≥18 years
Treatment
difference
P value Treatment differ-
ence
P value Treatment difference P value
Quality of life
(CFQ-R) - res-
piratory domain
(pooled)
8.4 0.009 -6.1 0.19 12.6 0.002
%
predicted FEV1 -
absolute change
from baseline
2.1 0.20 -6.3 0.03 5.0 0.01
%
predicted FEV1
- relative change
from baseline
5.0 0.06 -6.8 0.04 0.2 0.008
135Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 3. Outcomes for age subgroups in R117H study at 24 weeks (Continued)
BMI - abso-
lute change from
baseline
0.26 0.78 -0.18 0.87 0.31 0.78
Sweat chloride -
absolute change
from baseline
-24.0 <0.0001 -27.6 <0.001 -21.9 <0.001
Treatment difference was adjusted for age and % predicted FEV1
BMI: body mass index
CFQ-R: cystic fibrosis questionnaire - revised
FEV1: forced expiratory volume in one second
Table 4. Absolute change in FEV1 % predicted amongst pre-defined subgroups in the adult phase 3 G551D study at 48 weeks.
Subgroup Treatment effect P value
Baseline percent of predicted FEV1 of less
than 70%
10.6 < 0.001
Baseline percent of predicted FEV1 of
greater or equal to 70%
10.3 < 0.001
Participants from North America 9.0 < 0.001
Participants from Europe 9.9 < 0.001
Participants from Australia 11.9 0.008
Male 11.0 < 0.001
Female 11.6 < 0.001
Less than 18 years 11.4 0.005
Greater than or equal to 18 years 9.9 < 0.001
The treatment effect represents the difference between the ivacaftor group and the placebo group with respect to the absolute change
from baseline through week 48.
FEV1: forced expiratory volume at one second
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Table 5. Change from baseline in sweat chloride concentration in FEV1 responders and FEV1 non-responders in the phase 3
G551D studies
Paediatric phase 3 G551D study
(ENVISION 2013)
Adult phase 3 G551D study
(STRIVE 2011)
Treatment difference
(mmol/L)
P value Treatment difference (mmol/L) P value
Minimal responders (less
than 5% point improve-
ment)
-55.8 <0.0001 -46.1 < 0.0001
FEV1 responders (5%
point improvement)
-53.9 <0.0001 -49.7 < 0.0001
FEV1: forced expiratory volume at one second
A P P E N D I C E S
Appendix 1. Glossary
Term Explanation
CFTR (cystic fibrosis transmembrane regulator) A protein which is in the outer membrane of cells. It works by regulating transport
of salt in and out of the cell. Problems with the amount of CFTR in the cell
membrane, its structure, or the manner in which it functions can lead to altered
transport of salt across the cell membrane. In the lungs of people with CF, these
problems cause thick airway secretions. Abnormalities of CFTR can also lead to
problems in other organs
CFTR correctors Drugs or chemicals which work by increasing the amount of CFTR in the cell
membrane
CFTR potentiators Drugs or chemicals which increase the effectiveness of CFTR at transporting salt
across the cell membrane
CFTR stop-codon therapies Drugs or chemicals which help the cell to synthesise CFTR. They specifically
work in people with CF in whom the basic defect happens because CFTR which
is made is too short, and so functions abnormally
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Appendix 2. Electronic search strategies
Database / Resource Search terms Date last searched
European Medicines Agency
(www.clinicaltrialsregister.eu/)
cystic fibrosis AND ivacaftor 13 April 2018
US National Institute of Health trials
database
(clinicaltrials.gov/)
cystic fibrosis AND ivacaftor 13 April 2018
WHO ICTRP
(apps.who.int/trialsearch/)
cystic fibrosis AND ivacaftor 13 April 2018
WH A T ’ S N E W
Date Event Description
18 December 2018 New citation required and conclusions have changed One new trial was included (KONDUCT 2015). An
improvement in the respiratory domain of the CFQ-R
was demonstrated but no improvement in respiratory
function
Three authors have stepped down from the re-
view (Kerry Dwan, Carlos Echevarria and Michael
Schechter) and two new authors have joined the team
(Mica Skilton and Ashma Krishan)
18 December 2018 New search has been performed One trial has been included from the previous ongoing
studies section (KONDUCT 2015).
A search of the Cochrane Cystic Fibrosis and Ge-
netic Disorders Review Group’s Cystic Fibrosis Regis-
ter identified 99 new references (45 trials) which were
potentially eligible for inclusion in this review
There were 14 references to already included trials: two
references were added to the Accurso trial (Accurso
2010); six references were added to the Ramsey trial
(STRIVE 2011); three references were added to the
Davies trial (ENVISION 2013); and three references
which are linked to both the Davies and Ramsey trials
were also added (ENVISION 2013; STRIVE 2011).
A further four references were identified and added
to already excluded trials: three references to the
Kerem trial (Kerem 2014); one reference to the Davies
trial (Davies 2012). There were 29 references to 10
new trials identified, all were excluded (ALBATROSS
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(Continued)
2017; Berkers 2017; Davies 2016; Edgeworth 2017;
FLAMINGO 2017; Horsley 2018; McGarry 2015;
NCT02323100; RIO-CF 2017; Seliger 2015).
Two new references were added to studies awaiting
classification (Kazani 2016; Uttamsingh 2016).
A search of two clinical trials registries identified 33
new relevant trials, all of which were excluded
In a post hoc change, corrector and potentiator com-
bination therapy trials have not been referenced in the
review, meaning the remaining 52 references identified
have not been listed
C O N T R I B U T I O N S O F A U T H O R S
Roles and responsibilities
TASK WHO WILL UNDERTAKE THE TASK?
Protocol stage: draft the protocol IS with comments from all
Review stage: select which trials to include (2 + 1 arbiter) IS, SP, MS
Review stage: extract data from trials (at least 2 people) IS, SP, CE
Review stage: enter data into RevMan SP, KD
Review stage: carry out the analysis SP, KD
Review stage: interpret the analysis IS, SP, KD
Review stage: draft the final review SP with comments from all
Update stage: update the review MS, IS, SP, AK
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Full review 2016
We have made several changes since the protocol stage.
• The title has been changed from ’Mutation-specific therapies that potentiate cystic fibrosis transmembrane conductance
regulator (CFTR) function in cystic fibrosis’ to the current title of this review.
• We decided to only include trials that compare a CFTR potentiator to a placebo or other intervention. Trials comparing a
CFTR potentiator alongside another CFTR modulator will be published in a different review.
• For the primary outcome of survival, in a post hoc change, mortality data were also considered.
• We have decided to add cost of treatment as a secondary outcome of interest.
• In a post hoc change, we have edited the methods section that 99% confidence intervals will be used to analyse separate adverse
events. This is the most appropriate statistical approach for considering adverse events individually.
• We have added a Summary of Findings table based on the most clinically important outcomes, in line with the outcomes to be
reported in the ongoing review of CFTR correctors (Southern 2018).
Update 2018
• In a post hoc change, corrector and potentiator combination therapy trials have not been referenced in the review, meaning the
39 references to combination therapy identified in the 2018 searches have not been listed as excluded studies
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Mutation; Age Factors; Aminophenols [∗therapeutic use]; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cystic
Fibrosis [∗drug therapy; ∗genetics]; Cystic Fibrosis Transmembrane Conductance Regulator [drug effects; ∗genetics]; Forced Expiratory
Volume [drug effects]; Molecular Targeted Therapy [methods]; Mucociliary Clearance; Quality of Life; Quinolones [∗therapeutic use];
Randomized Controlled Trials as Topic
MeSH check words
Adult; Child; Humans
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